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General Introduction
Epilepsy
Epilepsy is a chronic disease of the brain characterized by an enduring predisposition to 
generate epileptic seizures (Fisher et al., 2014). This disease largely influences the patient’s 
life. It is one of the most common neurological disorders requiring long-term health care 
contact (Forsgren, 1992; Sander et al., 1996). Worldwide approximately 50 million people 
have epilepsy (Banerjee, 2009). One in 26 people will develop epilepsy during their 
lifetime (Hesdorffer et al., 2011). 
 Epilepsy is an expression of various brain disorders – not only a single disease. 
Consequently, any investigations or treatment needs to be individualized. The epilepsies 
represent a heterogeneous group of disorders with different electrographic, etiologies, 
behavioural and seizure patterns. In 1985, the first concept of epileptic syndromes was 
brought into consideration. Etiology was only ever mentioned briefly in the 1969, 1981, 
and 1989 International League Against Epilepsy (ILAE) classifications of seizures and 
syndromes, as well as later publications (Gastaut, 1969; Luders et al., 2004). In the 1989 
classification of epilepsies, these classes were given: localization-related epilepsies and 
syndromes, generalized epilepsies and syndromes, epilepsies and syndromes, undetermined 
whether focal or generalized, and special syndromes. In its 2010 report the last ILAE 
Commission confined its revisions to “new terminology and concepts” instead of “proposing 
a new classification (in the sense of organization) of epilepsies.” 
 This outmost current ILAE definition states that: “Epilepsy is a disorder of the brain 
characterized by an enduring predisposition to arise epileptic seizures and by the 
neurobiologic, cognitive, psychological, and social consequences of this condition. In this 
current classification from 2010 the terms “symptomatic”, “idiopathic” and “cryptogenic” 
have been changed by “structural-metabolic”, “genetic” and “unknown” but they do not 
list etiologic categories any further (see Table 1 middle panel) (Berg et al., 2010).
 Epilepsy should primary be classed according to etiology, succeed by a narration of 
the semiology of the seizure. However, this current classification has also been criticized 
and authors have deliberated the necessity for a more up-to-date way to the grouping of 
epileptic seizures and epilepsies (Luders et al., 2012). 
 In clinical practice the diagnosis of epilepsy is founded on the clinical history and 
physical inspection. However, it is important to get a detail picture of the seizure’s 
semiology as possible. Ictal symptoms, i.e. symptoms during the seizures, particularly at 
onset, are determined by the localization of seizure foci. Moreover, it is also significant to 
evaluate differential diagnoses like syncope, arrhythmia and non-epileptic seizures, since 
a wrong diagnosis of epilepsy is often common (Chadwick et al., 2002). Interictal electro-
encephalogram (EEG) can provide information about the diagnosis of epilepsy, although 
a normal EEG cannot exclude the diagnosis of epilepsy.
503055-L-bw-DAmore
12  |  Chapter 1
Ta
bl
e 
1 
 IL
A
E 
Pr
op
os
al
 fo
r r
ev
is
ed
 T
er
m
in
ol
og
y 
fo
r O
rg
an
iz
at
io
n 
of
 S
ei
zu
re
s 
an
d 
Ep
ile
ps
ie
s.
In
 th
e 
up
p
er
 p
an
el
 c
la
ss
ifi
ca
tio
n 
of
 th
e 
se
iz
ur
es
 a
re
 g
iv
en
, i
n 
th
e 
m
id
dl
e 
p
an
el
 th
e 
ep
ile
pt
ic
 s
yn
dr
om
es
 a
nd
 o
th
er
 e
pi
le
ps
ie
s 
gr
ou
p
ed
 b
y 
sp
ec
ifi
ci
ty
 o
f d
ia
gn
os
is
 a
re
 g
iv
en
, 
in
 th
e 
lo
w
er
 p
an
el
 th
e 
m
aj
or
 c
ha
ng
es
 in
 te
rm
in
ol
og
y 
an
d 
co
nc
ep
ts
 a
re
 s
ho
w
n.
503055-L-bw-DAmore
General introduction  |  13
1
Ta
bl
e 
1 
 IL
A
E 
Pr
op
os
al
 fo
r r
ev
is
ed
 T
er
m
in
ol
og
y 
fo
r O
rg
an
iz
at
io
n 
of
 S
ei
zu
re
s 
an
d 
Ep
ile
ps
ie
s.
In
 th
e 
up
p
er
 p
an
el
 c
la
ss
ifi
ca
tio
n 
of
 th
e 
se
iz
ur
es
 a
re
 g
iv
en
, i
n 
th
e 
m
id
dl
e 
p
an
el
 th
e 
ep
ile
pt
ic
 s
yn
dr
om
es
 a
nd
 o
th
er
 e
pi
le
ps
ie
s 
gr
ou
p
ed
 b
y 
sp
ec
ifi
ci
ty
 o
f d
ia
gn
os
is
 a
re
 g
iv
en
, 
in
 th
e 
lo
w
er
 p
an
el
 th
e 
m
aj
or
 c
ha
ng
es
 in
 te
rm
in
ol
og
y 
an
d 
co
nc
ep
ts
 a
re
 s
ho
w
n.
503055-L-bw-DAmore
14  |  Chapter 1
Absence Epilepsy
Poupart introduced “absence” as a term to describe seizures in 1705, which was followed 
by the terms “petit mal” in 1838, and “pyknolepsy” in 1916 (Loiseau, 2002). In 1981, the ILAE 
classified absence seizures in the generalized seizures category (see the 2011-2013 
classification Table 1), with electroclinical characteristics which they later defined, differen-
tiating between typical and atypical absence seizures (Loiseau, 1992). 
 Typical absence seizures (TAS) are accompanied by a highly characteristic pattern of 
brain activity, so called spike and wave discharges (SWDs), which can be recorded in the 
EEG of the patients. During these typical absence seizures the EEG shows generalized, 
regular and synchronous SWDs with a frequency of 3 Hz (Bosnyakova et al., 2007). They 
usually start with a slightly higher frequency of 4-5 Hz and gradually decrease to a 
frequency of 2.5 Hz at the end of the SWDs. The clinical phenotype is the marked 
alteration of consciousness, and it might be connected by automatisms if the episode is 
long (old concepts of simple and complex absence seizures), and occasionally also by 
slight myoclonus (ILAE, 1981; Onat et al., 2013). Atypical absence seizures epilepsy (AAS) 
are clinically distinct from typical absence seizures (Carmant et al., 1996) for the following 
reasons: (1) the SWDs frequency is less than 3 Hz, (2) there is voluntary movement and 
partial consciousness during the seizures, (3) they are accompanied by severe cognitive 
and neurodevelopmental impairments, and (4) they are often intractable to antiepileptic 
drugs (Nolan et al., 2005). Two more absence seizure types with specific features were 
identified by the ILAE in 2010 (Berg et al., 2010). In myoclonic absence seizures the EEG is 
similar to that of typical absence seizures, but the now seizures are accompanied by 
marked bilateral rhythmical clonic jerks. In eyelid myoclonia absence seizures, impairment 
of consciousness is bland and EEG shows rhythmic diffuse polyspike-wave discharges, 
normally at 5–6 Hz (Weiergräber  et al., 2010). 
 Above the seizures were described. Now the disease at which the seizures are seen 
are described. Childhood absence epilepsy (CAE) accounts for 2% to 8% of patients with 
epilepsy, with the main cause being predominantly genetic. About one-third of the 
families of children with CAE report a family history of similar seizures. The siblings of 
children with CAE have about a 10% chance of developing epilepsy. CAE is considered to 
be one of the relatively benign childhood epilepsies. For 65% of these children, the 
seizures respond to treatment and disappear. A recent investigation showed that children 
who initially obtained the first-line medication, ethosuximide (ESM), were less likely to 
experience subsequent relapses for any reason, when compared to children who were 
given valproic acid (VPA). After ≥5 years of follow-up, children who were initially treated 
with ESM were more likely to be seizure free for at least 5 years at their final follow-up. 
More importantly, they were much more likely to be in total remission (both 5 years 
seizure free and medication free).
 The seizures of CAE normally begin between the ages of 4 and 8 in children who 
have normal intelligence and neurologic functions (Loiseau et al., 2002). It seems that 
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during these seizures the child loses the ability to maintain contact with the environment 
(van Luijtelaar et al., 1991), the child’s eyes may roll up briefly, occasionally with some mild, 
myoclonic twitches of the facial muscles, and often not able to respond to external stimuli 
like a question addressed to them by their parent or teacher (Gloor, 1986). Often the child 
is not even aware that anything has happened. These episodes may occur 1 to 50 times 
per day. 
 Tonic-clonic seizures, with or without fever, might occur for a while before absence 
seizures develop and, from time to time, thereafter. Absence seizures persisting into adult 
life are rare, but they may happen sometimes. The presence of the SWDs in the EEG is the 
major diagnostic criterion for CAE, given the non-convulsive nature of this syndrome. 
As reviewed above, it must be noted, however, that there are also some other epileptic 
syndromes, i.e. juvenile absence epilepsy, juvenile myoclonic epilepsy, myoclonic absence 
epilepsy and eyelid myoclonia with absences, in which SWDs can be detected (Panayaio-
topoulos, 1999). 
Therapeutics for Epilepsy
Anti-seizure drugs 
There are a wide variety of drugs on the market today that treat the seizures themselves, 
that is, they reduce the probability that seizures occur (Kaminski et al., 2014), they are 
named antiseizure drugs, although the name anti-epileptic drugs is commonly used as 
well. 
 Anticonvulsants are the first line treatment option for those who have a convulsive 
seizure disorder. The mechanism of action of these drugs can vary significantly (for review 
see Löscher et al., 2013), but for those patients who respond well, an oral anticonvulsant 
may be the only necessary medical intervention for the disorder. 
 Anti-absence medications are similar to anticonvulsants, in that they treat the seizures 
themselves, but the mechanism of action of these medications is often quite different. 
It so happens that most typical anticonvulsants such as phenytoin, carbamazepine and 
tiagabine actually exacerbate non-convulsive seizures, and conversely, some medications that 
are used to treat non-convulsive seizures such as ESM are ineffective against convulsive 
seizures (Panayiotopoulos, 1999; Rogawski and Löscher, 2004).
 ESM (Table 2) is one of the most aged anti-absence drugs, next trimethadione, which 
is not longer used because of its toxicity. Although ESM’s action mechanism is not 
completely understood, the blockade of a specific voltage-gated calcium channel (the 
T-type channel) in thalamic neurons appears central to its anti-seizure activity. This 
blockade suppresses thalamic excitability, which is believed to be necessary in order to 
sustain the characteristic SWDs of absence seizures (Huguenard et al., 2002). Serious 
adverse events that are connected to ESM include aplastic anemia, pancytopenia, Ste-
503055-L-bw-DAmore
16  |  Chapter 1
vens-Johnson syndrome (SJS), systemic lupus erythematosus and effects on the digestive 
system (Panayiotopoulos, 2001 Tenney and Jain, 2014). There are no published evidences 
on ESM-caused absences exacerbation. ESM’s main impediment is the drug’s ineffective-
ness against other seizures types, especially tonic-clonic seizures (Panayiotopoulos, 2001). 
Anti-epileptogenic drugs
The ultimate goal of any drug therapy is to cure the patient of illness; whether the patient 
is then able to stop taking the medication may also be part of that goal. 
 A recent study showed that children who initially received ESM, still and for a long 
time it is considered as a first line medication, were less likely to experience subsequent 
relapses for any reasons compared to children who received VPA. After ≥5 years of 
follow-up, children initially treated with ESM were more likely to be at least 5-years seizure 
free at their last follow-up. Specifically, they were much more likely to be in complete 
remission (both 5-years seizure free and medication free). The difference appeared 
present even for 10-year remission. These findings are in line with those of studies in rat 
models of absence epilepsy (see below) and suggest potential disease modifying effects 
of ESM in childhood absence epilepsy (Berg et al., 2014). 
 Until now, it seems that our medical establishment is always a step behind illness, 
treating symptoms as they occur as opposed to treating the underlying cause of the 
illness or even better, being able to predict a particular illness and prevent it from 
occurring. This would be the goal of antiepileptogenesis; preventing the development of 
epilepsy in people who would otherwise have it. For example, it is known there is a 
likelihood of developing a seizure disorder in people who have had a traumatic brain 
injury (TBI, (Pitkänen and Bolkvadze, 2012)). If those people were given some treatment or 
compound that would prevent the neuropathological changes that lead to the seizure 
Table 2  From Vrielynck, 2013.
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disorder, this treatment would be called an antiepileptogenic (Löscher and Brandt, 2009). 
Such prevention treatment is not yet available for humans, although studies in animal 
models with ESM (Blumenfeld et al., 2008; van Luijtelaar et al., 2013), vigabatrin (Russo et 
al., 2011), levetiracetam (Kaminski et al., 2014) and cannabinoids (Vinogradova et al., 2015) 
are encouraging for future development of drugs preventing the development of 
epilepsy.
Rodent Models of Epilepsy
Animal Models: Necessary and Valid 
Animal models are necessary to investigate and understand basic principles of various 
diseases. Beyond the necessity of their use, epilepsy models used must be proven valid; 
this means that various conditions must be met. For example, the seizure model must 
correctly predict the response of standard drug and experimental treatments. Also, the 
model must reflect some of neuropathological changes that occur in the human condition. 
Finally, the overt behavior of the animal must mirror those seen in humans with the 
disease.
Genetic Models for epilepsy 
One of the greatest advantages of using mice in research is that the genetic sequence of 
the animal is well characterized. If one gene or a cluster of genes is thought responsible 
for a condition, it is relatively easy to manipulate that and create a sub-species knockout 
line wherein all of the offspring carry the deleted, silenced, or in some way mutated and 
quiescent version of the gene.
 Animal mutants or transgenic animals with spontaneously recurrent seizures are 
some examples of true models of epilepsy, which are obviously more closely related to 
human epilepsy than simple seizure models (Fig. 1). Unfortunately, researchers usually do 
not make a differentiation between animal models of epilepsy and animal models of 
epileptic seizures, in spite of this important difference when interpreting data obtained 
with such models. Models of epilepsy, e.g. mutant animals with inherent epilepsy, can of 
course be used as models of seizures, such as in anti-seizure drug potency studies. 
However, a pure seizure model in a non-epileptic animal is not applicable as a chronic 
epilepsy model. 
 The focus of this thesis is absence epilepsy: therefore the existing absence seizure 
models and absence epilepsy models will be introduced. A few models for other types of 
seizures and epilepsy will be briefly mentioned since some of the drug studies that will be 
discussed in the introduction and general discussion of this thesis, have used these animal 
models. First the genetic absence epilepsy mouse models will be described, such as 
lethargic, stargazer, and tottering mice (Fig. 1). Next, rats with a genetic form of absence 
503055-L-bw-DAmore
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epilepsy such as WAG/Rij rats and GAERS, and finally induced non-absence models such 
as DBA mice and the pilocarpine SE model.
Mouse models related to absence epilepsy
Lethargic mice
Mice of the lethargic (lh/lh) strain have an inherited mutation of the calcium channel β4 
subunit (Fig. 1). This mutation truncates the C-terminus of the β subunit of the P/Q type 
calcium channel such that the binding site for α- subunit is missing (Burgess et al., 1999). 
This ultimately results in drastically altered calcium channel kinetics and the “lethargic” 
phenotype of the mice. Specific work has pointed to the ventrolateral and reticular nuclei 
of the thalamus as the generator network of the seizures in lh/lh mice (Hosford et al., 
1992). Behaviorally, these mice are typically ataxic. When movements do occur, they are 
unstable, lurching and generally uncoordinated (Hosford and Wang, 1997). The EEG of lh/
lh mice shows periodic, spontaneous SWDs that is typically 3 to 4 times the amplitude of 
the background EEG signal and falls within the 4 to 6 Hz frequency range (Hosford et al., 
1992). Lethargic mice are known to respond well to the classic first-line therapeutic for 
absence epilepsy: ESM (Aizawa et al., 1997).
Figure 1  An overview of models of epilepsy or epileptic seizures. Note that there are 
numerous models not shown in this figure, including chronic epilepsy models, in which 
spontaneous recurrent seizures develop after traumatic brain injury, ischemic brain 
damage, or febrile seizures. For more details see Löscher and Pitkänen et al., 2006.
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Stargazer and tottering models
Other mouse models of genetic absence epilepsy include the stargazer and tottering 
models, among others (Sarkisian, 2001). These mice are quite similar to the lh/lh model in 
terms of behavioral phenotype. Stargazer mice also have an inherited mutation in the 
calcium channel regulating genes, although in this case it is in the gamma subunit (Osten 
and Stern-Bach, 2006). The tottering mouse, with a quite pronounced absence-like 
phenotype and motor dystonia, has a calcium channel dysfunction similar to that of the 
lethargic mouse (Fletcher et al., 1996; Campbell and Hess, 1999). 
Other mutant mice models
Abnormalities in excitatory and inhibitory neurotransmission in the cortico-thalamic 
network underlying absence seizures appear in mice with the genetic deletion of mGlu4 
receptors (Wang et al., 2005). In a recent study, mice with gene targeted deletion of mGlu4 
showed a significantly larger susceptibility to pilocarpine-induced acute convulsive 
epileptic seizures (Pitsch et al., 2007). However, these mice are resistant to chemically 
induced absence seizures (Snead et al., 2000). In line, pharmacological and gene targeting 
studies have provided evidence that the inhibition or absence of mGlu4 receptors render 
rodents resistant to absence epilepsy (Snead et al., 2000). It is suggested that transcrip-
tional regulation of mGlu4 expression occurs in response to convulsive seizures as a 
compensatory mechanism to counterweight changes in glutamatergic or GABAergic 
activity (Sperk et al., 2013). Normal mice are indeed protected against pentylenetetra-
zol-evoked absence seizures when bilaterally injected with an mGlu4 receptor antagonist 
in the thalamus (Snead et al., 2000). It then must be investigated whether changes in the 
expression/activity of mGlu4 receptors within the cortico-thalamo-cortical circuitry are in 
some way correlated with the occurrence of spontaneous absence seizures.
Rat absence epilepsy models 
After the discovery of the genetic rat models (Fig. 1), the mice models and the chemical 
absence models were less often used. Two rat-models are leading in the literature: Genetic 
Absence Epilepsy Rats from Strasbourg (GAERS) and Wistar Albino Glaxo rats from Rijswijk 
(WAG/Rij) (Fig. 2), both exhibit SWDs in the 7 to 11 Hz frequency range (van Luijtelaar and 
Coenen, 1986; Charpier et al., 1999; Polack et al., 2007. Coenen and van Luijtelaar, 2003, van 
Luijtelaar and Sitnikova, 2006). Both the GAERS and WAG/Rij rodents meet the criteria to 
be considered as valid models of absence epilepsy: the behavior of the epileptic animal is 
similar to epileptic humans, the neuropathology is similar and the response to the first 
line antiepileptic medication is similar (Coenen and van Luijtelaar, 2003; Depaulis and van 
Luijtelaar, 2006). Indeed, both types of rats exhibit behavioral arrest and impaired 
consciousness during the synchronous and bilateral EEG events, the SWDs (Marescaux et 
al., 1992; Coenen and van Luijtelaar, 2003; van Luijtelaar and Sitnikova, 2006). The EEG 
waveforms of the SWDs is strikingly similar to the ictal waveform seen in human patients 
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(Sitnikova and van Luijtelaar, 2007), although the frequency of the oscillations is higher in 
rodents than in patients (7-11 Hz in rodents, versus 3 Hz in humans)(van Luijtelaar and 
Coenen, 1986; Benbadis et al., 2001). 
Characteristics of SWDs in rat models of absence epilepsy
The spontaneous occurrence of SWDs in the cortical EEG does not only apply to GAERS 
and WAG/Rij rats. There are various types of other laboratory animals that have been 
indicated as having spontaneous SWDs (Chocholova, 1983; Klingberg and Pickenhain, 
1968; Buzsaki et al., 1990a; Buzsaki et al., 1990b; Inoue et al., 1990; Willoughby and 
Mackenzie, 1992; Shaw, 2004;), including e.g. the tottering mouse and lethargic mouse. 
However, it must be noted, that some of these animals also show other neurological 
disturbances next to SWDs (Crunelli and Leresche, 2002; Paz et al., 2011).
 A single gene may be responsible for the presence of SWDs, which has been shown 
in quantitative genetic studies in GAERS (Rudolf et al., 2004) and WAG/Rij rats. However, 
the amount of seizures is determined by only a few other genes (Peeters et al., 1992). 
SWDs are the same in both genders both in GAERS and WAG/Rij rats (Coenen and van 
Luijtelaar, 1987; van Luijtelaar et al., 2014), indicating that the genetic transmission is 
autosomal. SWDs in WAG/Rij rats are first detected around 60–80 days of age (Coenen 
and van Luijtelaar, 1987; Schridde and van Luijtelaar, 2004a; Schridde and van Luijtelaar, 
2004b; Schridde and van Luijtelaar, 2005). The first SWDs are few (1 or 2 hours) and 
short-lasting (1–3s) at that age, the wave is not developed yet, the inter-spike frequency 
during a discharge is also lower (4–5Hz), the spikes are not very sharp, and the pattern of 
SWDs is less ordered and exact. With age, the number, duration, morphology and 
Figure 2  Photograph of a WAG/Rij rat implanted with electrode for ECoG recording:  
Spontaneous incidence of SWDs: 16-20/hour - Mean duration: 5 seconds. 
(Photo Herbert van der Sluis).
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frequency of SWDs increases, whereas their amplitude is not modified. The number of 
animals also increases with SWDs depending on age: 50% of the WAG/Rij rats display fully 
developed SWDs at 3 months of age, and 100% of the animals show mature SWDs (about 
16–20 per hour) at 6 months of age, with a frequency of approximately 7-11 Hz, and a 
mean duration of about 5s (Coenen and van Luijtelaar, 1987; Chahboune et al., 2009). After 
6 months, there is still an age-dependent enhance in the number of SWDs and in the mean 
duration. The SWDs do not change to other type of seizures or spontaneously remit. 
The cortico-thalamic-cortical network
Disturbances in glutamatergic or GABAergic neurotransmission are among the causes 
responsible for the origin and spread of SWDs, characterizing absence epilepsy. The 
SWDs, the electroencephalographic hallmark of absence seizures, start in the deep layers 
of the somatosensory cortex and quickly spread over the cortex and to the cortico-thala-
mo-cortical (C-T-C) circuitry (Meeren et al., 2002; Blumenfeld et al., 2005; Polack et al., 2007). 
This circuitry consists of glutamatergic projections from the deep layer cortical neurons in 
the somatosensory cortex (S1po) to ventrobasal (VB) thalamic nuclei including the 
posterior nucleus PO and to the GABA-ergic reticular thalamic nucleus (nRT); glutamatergic 
projections from thalamic nuclei to the cortex and nRT and GABA-ergic projections from 
the nRT to the thalamic nuclei. These latter projections are responsible for widespread 
thalamic inhibition (Blumenfeld et al., 2005; van Luijtelaar and Sitnikova, 2006).
Response to antiepileptic drugs in WAG/Rij rat and GAERS
GAERS and/or WAG/Rij rats have been tested on with the well-known classical antiepileptic 
drugs in order to establish the pharmacological validity of both models. The four main 
AEDs which are effective against human absences suppress the SWDs: the typical 
anti-absence drugs ESM, the broad-spectrum drug VPA, the non-prescribed trimethadione, 
and, in principle, all benzodiazepines (van Luijtelaar et al., 2002; Manning et al., 2003). 
Contrastingly, SWDs are worsened by drugs that are either ineffective or aggravate SWDs 
in humans (such as carbamazepine, phenytoin, and locasemide, all sodium channel 
blockers). The results of pharmacological tests in GAERS and WAG/Rij rats therefore show 
great similarities to the pharmacological reactivity of typical absence seizures in humans 
(Panayiotopoulos, 1999; Glauser et al., 2010). Pentylenetetrazol or penicillin—weak GABAA 
antagonists known to induce “absence-like” discharges in normal rats—aggravate SWDs 
in GAERS (Depaulis and van Luijtelaar, 2006). 
Induced models for epilepsy
Beyond the various genetic models of epilepsy, other models for the study of epilepsy 
exist that involve the induction of seizures using an exogenous compound or stimulus. 
Genetic models may be thought to be superior and somehow “more valid” because of 
similarities in the pathology involved in the human and rodent epilepsies. However, 
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induced models of epilepsy are fast, reproducible and often repeatable within subjects, 
making them an appealing option for investigation. However, it should be highlighted 
that genetic models do not exist for most of the epilepsies. In fact, this is the reason why 
the pharmacologically induced or chemical models for other types of seizures or epilepsy 
are very necessary. Moreover, the induced models have also been used to evaluate effects 
of classic AED and also new compounds.  
Induction of seizures by stimulation 
DBA mice
One of the most serious concerns for patients with epilepsy and their families is sudden 
unexpected death in epilepsy (SUDEP). The 21-day-old DBA mice (Fig. 1 ), have generalized 
convulsions when exposed to intense auditory stimulation. Furthermore, DBA mice 
exhibit SUDEP in the phase immediately following audiogenic seizure (AGS), and 
respiratory arrest is the cause of death for these mice (RA) (Venit et al., 2004; De Sarro et al., 
2015). If resuscitation of the mice was administered quickly, death could be avoided 
(Collins, 1972). When the DBA mice’s oxygen levels were increased in the local environment, 
incidences of RA were reduced, and a greater percentage of these mice survived (Willott 
et al., 1976). This model has been retained in subsequent steps of preclinical AED 
development. DBA mice are useful models in the steps to clarifying the potency and 
spectrum of anticonvulsant activities that may be used to ward off different types of 
epileptic seizures. Clinical antiepileptic drugs such as diazepam, carbamazepine and VPA 
show therapeutic indications in DBA/2 mouse  (De Sarro et al., 1996; 2000; 2015).
Induction of seizures by exogenous compound 
Pilocarpine model
Multiple species, including rats and mice (Cavalheiro et al., 1996; Curia et al., 2008) and 
some non-human primates (Perez-Mendes et al., 2011) injected with the muscarinic 
agonist pilocarpine show generalized, convulsive seizures. The pilocarpine model (Fig. 1) 
is a model of both status epilepticus (SE, continuous seizure activity) and mesial temporal 
lobe epilepsy (Cavalheiro et al., 1996; Curia et al., 2008). Once pilocarpine is given, a period 
of SE develops wherein the animal exhibits more or less continuous behavioral and 
electrographic seizures that last for at least 30 minutes (Cavalheiro et al., 1996; Curia et al., 
2008). There are bouts of clonic/tonic seizures that occur during this time, and it has been 
found that SE precedes a profound increase in glutamate release in the hippocampus, 
likely contributing the neurotoxicity of the model (Costa et al., 2004). Following the initial 
bout of SE, the animal goes through a silent, or latent, period during which no behavioral 
seizures occur, but significant neurological changes are occurring that allow for the 
eventual development of spontaneous, recurrent seizures (Cavalheiro et al., 1996; Estrada 
et al., 2012).
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Pentylenetetrazol model
PTZ is a convulsive agent, which is generally used to different forms of experimental 
epilepsy models. It is a selective GABA
A
 receptor channel blocker and is related with a 
decrease of GABA- mediated neurotransmission (Bambal et al., 2011). Systemic injection of 
the GABA
A
 antagonist PTZ induces primary generalized seizures. In small doses, PTZ has 
been used as a model to induce absence seizures. In wild-type mice small doses of PTZ 
(30 mg/kg, s.c.), induced absence-like seizures characterized by bilaterally synchronous 
SWDs. The letter was also found in rat models (Snead OC 3rd, 1992). A higher PTZ dose 
arise convulsive seizures, and together with the Maximal Electroshock model (MES), one 
of the most commonly used models for antiepileptic drug assessment (Pitkänen, 2006; 
Löscher, 1982). A behavioural scoring system for PTZ induced non-convulsive and 
convulsive seizures has been described (Lüttjohann et al., 2009).
Ionotropic glutamate receptors
Ionotropic receptors are transmembrane molecules that are able to “open” or “close” a 
channel. This allows smaller particles to travel in and out of the cell. As the name 
suggests, ionotropic receptors permit various types of ions to enter or leave nerve cells via 
transport molecules in the cell membrane. Ionotropic receptors are neither always 
opened nor closed. They tend to be closed until another small molecule (called a ligand 
– in our case, a neurotransmitter) binds itself to the receptor. As soon as the ligand binds 
to the receptor, the receptor alters its conformation (the protein that forms the channel 
changes its shape). As this occurs, a small opening is created that is just big enough for 
ions to travel through.
 Glutamate (and aspartate or other excitatory endogenous compounds such as 
quinolinate (QUIN) or some sulfur-containing amino acids, in addition to more potent 
selective agonists including NMDA, AMPA, kainate, ibotenic acid and domoic acid) can 
cause convulsions when focally or systemically administered to experimental animals. 
Glutamate exerts its excitatory action by way of ligand-gated ion channels (NMDA and 
non-NMDA receptors) to raise sodium and calcium conductance. Innumerable reciprocal 
regulatory interactions occur between the activation of glutamatergic receptors and 
other transmitter systems, ion transport, gene activation and receptor modification. The 
flexibility and intricacy of these interactions puts glutamate-mediated transmission in a 
crucial position for tempering the excitatory threshold of pathways that are involved in 
the generation of seizures (Moldrich et al., 2003).
 The anticonvulsant properties of ionotropic glutamate receptor antagonists have 
been scrupulously reviewed (Chapman, 1995; Meldrum and Chapman 1999a; Rogawski, 
1992). All classes of NMDA receptor antagonists (competitive NMDA antagonists, channel 
site antagonists, glycine site antagonists, polyamine site antagonists), in addition to 
competitive and noncompetitive AMPA/kainate antagonists, exhibit wide-spectrum 
anticonvulsant properties in both acute and chronic animal epilepsy models. These are 
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associated with varying degrees of behavioral side effects, which can include from 
minimal for some of the glycine site or competitive NMDA antagonists, to extensive for 
some of the high-affinity NMDA antagonists. 
 Moreover, it has been showed that injection of noncompetitive NMDA, AMPA 
receptor agonists, developed a fast dose-dependent increase in the number of SWD in 
WAG/Rij rats (Peeters et al., 1994a). And indeed noncompetitive NMDA, antagonist caused 
a dose-dependent reduction in the number of SWDs in the same  model (Peeters et al., 
1990; Peeters et al., 1994b).
Metabotropic glutamate receptors
MGlu receptors make up a family of eight subtypes that are subdivided into three groups 
based on amino acid sequence, pharmacologic profile, and G-protein coupling (Conn and Pin, 
1997). As can be seen in Fig. 3 A, group I is comprised of mGlu1 and mGlu5 receptors, 
which are coupled to Gq proteins. Their activation encourages polyphosphoinositide 
hydrolysis to form inositol-1,4,5-trisphosphate and diacylglycerol. mGlu1 and mGlu5 
receptors also control the activity within various types of calcium and potassium channels 
(Hermans and Challiss, 2001). Group II receptors (mGlu2 and mGlu3 respectively), which 
are coupled to Gi/Go proteins and negatively modulate the activity of adenyl cyclase and 
voltage-sensitive calcium channels (VSCCs). Group III (mGlu4, mGlu6, mGlu7, and mGlu8 
receptors), which are also coupled to Gi/Go proteins (Conn and Pin, 1997) (Fig. 3 A).
Figure 3A  mGlu Receptors Group I subtypes, classification, signaling and pathway.
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Localization of mGlu receptors in the network of absence seizures
mGlu receptors are located at synapses of the C-T-C network, which arise SWDs connected to 
absence seizures. This indicates that these receptors are possible targets for the treatment of 
absence epilepsy (Ngomba et al., 2011). Group I mGlu receptors are preferentially expressed in 
the peripheral portion of the postsynaptic density, where they arise excitatory responses 
and control mechanisms of synaptic plasticity. mGlu1 and mGlu5 receptors are also 
express postsynaptically on neurons of ventrobasal (VB) thalamus. Thalamic relay neurons 
in particular display a high density on their dendrites of two isoforms of mGlu1 receptors, 
specifically mGlu1a and mGlu1c receptors (Ferraguti et al., 2008), postsynaptic to axon 
terminals originating from cortical layer VI neurons (Martin et al., 1992; Shigemoto et al., 
1992; Baude et al., 1993; Godwin et al., 1996; Vidnyanszky et al., 1996; Liu et al., 1998). 
 On the other hand, mGlu2, mGlu3, mGlu4, mGlu7, and mGlu8 receptors occur 
preferentially (though not exclusively) in presynaptic terminals, where they negatively 
control neurotransmitter release (Ferraguti and Shigemoto, 2006). mGlu6 Receptors exist 
almost exclusively on retinal ON-bipolar cells, and therefore do not play a direct role in the 
C-T-C circuits (Pin and Duvoisin, 1995; Morgans et al., 2010) (Fig 3 B).
Electrophysiology of group I mGlu receptors in the network of 
absence seizures
The neocortex and thalamus have been extensively reviewed on their circuitry and the 
network properties of the connections between them (McCormick and Bal, 1997; Sherman 
and Guillery, 2002; Alexander and Godwin, 2006a). The firing patterns of thalamic neurons 
are contingent on the complex interaction between a number of fundamental 
conductances of thalamic relay cells and interneurons (McCormick and Bal, 1997; Crunelli 
et al., 2002). 
 The group I receptors’ role in modulating the excitability of thalamic relay cells has 
been well characterized on the basis of studies done on rodents and non rodents in 
numerous relay nuclei (Salt and Eaton, 1996; Alexander and Godwin, 2006a). It appears 
that under physiologic conditions these receptors take part in sensory processing by 
acting as mediators for cortical inputs back into the thalamus (Salt and Turner, 1998a; 
Rivadulla et al., 2002). Repetitive, high-frequency stimulation of cortico-thalamic afferents 
that are thought to arise from layer VI of the cortex can synaptically activate these mGlu1 
receptors (Hughes et al., 2002; Reichova and Sherman, 2004), and they can control the 
oscillatory properties of thalamic relay cells (Crunelli et al., 2002; Hughes et al., 2002). 
 The hypersynchronous oscillatory activity of thalamic relay neurons underlying SWDs 
is prolonged by the activation of T-type VSCCs, which recovers from inhibition in the 
 hyper polarizing environment created by the GABAergic input from nRT projection 
neurons (reviewed by Crunelli and Leresche, 2002; Blumenfeld, 2005). More specifically, 
the activation of mGlu1 receptors leads to an intrinsic slow (<1 Hz) oscillation in thalamic 
relay neurons, which suggests there is a role for these receptors in the production of 
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slow-wave sleep rhythms (Hughes et al., 2002). This mechanism relies on the ‘‘window’’ 
component of the T-type calcium channels - Ca2+-current and a Ca2+-activated -, 
nonselective cation current (Hughes et al., 2002). mGlu5 receptors in the thalamus have 
an excitatory effect comparable to that mediated by mGlu1 receptors. Consequently, they 
can partake in sensory responses of thalamic relay cells (Salt and Binns, 2000).
Figure 3B  Schematic diagram of the cortico-thalamo-cortical loop highlighting the 
synaptic distribution of distinct mGlu receptor subtypes. Thalamic relay neurons (light 
blue) in the ventrobasal thalamus (VB) send glutamatergic projections (triangular endings) 
to layer IV pyramidal neurons (orange) and interneurons (green) of the neocortex (blue 
box). In turn, pyramidal neurons in layer VI send topographically organized glutamatergic 
afferents back to thalamic relay neurons, and to neurons of the reticular thalamic nucleus 
(nRT, pink). Neurons of the nRT send GABAergic projections (round endings) to relay 
neurons and local collaterals to other nRT neurons. Most of these synapses are ensheathed 
by processes of astrocytes (purple). Sensory afferents (SA) to relay neurons are exemplified by 
the gray line. The subcellular distribution of distinct mGlu receptors (displayed in different 
colors, as shown in the box) is shown for specific synapses (dotted circles). Glutamatergic 
terminals are shown with blue lines and vesicles, whereas GABAergic terminals are 
depicted with red lines and vesicles. Astrocytic processes are in purple. A thicker gray line 
in the postsynaptic element defines the postsynaptic specialization of asymmetric synapses. 
mGlu1 and mGlu5 receptors are mostly present perisynaptically at asymmetrical synapses 
(Ngomba et al., 2011).
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Orthosteric vs. allosteric modulators
Various compounds have been well-developed (Table 3) that specifically target singular 
mGlu receptor subtypes or groups of subtypes. Orthosteric agonists or antagonists 
interact with the glutamate binding site expressed in the N-terminal domain of mGlu 
receptors, while the binding sites for positive and negative allosteric modulator (PAMs 
and NAMs) are most often expressed in the 7-TM domain (reviewed by Pin et al., 2005). By 
exclusively recruiting receptors activated by an endogenous ligand, such as glutamate, 
PAMs amplify the receptor’s function in the presence of an orthosteric agonist. 
Furthermore, these compounds may preserve the standard role of endogenous neu-
rotransmitters. This is specifically true for PAMs, which need the regular release of the 
endogenous neurotransmitters on the G protein-coupled receptor (GPCR). They also 
enhance neurotransmitter action in a more physiological suitable manner. Therefore, 
preserving the natural mechanisms that regulate synaptic function may elicit fewer 
adverse effects and greater efficacy than would be the case with a traditional agonist, 
which bypasses normal mechanisms for regulating synaptic transmission (Wootten et al., 
2013) (Fig. 4).
 For example, mGluR5 plays a considerable function in two opposing forms of 
synaptic plasticity in the hippocampus. These two are included by highly specific patterns 
of activity of glutamatergic afferents and are known as long-term potentiation (LTD) and 
long-term depression (LTD) of synaptic strength (Mukherjee and Manahan-Vaughan, 
2013). In fact, mGluR5 orthosteric agonists provoke profound LTD at the cost of LTP 
(Gasparini et al., 1999; Huber et al., 2001). This shift in the balance of LTP and LTD arises 
with enhanced mGluR5 function in fragile X syndrome (FXS) and is believed to lead to 
cognitive disruption in patients with FXS (Bear et al., 2004). Therefore, mGluR5 activation 
with a PAM could improve both forms of synaptic plasticity at the same time, thereby 
enhancing cognitive function (Noetzel et al., 2012; Ayala et al., 2009). This creates an ideal 
profile for increasing cognitive function, and mGluR5 PAMs certainly enhance cognitive 
function in multiple rodent models (Chan et al., 2008; Gastambide et al., 2013). 
 Remarkable is that, depending on the synapse-specific modulatory function of mGlu 
receptors, one is able to predict a better profile of safety and tolerability of the mGlu 
allosteric modulators, when compared to ionotropic (AMPA or NMDA) receptor antagonists 
(see Bruno et al., 2001). The discoveries of the mGluR1 NAM CPCOOEt (Litschig et al., 1999) 
and the mGluR5 NAM SIB-1757 (Varney et al., 1999) uncovered the first highly selective 
antagonists for any individual mGluR subtype. These developments paved the way for 
intense investigations that have yielded highly selective NAMS and PAMs for most of the 
eight mGluR subtypes (O’Brien et al., 2004; Niswender et al., 2008; Urwyler, 2011; Byun et 
al., 2014). Some of these have already been evaluated in epilepsy and seizure models. 
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Effects of mGlu ligands in animal models of convulsive epilepsies
DBA/2 mice
Older studies with two non-selective Group I mGluR antagonists ((S)-4-carboxy-3- hydroxy-
phenylglycine and (S)-4-carboxyphenylglycine) first demonstated a role for mGluR in 
epilepsy and that compounds of this group may be anticonvulsant (Thomsen et al., 1994; 
Dalby and Thomsen, 1996).
•	 Group I mGluR antagonists (phenylglycine-like) have potent anticonvulsant activity.
Figure 4  Orthosteric agonists bind to the G protein-coupled receptor (GPCR), which 
induces a conformational change that results in the activation of downstream signaling. 
Positive allosteric modulators are allosteric ligands that bind to a topographically distinct 
site to the orthosteric agonist and enhance the affinity (cooperativity factor-α) and/or 
efficacy (modulation factor-β) of the orthosteric agonist. Negative allosteric modulators 
are allosteric ligands that decrease the affinity (cooperativity factor-α) and/or efficacy 
(modulation factor-β) of the orthosteric agonist. Allosteric ligands that have no effect on 
the affinity and/or efficacy mediated by the orthosteric agonist are termed neutral 
allosteric ligands. The red arrows denote the allosteric interaction of the modulator with 
the orthosteric ligand, and the black arrows denote the allosteric interaction between the 
ligand binding sites and the effector binding site within the GPCR, resulting in downstream 
activation of signaling pathways ((this is known as orthosteric agonism: Wootten, Christopoulos 
and Sexton, 2013)).
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Pentylenetetrazol model
Previous reports found that an intracerebroventricular (i.c.v.) injection of an antagonist 
mGlu1, AIDA, showed anti-absence effects in the PTZ model (Chapman et al., 1999; Tang 
et al., 2004). Low doses of PTZ induce typical changes in the EEG characterized by trains of 
SWDs at 5 ± 7 Hz with no clear overt behavioural response. LY367385 (mGluR1 antagonist) 
and 6-Methy l-2- (phenylethynyl) pyridinehydrochloride;2-methyl-6-(phenylethynyl) 
pyridine hydrochloride; MPEP (Hydrochloride; mGluR5 antagonist) were also used in order 
to investigate their effects on PTZ induced non-convulsive seizures (Table 3). Both drugs 
exhibited antiepileptic efficacy against seizures induced by low doses of PTZ, but they 
were not effective in opposing seizures provoked by higher PTZ doses (Nagaraja and 
Grecksch, 2004), suggesting an anti-absence effect but not an anticonvulsive effect. 
 SIB 1893 (a non-competitive antagonist of group I mGluR5) given at 40 mg/kg (but 
not at 20–30 mg/kg), failed to influence PTZ-caused convulsions in mouse (Borowicz et al., 
2003, see Table 3). The selective group II mGluR agonist LY354740, administered prior to an 
injection of PTZ, generated a dose-dependent reduction in the number of mice showing 
clonic convulsions (Linden et al., 2002).
•	 Low dose PTZ is a model for absence seizures.
•	 Antagonist mGlu1 (AIDA, LY367385) and antagonist mGlu5 (MPEP) have anti-absence 
effects in low dose PTZ model.
•	 The non-competitive mGluR1 antagonist SIB 1893 failed to influence PTZ-induced 
convulsions in mice.
•	 The group II mGluR agonist LY354740 is an anticonvulsant drug as appeared from the 
high-dose PTZ model. 
Pilocarpine model
In the pilocarpine SE mouse model, Chen et al. (2005) displayed an enhanced expression 
of inhibitory mGluR4 and downregulation of excitatory mGluR1 in epileptic mice, as well 
as a reduction in the excitatory mGluR1 and 5 in wild-type C57BL/6 strain – this suggests 
differential expressions of group I and III mGluR in different groups of animals. The action 
of a Group 2 mGluR agonist, LY379268, was investigated in a series of experiments using 
the pilocarpine model. The results showed that treatment with LY379268 was effective at 
reducing both behavioral correlates and power in EEG bandwidths associated with the 
spontaneous occurring seizures (Caulder et al., 2013).
•	 The group II mGluR agonist LY379268 is an anticonvulsant in the pilocarpine mouse SE 
model.
503055-L-bw-DAmore
30  |  Chapter 1
Effects of mGlu ligands in animal models of absence epilepsies
Low dose pentylenetetrazol model
The effects of mGlu ligands in low dose PTZ model were already described above (see 
pg.30).
Lethargic mice
Group I
Blockade with the orthosteric mGlu1 receptor antagonists, AIDA or LY367385, decreases 
the SWD occurrence (Burgess et al., 1997; Chapman et al., 1999;). A functional coupling 
between T-type VSCCs and mGlu1 receptors (Hildebrand et al., 2007; 2009) may be part of 
SWD regulation by mGlu1 receptors. 
 mGlu1 receptor blockade with the orthosteric antagonists, AIDA or LY367385, reduces 
the incidence of SWDs (Chapman et al., 1999). A functional coupling between mGlu1 
receptors and T-type VSCCs (Hildebrand et al., 2007; 2009) might be involved in the 
regulation of SWDs by mGlu1 receptors. If so, this coupling might by affected by a mutated 
b4 subunit of T-type VSCCs, as occurs in lethargic mice (Burgess et al., 1999). Furthermore, 
the selective mGlu5 antagonists, MPEP, caused a marked reduction in the incidence of 
spontaneous SWDs (Ngomba et al., 2011). It has been suggested that MPEP and another 
much more selective mGluR5 antagonist and to a lesser degree, an agonist of mGluR4, 
SIB-1893, both in vitro and in vivo act as NMDA receptor antagonists at somewhat higher 
doses than are required for mGlu5 antagonism (O’Leary et al., 2000; Movsesyan et al., 
2001). Activation of mGlu5 receptors enables the triggering of NMDA receptors, and vice 
versa (Salt and Binns, 2000; Bertaso et al., 2010). This interaction could explain the 
protective activity of MPEP, at least in lh/lh mice, because the NMDA receptor blockade 
may also decrease SWDs (Peeters et al., 1990; Coenen and van Luijtelaar, 2003). For an 
overview of the effects of group I ligands on the incidence of SWDs see Table 3.
•	 mGluR1 antagonist (AIDA or LY367385) and mGluR5 antagonist (MPEP) have an anti- 
absence action in the lethargic mice absence model. 
Group II
The activity of mGlu2/3 receptor ligands is not uniform in different animal models of 
absence seizures. To illustrate, in lh/lh mice, activation of mGlu2/3 receptors with the selective 
group II mGlu receptor agonist, LY379268, minimized absence seizure occurrences 
(Moldrich et al., 2001) while in WAG/Rij rats, the same agonist increased the incidence of 
SWDs (Ngomba et al., 2005). These opposite results might be explained if it is assumed 
that mGlu2 and mGlu3 receptors have distinct roles in the pathophysiology of absence 
seizures, and they are differentially expressed in lethargic mice and WAG/Rij rats. 
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Group III 
•	 The absence of optimal subtype selective ligands has hampered the study of the 
function of individual group III mGluRs.
WAG/Rij rats
Group I
•	 The role of  group I metabotropic receptor agonist/antagonist in the WAG/Rij absence 
model will be evaluated in this thesis. 
Group II 
Previously it was found that symptomatic 6-month-old WAG/Rij rats exhibited an 
enhanced expression of mGlu2/3 receptors in the ventrolateral area of the somatosensory 
cortex (Ngomba et al., 2005). This includes the putative SWDs’ “triggering zone” (Meeren 
et al., 2002). There was also an increase in receptor expression in the ventrobasal (VB) 
thalamus and in the hippocampus, but not  in the nRT. 
 LY379268, an orthosteric agonist, is almost inert at mGlu1, mGlu4, mGlu5 and mGlu7 
receptors, and binds to mGlu8 receptors with micromolar affinity. By comparison, the 
orthosteric antagonist LY341495 binds all mGlu receptor subtypes at micromolar concentrations 
(reviewed by Johnson et al., 1999). It was found that the agonist LY379268 in WAG/Rij 
largely enhanced the number of SWDs (Ngomba et al., 2005). LY341495, a drug that 
behaves as a preferential antagonist of these receptors, decreased SWDs in WAG/Rij rats.
•	 The orthosteric agonist LY379268  has  a pro-absence action.
•	 The orthosteric antagonist LY341495 has  an anti-absence action. 
Group III 
WAG/Rij rats display an enhanced prevalence of pathological SWDs when treated with 
the selective mGlu4 receptor enhancer, N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen- 
1a-carboxamide (PHCCC) (Ngomba et al., 2008). The mGlu4 receptor gene in humans is 
localized at a susceptibility locus for juvenile myoclonic epilepsy (Izzi et al., 2003; Wong et al., 
2001), which is characterized by absence seizures, as well as by myoclonus and tonic-clonic 
seizures. The mGlu7 receptor, another group-III mGlu receptor, is also related to the 
development of absence seizures:  mGluR7 knockout mice develop absence seizures 
when mGlu7 receptors are unable to interact with PICK1 (protein interacting with C kinase 
1) (Bertaso et al., 2008; Zhang et al., 2008). The same occurs with mice injected with a 
peptide that disturbs the interaction between PICK1 and mGlu7 receptors (Bertaso et al., 
2008). Compounds for mGlu7 receptors have not yet been developed and this fact has 
limited studies on the function of mGlu7 receptors in animal models of absence epilepsy.
•	 The selective mGlu4 receptor enhancer PHCCC  has a pro-absence action. 
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Effects of group I mGlu receptor modulators in epilepsy
In Table 3 the pro- and anticonvulsant activity of group I modulators is shown. Several 
ligands have been developed which specifically target singular mGlu receptor subtypes 
or groups of subtypes. Orthosteric agonist of Group I are proconvulsive agents, while all 
orthosteric antagonist are both anticonvulsant as well as anti absence drugs. A charming 
approach may be to exploit the development of new ligands such as subtype-selective 
PAMs or NAMs, in order to establish the functions of mGlu receptors during activation by 
endogenous glutamate in a physiologic environment. First of all, based on the outcomes 
of Table 3, in which the action of Group I orthosteric agonists and antagonists is compared 
between convulsive and non-convulsive epilepsy, it is striking that  group I antagonist 
have the same pharmacological epilepsy reducing effects in convulsive and in non- 
convulsive epilepsy. This agrees with the proconvulsive action of the orthosteric agonists, 
while their effects in non-convulsive epilepsy have not been assessed. As can be seen in 
Table 3, in lh/lh mice and in low dose PTZ, group I antagonists are anti-absence, thus, 
decreasing epilepsy. By extrapolating from this, we predict that a selective modulator 
such as a group I NAM  might have an anti-absence and a selective PAM a pro-absence 
effect. 
Overview of all metabotropic compounds in two absence epilepsy 
models
An overview of different metabotropic compounds (agonist/antagonist) administered in 
lh/lh mice and WAG/Rij rat is presented in Table 4. Here, what is shown are the pharmaco-
logical effects of agonist or antagonist of group I/II/III in terms of SWDs incidence in both 
animal models. Based on the outcomes of Table 4, it can be seen that the role of mGluR 
receptors is not uniform in two different absence epilepsy models. Indeed, agonists of 
group II are anti absence drugs in the lh/lh model, in WAG/Rij rat the same agonists are 
pro absence, while, group II/III antagonist are anti absence in the WAG/Rij model. In lh/lh 
mice, no group I or III agonist has been exposed to test, and until now no group I agonist 
or antagonist has been tested in the WAG/Rij model. Considering the location of mGluR 
in the C-T-C network and the effects in the mice model, it might be expected that  group 
I PAMs/NAMs could exert an effect on  SWDs. More specifically, a Group I agonist should 
be pro-absence since the antagonists hava an anti-absence action. Another way of 
reasoning and also based on the results as presented in Table 4 regarding the opposite 
action of group II drugs (as has been demonstrated for LY379268) in the two models and 
the opposite action of Group I and Group II agonists on absence epilepsy, a anti-absence 
action is predicted for Group I agonists in the WAG/Rij model. 
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Possible clinical use of metabotropic allosteric modulators
So far, no GPCR allosteric modulators have been authorized for the treatment of psychiatric 
and neurological disorders. On the other hand, multiple allosteric modulators have been 
submitted for clinical development. mGlu5 receptor PAMs are already being developed 
for use in the treatment of schizophrenia, with the only concern being the neurotoxicity 
and convulsive seizures provoked by very high doses of these compounds (Parmenti-
er-Batteur et al., 2014). Phase II clinical trials have recently revealed promising effects of 
mGluR5 NAMs when treating anxiety and affective disorders, Parkinsons’s disease and 
fragile X syndrome (Emmitte, K.A. a patent review 2010-2012; Rocher et al., 2011). 
Aim and outline of the thesis
The aim of this thesis:
The experiments, as described in this thesis investigate the involvement of group I mGluR 
(mGluR1 and mGluR5 respectively) in the pathophysiology of absence epilepsy. This will 
be done in a well-established and often used model: rats of the WAG/Rij strain. The role of 
this class of receptors will be investigated by establishing their expression and signaling in 
the brain regions where the pathological SWDs initiate, spread and are maintained: the 
Table 4   1Burgess et al., 1997; 2Chapman et al., 1999; 3Chapman et al., 2000; 4Lojkova´ and 
Mares., 2005; 5Cheong et al., 2009; 6Ngomba et al., 2005; 7Moldrich et al., 2001; 
8Ngomba et al., 2008; 9Ngomba et al., 2011.
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C-T-C network. Furthermore, a series of pharmacological EEG-behavioural studies will be 
carried out with the aim to establish whether PAMs or NAMs of this group can be 
developed as putative anti-absence drugs. These compounds might be useful as drugs 
for the treatment of absence epilepsy, in particular for those patients who are refractory to 
conventional treatment. In tangible terms, the following steps are taken to realize the 
above goals:
 In Chapter 2 the role of type-1 mGluR in the occurrence on SWDs will be evaluated. 
First the expression and signaling of mGlu1 receptors will be evaluated in thalamic nuclei.
Immunohistochemical techniques will be used for a precise localization of the mGlu1 
receptor expression seen in symptomatic rats in the dorsal, medial and lateral complex of 
the thalamus of WAG/Rij and control rats. An in vivo method (in situ hybridization), the 
DHPG-stimulated PI hydrolysis, will be used in order to evaluate whether mGlu1 receptor 
signaling is odd in the thalamus of WAG/Rij rats. Next, the effects of the selective receptor 
mGlu1 enhancer SYN119 at the doses of 3, 10 and 30 mg/kg, s.c., and with an antagonist, 
JNJ16259685 (2.5 and 5mg/kg, i.p.) on the SWDs occurrence in symptomatic 8-month-old 
rats will be examined. Finally, in order to see if motor side effects occur after  drug 
administration, the behavior of the rats will be quantified before, as well as after drug 
administration. 
 In Chapter 3 the role of mGlu5 receptors in absence epilepsy will be  elucidated. The 
study will be  extended to mGluR5, by using a novel enhancer, the VU0360172 PAM, which 
may adjust the abnormalities in mGlu5 receptor signaling without recruiting “silent” 
mGlu5 receptors that might arise dose-related adverse effects as the orthosteric 
compounds does. It should be emphasized that more than 20% of patients with absence 
epilepsy syndrome and those with atypical absence seizure are refractory to conventional 
medications (reviewed Niswender and Conn, 2010). 
 From a therapeutic stand point of view, it is crucial to establish whether putative 
anti-epileptic drugs will develop tolerance since medication will be given chronically. 
Establishing tolerance is important for the preclinical and clinical development of mGlu 
receptor PAMs for the treatment of absence epilepsy in humans. 
 In Chapter 4 tolerance will be investigated. VU0360172 (mGlu5 PAM) or RO0711401 
(mGlu1 PAM) will be  given to rats twice a day for ten days, followed by a 2 day wash out 
period, then a challenge with each of the two drugs will be performed after 3 days of 
withdrawal. EEG and behavior will be recorded during all days of the study. 
 In order to explain the receptor selectivity in the adaptive changes caused by the 
two PAMs, pharmacodynamic effects of the two compounds will be established in a 
parallel study, in which the expression of mGlu1α and mGlu5 receptors in the thalamus 
and cortex will be measured. This analysis will also be carried out on non epileptic Wistar 
rats treated with the two drugs. Next, the concentration of RO0711401 and VU0360172 in 
cortex and thalamus via Liquid Chromatography–tandem mass spectrometry analysis will 
be evaluated. 
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 In Chapter 5 a C-T-C circuit demarcation strategy will be adopted by independent 
bilateral intra-cortex or intra-thalamus micro-infusions to investigate site-specific effects 
on the regulation of SWDs in symptomatic WAG/Rij rats. In order to do so, a micro-infusion 
of RO0711401 or VU030172 PAMs will be performed. Moreover, it is well known that not 
only the glutamatergic neurotransmission is known to be one of the causes responsible 
for the initiation and spread of seizures, but also the GABAergic neurotransmission and 
often glutamate and GABA interact at the same synapses. Therefore tiagabine, a GABA 
reuptake inhibitor at the neuronal or glial GAT-1 transporter, will be micro-injected and in 
combination with VU0360172 to examine whether GABA alone, or in combination with 
VU0360172, and in which direction, an enhanced availability of extra-synaptic GABA 
influences responses to VU0360172, in thalamus and somatosensory cortex. 
 In Chapter 6  ‘‘Is there a future for mGlu5 PAMs in absence epilepsy? a comparison 
with Ethosuximide’’, is made. Here the need for new treatment options in absence 
epilepsy is emphasized since 47% of subjects treated with ETX failed in therapy. The 
assumed working mechanisms of ETX, the neurochemical and pharmacological studies 
of the new anti-absence drugs mGlu1 and mGlu5 PAMs, RO0711401 and VU0360172, are 
described and also a comparison between ETX and VU0360172 is fully given.
 Chapter 7: it is often difficult good to get good seizure control with only a single 
antiepileptic drug and therefore interaction studies between different antiepileptic drugs 
are indicated. Moreover, antiepileptic drugs may alter cognition and psychomotor 
functioning. A primary goal of epileptology is to recognize treatments that are not just 
symptomatic, but disease-modifying. It is well known that ESM has become the drug of 
choice in the treatment of patients with absence seizures taking into account its efficacy, 
tolerability and antiepileptogenic properties in man and in genetic absence models. Here 
it will be investigated if anti-epileptogenesis, induced by chronic ESM interacts with the 
putative anti-absence drug VU0360172. Next, a biochemistry analysis of the receptors 
expression will be done in cortex and thalamus in young presymptomatic WAG/Rij rats 
and in the chronically ESM treated rats. Finally, a learning task was performed to investigate 
the impact of antiepileptogenesis on cognition.
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Abstract
We examined the expression and function of mGlu1 receptors in the thalamus of WAG/Rij 
rats, which develop spontaneous absence seizures at >3 months of age. Reduced mGlu1 
receptor mRNA levels were found in a thalamic region comprising the LDVL/LPMR 
thalamic nuclei (ventrolateral part of the laterodorsal thalamic nucleus/mediorostral part 
of the lateral posterior thalamic nucleus) of symptomatic 8-month old WAG/Rij rats as 
compared to pre-symptomatic 2-month old WAG/Rij rats or age-matched non-epileptic 
control rats. mGlu1 receptor mRNA levels were undetectable in the reticular thalamic 
nucleus (RTN). Immunoblot and immunohistochemical analysis of mGlu1α receptor 
protein confirmed the reduction of mGlu1 receptor expression in thalamic relay nuclei of 
symptomatic WAG/Rij rats. mGlu1 receptor signalling was also reduced in the thalamus of 
8-month old WAG/Rij rats, as assessed by measurements of agonist-stimulated polyphos-
phoinositide hydrolysis in living animals. Moving from these findings, we examined 
whether pharmacological activation of mGlu1 receptors could affect the epileptic 
phenotype of WAG/Rij rats. Systemic treatment with the selective mGlu1 receptor 
enhancer, SYN119 (10 mg/kg, s.c.; corresponding to RO0711401), substantially reduced the 
incidence of spike and wave discharges (SWDs) in WAG/Rij rats without affecting SWD 
duration or spontaneous motor activity. In contrast, treatment with the mGlu1 receptor 
antagonist, JNJ16259685 (2.5 and 5 mg/kg, i.p.), enhanced the incidence of SWDs. These 
data suggest that absence epilepsy might be associated with a reduction of mGlu1 
receptors in the thalamus, and that compounds that amplify the activity of mGlu1 
receptors might be developed as novel anti-absence drugs.
Keywords: Absence seizures; “in vivo” mGlu1 receptors signalling; spike and wave discharges; 
WAG/Rij rats.
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Introduction
A growing body of evidence suggests a role for metabotropic glutamate (mGlu) receptors 
in the pathophysiology of absence epilepsy, characterized by spontaneous seizures and 
spike-wave discharges (SWDs) in the electroencephalogram. mGlu receptors form a 
family of eight subtypes (mGlu1-8) subdivided into three groups on the basis of their 
amino acid sequence, pharmacological profile, and transduction mechanisms. Group I 
includes mGlu1 and mGlu5 receptors, which are coupled to G
q
/G
11
 proteins and are 
predominantly localized in the peripheral portion of postsynaptic densities. Group II 
includes mGlu2 and mGlu3 receptors, which are coupled to G
i
/G
o
 proteins and are 
localized in the pre-terminal region of axon terminals, where they negatively regulate 
neurotransmitter release. Group III includes mGlu4, mGlu6, mGlu7, and mGlu8 receptors, 
which are also coupled to G
i
/G
o
 proteins in heterologous expression systems. mGlu4, 
mGlu7, and mGlu8 receptors are presynaptically localized near the active zone of neu-
rotransmitter release; mGlu6 receptors are exclusively expressed by ON bipolar cells of the 
retina. mGlu3 and mGlu5 receptors are also present in astrocytes (reviewed by Niswender 
and Conn, 2010). Studies with chemical and genetic models of absence epilepsy have 
consistently shown that the mGlu4 receptor has a permissive role in the development of 
absence seizures. Mice with genetic deletion of mGlu4 receptors show abnormalities in 
excitatory and inhibitory neurotransmission in the corticothalamic network underlying 
absence seizures (Wang et al., 2005), and are resistant to chemically induced absence 
seizures (Snead et al., 2000). Wistar Albino Glaxo from Rijswijk (WAG/Rij) rats, which provide 
a validated genetic rat model of absence epilepsy (Coenen and van Luijtelaar, 2003; van 
Luijtelaar and Sitnikova, 2006), show an increased incidence of pathological SWDs when 
treated with the selective mGlu4 receptor enhancer, N-phenyl-7-(hydroxyimino)
cyclopropa[b]chromen-1a-carboxamide (PHCCC) (Ngomba et al., 2008). In humans, the 
mGlu4 receptor gene is localized at a susceptibility locus for juvenile myoclonic epilepsy 
(Izzi et al., 2003; Wong et al., 2001), which is characterized by absence seizures in addition 
to myoclonus and tonic-clonic seizures. Another group-III mGlu receptor, the mGlu7 
receptor, is also associated with the development of absence seizures. Mutant mice in 
which mGlu7 receptors fail to interact with PICK1 (protein interacting with C kinase 1) 
develop absence seizures (Bertaso et al., 2008; Zhang et al., 2008), as do mice injected with 
a peptide that disrupts the interaction between mGlu7 receptors and PICK1 (Bertaso et al., 
2008). The precise mechanism whereby interaction between mGlu7 receptors and PICK1 
restrains SWDs in the corticothalamic network remains to be determined. The role of 
mGlu2 and mGlu3 receptors in absence seizures is controversial. Pharmacological 
blockade of mGlu2/3 receptors reduces the incidence of SWDs in WAG/Rij rats, whereas 
treatment with a selective mGlu2/3 receptor agonist increases absence seizures in these 
rats (Ngomba et al., 2005). In contrast, the activation of mGlu2/3 receptors reduces the 
occurrence of absence seizures in lethargic mice (Moldrich et al., 2001), these mice show 
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an epileptic phenotype because of a mutation in the gene encoding the β4 subunit of 
voltage-sensitive calcium channels (Burgess et al., 1999). 
 mGlu1 receptors are highly expressed in thalamic relay neurons (Baude et al., 1993; 
Ferraguti et al., 2008; Godwin et al., 1996; Liu et al., 1998; Martin et al., 1992; Shigemoto et 
al., 1992; Vidnyanszky et al., 1996), which are part of a thalamocortical loop involved in the 
generation of absence seizures (reviewed by Blumenfeld, 2005; van Luijtelaar and 
Sitnikova, 2006). However, evidence linking mGlu1 receptors to the development of 
absence seizures is still indirect and controversial. Deletion of phospholipase C beta4 
(PLCβ4) in thalamocortical relay nuclei leads to absence seizures  in mice (Cheong et al., 
2009). PLCβ4 colocalizes with mGlu1 receptors, and mediates mGlu1 receptor signalling in 
thalamic nuclei (Miyata et al., 2003; Watanabe et al., 1998). The hypothesis that an impaired 
mGlu1 receptor signalling in the thalamus facilitates the development of absence seizures is 
not in line with data obtained in lethargic mice, where treatment with orthosteric mGlu1 
receptor antagonists reduces the occurrence of SWDs (Burgess et al., 1997; Chapman 
et al., 1999). We therefore decided to examine in detail the possible link between mGlu1 
receptors and spontaneous absence seizures using WAG/Rij rats as a model. We report 
that symptomatic 8-month old WAG/Rij rats show a reduced expression and signalling of 
mGlu1 receptors in thalamic nuclei, and that pharmacological activation of mGlu1 
receptors with a selective enhancer reduces the incidence of spontaneous absence 
seizures. Part of these data have been presented in Abstract form (Ngomba et al., 2009).   
Methods 
Drugs
JNJ16259685((3,4-dihydro- 2H-pyranol [2,3-b]quinolin-7yl) (cis-4-methoxycycloexyl) 
methanone), DHPG (3,5-dihydroxyphenylglycine), MPEP (2,methyl-6-(phenylethynyl)- 
pyridine), and diazepam were purchased from Tocris Cookson Ltd. (Bristol, UK); SYN119 
(9H-xanthene-9-carboxylix acid (4-trifluoromethyl-oxazol-2-yl) amide, corresponding to 
RO0711401, was kindly provided by Synosia Therapeutics Ltd (Basel, Switzerland). 
JNJ16259685 was dissolved in saline containing 10% hydroxypropyl-b-cyclodextrin, and 
injected i.p.. SYN119 was dissolved in peanut oil, and injected s.c.. 
Animals
Male WAG/Rij and ACI (Augouti Copenhagen Irish) rats were kept under environmentally 
controlled conditions (ambient temperature = 22 oC, humidity = 40%) in a room with 
reversed light-dark cycle (light on from 8:00 p.m. to 8:00 a.m.), with food and water ad 
libitum. Experiments were carried out during the dark phase of the cycle in which WAG/
Rij rats have the largest amount of SWDs (van Luijtelaar and Coenen, 1988). All animals 
were handled prior to EEG registrations. For biochemical studies, age matched ACI rats 
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were used as controls; rats of this strain have no or at least very few SWDs and in all cases 
they have much fewer SWDs than do WAG/Rij rats of the same age (Inoue et al., 1990; 
Schridde & van Luijtelaar, 2004). Of all inbred rats investigated, ACI rats have the lowest 
number of SWDs (Inoue et al., 1990). Therefore, ACI rats are commonly used as controls in 
experiments with WAG/Rij rats (Ngomba et al., 2008; van Rijn et al., 2010). We used both 
strains of rats at 2 or 8 months of age. WAG/Rij rats of 2 months of age do not show SWDs 
as yet, and, therefore, are considered “presymptomatic”. This study was performed in 
accordance with the guidelines of the European Community for the use of experimental 
animals. Approval of the local ethics committee for animal studies was obtained.
Analysis of mGlu1 receptor
In situ hybridization of mGlu1 receptor mRNA
In situ hybridization was carried out as described previously (Simonyi et al., 2005). Twelve 
micron coronal sections were fixed in 4% paraformaldehyde/phosphate-buffered saline 
(PBS) for 5 min, rinsed in PBS, and soaked in 0.25% acetic anhydride in 0.1M triethanol-
amine hydrochloride/0.9% NaCl (pH 8.0) for 10 min. Sections were rinsed in 2 X SSC (300 
mM NaCl/30 mM sodium citrate), dehydrated through a graded series of ethanol, 
delipidated in chloroform, rehydrated to 95% ethanol and air-dried. Fifty microliters of 
hybridization buffer was applied to each slide, covered with a coverslip, and incubated at 
42oC overnight. The hybridization buffer contained 50% formamide, 4 X SSC, transfer RNA 
(250 μg/ml), sheared, single-stranded salmon sperm DNA (100 μg/ml), 1 X Denhardt’s 
solution (0.02% BSA, Ficoll, and polyvinylpyrrolidone), 10% (w/v) dextran sulfate (MW 
500,000), 50 mM DTT and 1 X 106 cpm probe. Probes were 3’ end-labeled by terminal de-
oxynucleotidyl transferase (Roche, Indianapolis, IN) with 35S-dATP (NEN, Boston, MA). The 
probe for metabotropic glutamate receptor 1 subtype was the same as in our earlier 
publications (Simonyi et al., 2005). The oligomer sequence of the mGlu1 receptor probe 
was complementary to cDNA sequence 1450-1495 (Masu et al., 1991) and it recognizes all 
the splice variants of mGlu1 receptor. After hybridization, coverslips were removed in 1 X 
SSC. Slides were washed in 1 X SSC (2 mM DTT) at 55oC for 4 X 15 min.  Following two 30 
min rinses in 1 X SSC at room temperature, the tissues were dipped in distilled water, 
immersed in 70% ethanol and air-dried. All tissues to be evaluated by a single statistical 
test were included in the same hybridization. Slides were held against KODAK BIOMAX 
MR films with standards (American Radiolabeled Chemicals Inc., St. Louis, MO) in X-ray 
cassettes. Microdensitometry was performed on the signal over different brain regions 
using the BIOQUANT True Color Windows 95 software version 2.50, as previously 
described (Simonyi et al., 2005). [14C]-Microscale standards were used to construct 
calibration curves and quantitate signals in nCi/g tissue equivalents. The average density 
measured from experimental regions fell within the linear range of the standards. 
Background signal was subtracted from all measurements. Values were averaged from 
the analysis of two sections for each animal (5-6 per group) before being evaluated for 
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statistical significance. The Paxinos and Watson atlas (2005) was used for identification of 
brain nuclei. Sections were examined by two independent operators who were not aware 
of the experimental protocol.
Western blot analysis of mGlu1 receptors
Male WAG/Rij and matched control ACI rats of 2 or 8 months of age were anesthetized 
with ether, decapitated and brains were rapidly removed from the skulls and frozen. Brains 
from each rat were coded and codes were released after Western blot analysis. Brains 
were frontally dissected on a cryostat, and a thalamic portion containing the reticular 
thalamic nucleus (RTN) or another portion containing all other thalamic nuclei (referred to 
as “ventrobasal” – VB – thalamus) were manually dissected out under the guide of the 
Paxinos and Watson atlas (2005). To examine the specificity of the mGlu1α antibody, we 
also performed immunoblot analysis on brain regions dissected from 2-month old male 
homozygous mutant mice carrying the cervelet-4 (crv4) mutation or age-matched BALB/c 
control mice. Homozygous crv4 mice are characterized by the absence of the mGlu1 
receptor protein due to the insertion of a 190-bp LTR fragment in intron 4 of the Grm1 
gene (Conti et al., 2006). Tissue was homogenized at 4°C in 50 mM Tris-HCl buffer, pH 7.4, 
containing 1 mM EDTA, 1% Triton X-100, 1 mM PMSF, 1 μg/ml aprotinin, 1 μg/ml pepstatin, 
and 1 μg/ml leupeptin. After sonication, 2 μl of total extracts were used for protein 
determinations. One hundred micrograms of protein extract were resuspended in 
SDS-bromophenol blue reducing buffer with 40 mM DTT. Western blot analyses were 
carried out by loading 35 μg of total proteins per lane into 8% SDS polyacrylamide gels, 
which were electroblotted on immunblot PVDF membranes (BioRad, Milano, Italy). The 
PVDF membranes were blocked overnight in TBS-T buffer (100 mM Tris-HCl; 0.9% NaCl, 
0.1% Tween 20, pH 7.4) containing 5% non-fat dry milk. Blots were then incubated for 1 h 
at room temperature with rabbit polyclonal anti-mGlu1α antibodies (1:500, Upstate 
Biotechnology, Lake Placid, NY) and a mouse monoclonal antibody to label β-actin 
(1:100.000, Sigma, St. Louis, MO). Filters were washed with TBS-T buffer and then incubated 
for 1 hour with secondary antibodies (peroxidase-coupled anti-rabbit or anti-mouse; 
1:7000; Amersham, Piscataway, NJ). Immunoreactivity was revealed by ECL.
Immunohistochemistry
Brains from WAG/Rij rats, ACI rats, homozygous crv4 mice, and BALB/c control mice were 
fixed in Carnoi, embedded in paraffin, and sectioned at 10 µm. Subsequently, 
deparaffinized sections were treated in 10 mM, pH 6.0, citrate buffer, and heated by 
microwave for 10 min for antigen retrieval, and immersed in 3% H
2
O
2
 for 10 min to quench 
endogenous peroxidase activity. The slides were allowed to cool for 20 min in the same 
solution at room temperature and then washed in TBS. The antibodies were dissolved in 
TBS containing 2% normal goat serum. Sections were preincubated for 1 hour with 
normal goat serum (Vector Laboratories, Burlingame, CA) and with polyclonal anti-mGlu1α 
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antibodies (Upstate Biotechnology; 1:50), and then for 1 hour with secondary biotinylated 
anti-goat antibodies (1:200; Vector Laboratories). 3,3-Diaminobenzidine tetrachloride was 
used for detection (ABC Elite kit; Vector Laboratories). Control staining was performed 
without the primary antibodies. Intensity of mGlu1α immunoreactivity in three thalamic 
regions (see Fig. 3b) was quantified by measuring the relative optical densities. Images 
were acquired at low magnification (2.5x) and the densitometric analysis was performed 
by assessing the intensity of the background values (i.e. the optical density measured in 
unlabeled areas present in the section, such as corpus callosum).
The optical density values were obtained from the dorsal complex , D  = [lateral posterior 
thalamic nucleus, mediorostral part (LPMR) + laterodorsal thalamic nucleus, ventrolateral 
part (LDVL) + laterodorsal thalamic nucleus, dorsomedial part (LDDM)], the medial 
complex, M =[posterior thalamic nuclear group (Po) + the internal ventroposteromedial 
part (VPM)] and lateral complex, L = [ventroposterolateral (VPL) nucleus] (see Fig. 3b).
In vivo experiments
Measurement of DHPG-stimulated polyphosphoinositide (PI) hydrolysis in living rats 
ACI and WAG/Rij rats were anesthetized with ketamine (100 mg/kg) plus xylazine (10 mg/
kg) and injected with [myo-3H]inositol (2 µCi/5 µl/2 min, i.c.v.). Twenty-four hours later, rats 
were treated with lithium ions (administered as LiCl, 10 mmol/kg, s.c.) to inhibit the 
conversion of inositol monophosphate (InsP) into free inositol. The mGlu1/5 receptor 
agonist, DHPG (500 nmol/5 µl saline containing 50% dimethyl sulfoxide), was injected 
i.c.v., 1 hour after LiCl injection. Control rats were injected with the vehicle alone. The 
selective mGlu5 receptor antagonist, MPEP (10 mg/kg), and diazepam (10 mg/kg) – used 
as an anti-convulsant - were injected i.p. 30 min before DHPG. Rats were killed 1 hour after 
treatment with DHPG or vehicle. The thalamus was quickly removed and stored at -80°C. 
On the day of the assay, tissue was sonicated in 1.25 ml of water containing 10 mM LiCl. 
After centrifugation at 10,000 x g for 20 min, the [3H]InsP present in the supernatant was 
separated by anion exchange chromatography in 10 ml columns containing 1.5 ml of 
Dowex 1-X-8 resin (formate form, 100–200 mesh; Bio-Rad). Columns were washed twice 
with water, once with a solution of 5 mM sodium tetraborate and 40 mM sodium formate 
to elute cyclic InsP and glycerophosphoinositols, and then with 6.5 ml of 0.2 M ammonium 
formate and 0.1 M formic acid for the elution of InsP (Nicoletti et al., 1986). Total radioactivity 
in the brain regions was determined by counting a 100 µl aliquot of the whole 
homogenate. 
EEG recordings
Male WAG/Rij rats (8-month old) with a mean body weight of 390 ± 17 g, were used. 
Animals were individually housed in Macrolon cages in a room illuminated with white 
lights from 8:00 p.m. to 8:00 a.m.. A permanent cortical tripolar electrode set was 
implanted under complete isoflurane anesthesia, one electrode into the frontal region 
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(coordinates with the skull surface flat and from bregma zero-zero, AP +2.0; L -2.5), and the 
other in the parietal region (A -6.0; L -4.0) (Paxinos and Watson, 2005). The ground 
electrode was placed over the cerebellum. After the surgery, animals were allowed to 
recover for two weeks. Rats were put into transparent recording cages, connected to an 
EEG cable which allowed free movement, and habituated to the experimental conditions 
for 12 h. The EEG was filtered (only frequencies between 0.1 and 100 Hz, were allowed to 
pass, digitalized with a sample frequency of 512 Hz, and stored for an off-line analysis 
using Windaq system (DATAQ Instruments, Akron, OH, USA). Baseline EEG was recorded 
during the dark period (9:00-10:00 a.m) for 1 hour prior to injection and thereafter, 
following injection of the selective mGlu1 receptor antagonist, JNJ16259685 (2.5 or 5 mg/
kg, i.p.) and the mGlu1 receptor positive allosteric modulator (PAM), SYN119 (3 or 10mg/kg, 
s.c.), or vehicle. The post injection EEG was registered during the next 6 hours. SWDs were 
marked at visual inspection based on commonly used criteria: trains of sharp spikes and 
slow waves lasting minimally 1 sec, the amplitude of the spikes minimally twice the 
background, frequency of the SWDs between 7 and 10 Hz and an asymmetric appearance 
of the SWDs (van Luijtelaar and Coenen, 1986).
Recording of spontaneous motor activity
As previously reported by van Rijn et al. (2010), spontaneous motor activity in symptomatic 
WAG/Rij rats was recorded by means of an analogic passive infrared detector (PIR) (Luna 
PR, Rokonet Electronics LTD, Rishon Le Tzion, Israel). The analog signal was digitalized 
simultaneously with the EEG signal. Movements were quantified by calculating the mean 
of the absolute value of the PIR signal per hour. The value of the post injection hours of 
each separate animal was related to the mean baseline value of all animals.
Results
Reduced expression of mGlu1 receptors in the ventrobasal 
thalamus of symptomatic WAG/Rij rats
We examined the expression of mGlu1 receptor mRNA by in situ hybridization using a 
pan-probe that detects all receptor variants. Data obtained in the somatosensory cortex, 
thalamic relay nuclei, dorsal striatum, and hippocampal dentate gyrus (DG), CA1 and CA3 
regions are shown in Table 1. Background level hybridization signal was observed in the 
reticular thalamic (RT) nucleus (not shown), whereas intense labelling was detected in all 
thalamic relay nuclei, in agreement with previous studies (Shigemoto and Mizuno, 2000). 
mGlu1 receptor mRNA levels did not change in any brain region between control rats at 
2 and 8 months of age and between control rats and pre-symptomatic WAG/Rij rats at 
2 months of age. mGlu1 mRNA levels were lower in LDVL/LPMR thalamic nuclei (ventrolateral 
part of the laterodorsal thalamic nucleus/mediorostral part of the lateral posterior 
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thalamic nucleus) of symptomatic 8-month old WAG/Rij rats as compared to either 
age-matched control rats or pre-symptomatic 2-month old WAG/Rij rats. No changes in 
mGlu1 receptor mRNA levels were found in the ventroposterolateral (VPL) thalamic 
nucleus, somatosensory cortex, and hippocampal subregions of 8-month old WAG/Rij 
rats as compared with all other groups of rats (Table 1).
 We examined the expression of mGlu1α receptor protein using a polyclonal antibody 
that recognizes the C-terminus domain of the receptor. The specificity of the antibody has 
been tested by immunoblotting and immunohistochemistry using brain tissue from 
wild-type mice or from cervelet-4 (crv4), homozygous mutant mice lacking the mGlu1 
receptor protein (Conti et al., 2006). Immunoblot analysis showed a prominent expression 
of mGlu1α receptors in the cerebellum and thalamus of wild-type mice, as shown by a 
band of about 140 kDa, which likely corresponds to receptor monomers, and a higher 
molecular size band, which may correspond to receptor dimers. Receptor expression was 
lower in the olfactory bulb and cerebral cortex of wild-type mice, as expected (Shigemoto 
and Mizuno, 2000). The receptor was virtually absent in all brain regions of crv4 mice (Fig. 1A). 
These data were paralleled by immunohistochemical analysis, which showed a prominent 
mGlu1α receptor immunostaining in the cerebellum and thalamus of wild-type mice, and 
no staining in crv4 mice, with the exception of some staining in the external portion of 
the cerebellar cortex, which may be non-specific (Fig. 1B). Expression data of the mGlu1α 
receptor in the ventrobasal thalamus of WAG/Rij rats and their controls are shown in Fig. 2. 
Immunoblot analysis showed that expression of mGlu1α receptor was lower in the 
thalamus (dissected out as in Fig. 2A) of 8-month old WAG/Rij rats, as compared to either 
Table 1   In situ hybridization analysis of mGlu1 receptor mRNA levels in selected brain 
regions of controls (ACI rats and WAG/Rij rats at 2 and 8 months of age.
503055-L-bw-DAmore
56  |  Chapter 2
2-month old WAG/Rij rats and 8-month old control rats (Fig. 2B,C). Expression of mGlu1α 
receptors was nearly undetectable in a more lateral portion of the thalamus cut inside-out 
from the internal border of the RTN (not shown). Immunohistochemical analysis (Fig. 3A) 
showed that the reduced expression of mGlu1α receptors observed in 8-month old 
sympthomatic WAG/Rij rats was restricted to portions of the thalamus comprising LDVL 
and LPMR (D = dorsal complex), or the posterior thalamic nuclear group (Po) and the 
internal part of the ventroposteromedial (VPM) nucleus (M = medial complex). The 
intensity of immunostaining was not different in a more external portion of the thalamus 
including the ventroposterolateral (VPL) nucleus (L = lateral complex) (Fig. 3B,C).
Reduced mGlu1 receptor signalling in the thalamus of 
symptomatic WAG/Rij rats
To examine whether mGlu1 receptor function was defective in the thalamus of 
symptomatic WAG/Rij rats, we used an in vivo method that allows measurements of ago-
nist-stimulated PI hydrolysis after incorporation of [3H]inositol into the phospholipids of 
living rats (Molinaro et al., 2009). Eight-month old WAG/Rij rats and their age-matched 
controls were injected i.c.v. with [3H]inositol and treated, 24 hours later, with litium ions to 
inhibit the conversion of [3H]InsP into free [3H]inositol. Afterwards, rats were treated 
Figure 1  Reduced mGlu1 receptor signalling in  the thalamus of symptomatic WAG/Rij 
rats. In vivo measurements of PI hydrolysis in the thalamus of 8-month old WAG/Rij rats 
and age-matched controls (ACI rats) was carried out as outlined in (A). PtdIns-4,5,P
2
 = 
phosphatidylinositol-4,5-bisphosphate; Ins-1,4,5-P3 = inositol-1,4,5-trisphosphate; InsP = 
inositolmonophosphate; hrs = hours. (B) DHPG-stimulated PI hydrolysis in the thalamus of 
WAG/Rij (n = 5 animals per group). *p < 0.05 (Student’s t test) vs. values obtained in 
controls rats. Basal values of [3H] InsP formation normalized by the amount of total 
radioactivity in each sample were 1.66 ± 0.05 and 1.64 ± 0.12 (means ± S.E.M.)  in  the 
thalamus of ACI and WAG/Rij rats, respectively.
A B
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Figure 2  Reduced expression of mGlu1a receptors in the thalamus of symptomatic WAG/
Rij  rats: immunoblot analysis. Specificity of the antibody used for the detection of mGlu1α 
receptors is shown in A-B. Western blot analysis of mGlu1a receptors in different regions of 
wild-type (WT) BALB/c mice and homozygous crv4 mice is  shown in (A). mGlu1a 
immunostaining in a sagittal section of the whole brain of WT and crv4 mice is shown in 
(B). Scale bar ¼ 1 mm. The portion of the thalamus dissected for immunoblot analysis is 
shown in (C). Note that the RTN is excluded from this area. A representative immunoblot 
showing the expression of mGlu1a receptors in the thalamus of 2- and 8-month old  WAG/ 
Rij rats and age-matched controls (ACI rats) is shown in (D). Densitometric analysis is 
shown in (E), where values are means ± S.E.M. of 5e6 determinations. *p < 0.05 (One-way 
ANOVA þ Fisher’s PLSD) vs. all other values.
A
B
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E
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systemically with a cocktail of MPEP (to prevent the activation of mGlu5 receptors) and 
diazepam (to prevent convulsive seizures), followed by i.c.v, injection of the mGlu1/5 
receptor agonist, DHPG (Fig. 4A). Treatment with DHPG increased PI hydrolysis by >2.5 fold 
in the thalamus of 8-month old ACI control rats, and only by 80% in 8-month old WAG/Rij 
rats (Fig. 4B). Thus, mGlu1-receptor mediated PI hydrolysis was reduced by about 50% in 
the thalamus of symptomatic WAG/Rij rats as compared to age-matched controls.
Figure 3  Reduced expression of mGlu1a receptors in the thalamus of symptomatic WAG/
Rij rats: immunohistochemical analysis. A representative mGlu1a immunostaining in the 
thalamus of 8-month old WAG/Rij rats and age-matched controls (ACI rats) is shown in (A), 
where arrowheads indicate the regions of reduced immunolabeling in WAG/Rij rats (scale 
bar = 250 mm). The thalamic regions selected for densitometric analysis are shown in (B), 
and densitometric data are shown in (C). Values are means ± S.E.M. and were calculated 
from the average of 8 coronal sections for each animal (n = 6 animals per group). *p < 0.05 
(Student’s t test) vs. the corresponding values obtained in  control rats.
A
B C
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Figure 4  Pharmacological activation of mGlu1 receptors reduces the incidence of SWDs 
in WAG/Rij rats. A representative EEG recording of SWDs is shown in (A) where segments 
of recording at an expanded timescale is marked by the black bars. The incidence of 
SWDs in 8-month old WAG/Rij rats treated systemically with vehicle or two different doses 
of the mGlu1 receptor PAM, SYN119, is shown in (B), (C) and (D). Mean duration of SWDs in 
WAG/Rij rats treated with vehicle or with the higher doses of SYN119 (10 mg/kg and 30 
mg/kg) are shown in (E) and (F). Values are means ± S.E.M. of 6-8 animals. p < 0.05 (ANOVA 
for repeated measures followed by Dunn’s t test) vs. the corresponding values at baseline 
(T0) (*) or vs. the corresponding values obtained in WAG/Rij  rats treated with vehicle (#).
A
C D
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Pharmacological activation of mGlu1  receptor reduces the  
incidence of SWDs in WAG/Rij rats
To examine the impact of mGlu1 receptors on the occurrence of spontaneous absence 
seizures, 8-month old WAG/Rij rats were treated systemically with compound SYN119 
(3 or 10 mg/kg, s.c., corresponding to RO0711401), which behaves as a selective PAM of 
mGlu1 receptors (Vieira et al., 2009). By definition, a PAM exclusively amplifies receptors 
that are activated by endogenous glutamate (or by another orthosteric agonist), thus 
acting in a activity-dependent fashion. We used SYN119 at doses that are known to be 
centrally active (Fazio et al., 2008). EEG was recorded in WAG/Rij rats for 1 hour at baseline 
(T0) and then for 6 hours following SYN119 administration. A typical EEG recording of 
SWDs in WAG/Rij rats is shown in (Fig. 5A). Treatment with vehicle invariably led to an 
increase in the incidence of SWDs in the first hour, followed by a reduction afterwards. 
Figure 5  Pharmacological inhibition of mGlu1 receptors enhances the incidence of SWDs 
in WAG/Rij rats. The incidence of SWDs in 8-month old WAG/Rij rats treated systemically 
with vehicle or two different doses of the mGlu1 receptor NAM, JNJ16259685 (JNJ) is 
shown in (A). Values are means ± S.E.M. of 8 animals per group. p < 0.05 (ANOVA for 
repeated measures followed by Dunn’s t test) vs. the corre- sponding values at baseline 
(T0) (*); vs. the corresponding values obtained in rats treated with vehicle (#); or vs. the 
corresponding values obtained in rats treated with lower dose of JNJ16259685 (x). Mean 
duration of SWDs and spontaneous motor activity in WAG/Rij rats treated with vehicle or 
both doses of JNJ16259685 are shown in (B) and (C), respectively.
A
C
B
503055-L-bw-DAmore
mGluR1 and absence epilepsy  |  61
2
This increase might reflect the stress associated with the injection as corticosteroids tend to 
enhance SWDs (Schridde and van Luijtelaar, 2004). Treatment with the highest dose of 
SYN119 (10 mg/kg) significantly reduced the incidence of SWDs at all times. After the first 
hour, the incidence of SWDs was significantly lower than that recorded at baseline (Fig. 5B,C). 
Treatment with the lowest dose of SYN119 (3 mg/kg) significantly reduced the incidence 
of SWDs only during the first hour (Fig. 5B). This indicated that a dose of SYN119 of 10 mg/kg 
was required for a substantial reduction in the incidence of absence seizures in WAG/Rij 
rats, whereas the dose of 3 mg/kg of SYN119 could only abolish the early stress-related 
increase in the incidence of SWDs. At the most effective dose (10 mg/kg) SYN119 had no 
effect on the mean duration of single SWD episodes (Fig. 5D), and showed only marginal 
and non-significant effects on spontaneous motor activity (Fig. 5E). To further demonstrate a 
protective role for mGlu1 receptors against spontaneous absence seizurers, additional groups 
of 8-month old WAG/Rij rats were systemically injected with compound JNJ16259685 (2.5 
or 5 mg/kg, i.p.), which behaves as a selective negative allosteric modulator (NAM) of 
mGlu1 receptors. Treatment with JNJ16259685 increased the incidence of SWDs in a 
Figure 6  Pharmacological inhibition of mGlu1 receptors does not alter baseline EEG 
recordings in ACI rats. Representative EEG recordings from ACI rats shown in (AeC); The 
EEG segments were extracted from recordings during baseline (A) and from the second 
hours post injection of either vehicle (B) or 10 mg/kg, i.p. of JNJ16259685 (C).
A
B
C
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dose-dependent manner. The incidence of SWDs was increased by as much as 5 fold in 
the first 2 hours after treatment with the highest dose of JNJ16259685 (Fig. 6A). Again, 
treatment with the mGlu1 receptor NAM did not change neither the mean duration of 
SWDs (Fig. 6B) nor the spontaneous motor activity (Fig. 6C) in WAG/Rij rats.
Discussion
WAG/Rij rats are widely used as a genetic animal model of absence epilepsy. After 3 
months of age, these rats develop generalized bilateral SWDs (frequency: 7-9 Hz; duration 
of 1-30 sec) associated with behavioural manifestations that mimic those of the human 
petit male attack (Coenen and van Luijtelaar, 2003; van Luijtelaar and Sitnikova, 2006). The 
incidence of SWDs in WAG/Rij rats is reduced by typical anti-absence drugs, such as 
ethosuximide and valproate, and is increased by drugs that are known to aggrevate 
absence epilepsy, such as phenytoin, carbamazepine, and vigabatrine (Bouwman et al., 
2007; Coenen and van Luijtelaar, 2003; Peeters et al., 1989). Thus, this model is particularly 
helpful for the study of the pathophysiology of absence seizures, and has predictive value 
for the clinical development of new anti-absence drugs. We have shown here that 
symptomatic (8-month old) WAG/Rij rats show a reduced expression and function of 
mGlu1 receptors in the thalamus as compared to non-epileptic control rats, and respond 
to the amplification of residual mGlu1 receptors with a selective PAM with a reduced 
incidence of absence seizures. In contrast, selective pharmacological blockade of mGlu1 
receptors increased the incidence of absence seizures. Remarkably, we have demonstrated 
the reduction of mGlu1 receptor signalling in the thalamus of WAG/Rij rats using a method 
that allows the detection of agonist-stimulated PI hydrolysis in living animals (Molinaro et 
al., 2009). Rats were injected i.c.v. with radioactive inositol, and treated with DHPG and 
MPEP to selectively activate mGlu1 receptors. This method is highly reliable and avoids 
the bias of the slice preparation for the evaluation of receptor signalling. The reduction of 
mGlu1-receptor stimulated PI hydrolysis found in the thalamus of WAG/Rij rats is in nice 
agreement with the evidence that deletion of PLCβ4 (the enzyme activated by mGlu1 
receptors) in thalamic relay nuclei leads to absence seizures (see Introduction and 
references therein). Taken together, our data strongly suggest that mGlu1 receptors have 
a protective function against absence seizures and that WAG/Rij rats develop absence 
seizures because of an age-dependent reduction in the expression and function of 
thalamic mGlu1 receptors. The mGlu1 receptor PAM may relieve absence seizures by 
amplifying the activation of residual thalamic mGlu1 receptors. The advantage of the PAM 
is that it recruits only those mGlu1 receptors that are activated by the endogenous 
glutamate, thereby acting in an activity-dependent manner. 
 Absence seizures are generated within a cortico-thalamo-cortical loop that comprises 
ventrobasal (VB) thalamic relay neurons, the triggering zone in the somatosensory cortex 
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(Meeren et al., 2002), cortical pyramidal neurons and interneurons, and inhibitory neurons 
of the reticular thalamic (RT) nucleus and their anatomical connections. The cortex (layer 
V and VI) send excitatory glutamatergic projections to the RTN and ventrobasal complex, 
at his turn VB thalamic neurons send excitatory glutamatergic projections to cortical 
pyramidal neurons and RTN, RT neurons send inhibitory GABAergic connections to VB 
thalamic neurons but not to the cortex. RT neurons are also connected to each other via 
inhibitory GABAergic synapses and gap junctions (Blumenfeld, 2005; van Luijtelaar and 
Sitnikova, 2006; Zhang and Jones, 2004). Thalamocortical neurons produce two distinct 
firing patterns that are thought to reflect the status of signal transmission from the 
thalamus to the cortex. Tonic firing is believed to represent a relay mode of afferent 
sensory signals to the cortex (McCormick and von Krosigk, 1992). On the contrary, 
low-threshold burst firing has been related to drowsy/sleeps states or decrease of 
consciousness associated with absence seizures (Crunelli and Leresche, 2002; Yu and 
Blumenfeld, 2009). At least two splice variants of mGlu1 receptors, mGlu1α and mGlu1αre-
ceptors (Ferraguti et al., 2008), are present at high levels on dendrites of thalamic relay 
neurons, postsynaptic to axon terminals originating from cortical layer VI neurons (Baude 
et al., 1993; Godwin et al 1996; Liu et al., 1998; Martin et al., 1992; Shigemoto et al., 1992; 
Vidnyanszky et al., 1996). Activation of mGlu1 receptors in thalamic relay neurones causes 
a slow depolarising response mediated by the reduction of a potassium conductance, 
and may participate in sensory processing by mediating cortical inputs back into the 
thalamus (Crunelli et al., 2002; Hughes et al. 2002; Reichova and Sherman 2004; Rivadulla 
et al., 2002; Salt and Turner, 1998; Turner and Salt 2000). Thus, mGlu1 receptors are critically 
localized to regulate the firing rate and oscillatory properties of thalamic relay neurons. 
Neurons of the RT nucleus do not express mGlu1 receptor mRNA (Shigemoto et al., 1992), 
whereas, in the cortex, postsynaptic mGlu1 receptors are found in GABAergic interneurons, 
but not in pyramidal cells (Stinehelfer et al., 2000). The role for cortical mGlu1 receptors in 
the overall activity of the thalacocortical network remains to be examined.  
 The abnormal hypersychronous oscillatory activity of thalamic relay neurons that 
underlies absence seizures is sustained by a pathological activity of T-type voltage-sensi-
tive Ca2+ channels (VSCCs), which recover from inhibition in the hyperpolarizing milieu 
generated by the GABAergic input from RT projection neurons (reviewed by Blumenfeld, 
2005). Interestingly, recent evidence indicates that mGlu1 receptors are functionally 
coupled to T-type VSCCs in both heterologous expression systems and dendritic spines of 
Purkinje cells (Hildebrand et al., 2009). In recombinant expression systems, mGlu1 receptor 
modulation is subtype-specific, potentiating Ca
v
3.1 and Ca
v
3.2 isoforms while inhibiting 
Ca
v
3.3 T-type channels (Hildebrand et al., 2009). Inhibition of Ca
v
3.3 T-type VSSCs is shared 
by muscarinic receptors coupled to Gq/G
11
 protein, and appears to involve the βγ subunits 
of the G protein (Hildebrand et al., 2007; 2009). The possibility that mGlu1 receptors 
modulate T-type VSCCs in thalamic relay neurons is attractive and warrants further 
investigation. A functional coupling between mGlu1 receptors and T-type VSCCs in the 
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thalamus might contribute to explain the difference between our data obtained in WAG/
Rij rats and data obtained by Burgess et al. (1997) and Chapman et al. (1999) in lethargic 
mice, which respond to treatment with orthosteric mGlu1 receptor antagonists with a 
reduction of absence seizures. Lethargic mice have a mutated β4 subunit of VSCCs 
(Burgess et al., 1999), which might affect the modulation of T-type VSCCs by mGlu1 
receptors in thalamic relay neurons. 
 Subtype-selective ligands of mGlu receptors are under clinical development for the 
treatment of a variety of neurological and psychiatric disorders (reviewed by Nieswender 
and Conn, 2010). Phase I and II clinical studies suggest that mGlu receptor ligands are in 
general well tolerated and devoid of the CNS adverse effects that are typically seen with 
ionotropic glutamate receptor antagonists. Thus, in principle, mGlu1 receptor PAMs might 
be developed for the treatment of patients with absence epilepsy that are refractory to 
conventional medication. However, it should be highlighted that mGlu1 receptors 
mediate synaptic transmission and plasticity at the synapse between parallel fibres and 
Purkinje cells in the cerebellar cortex, and genetic deletion or blockade of mGlu1 receptors 
causes ataxia and other cerebellar motor symptoms (Aiba et al., 1994; Marignier et al., 
2010; Sillevis Smitt et al., 2000). Although we never observed motor incoordination in 
WAG/Rij rats treated with the mGlu1 receptor PAM, we cannot exclude that a chronic 
activation of mGlu1 receptors in Purkinje cells may disrupt cerebellar function and motor 
learning.
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Abstract
Absence epilepsy is generated by the cortico-thalamo-cortical network, which undergoes 
a finely tuned regulation by metabotropic glutamate (mGlu) receptors. We have shown 
previously that activation of mGlu1 receptors reduces spontaneous spike and wave 
discharges (SWDs) in the WAG/Rij rat model of absence epilepsy, whereas activation of 
mGlu2/3 and mGlu4 receptors produces the opposite effect. Here, we have extended the 
study to mGlu5 receptors, which are known to be strongly expressed within the cortico- 
talamo-cortical network. WAG/Rij rats showed a reduction in the mGlu5 receptor protein 
levels and in the mGlu5-receptor mediated stimulation of polyphosphoinositide 
hydrolysis in the ventrobasal thalamus, whereas the expression of mGlu5 receptors was 
increased in the somatosensory cortex. Interestingly, these changes preceded the onset 
of the epileptic phenotype, being already visible in pre-symptomatic WAG/Rij rats. 
Absence seizures in 8-month old WAG/Rij rats were not influenced by pharmacological 
blockade of mGlu5 receptors with MTEP (10 or 30 mg/kg, i.p.), but were drastically 
decreased by mGlu5 receptor activation with the novel enhancer, VU0360172-6 (3 or 
10 mg/kg, i.p.). The action of VU0360172-6 was prevented by co-treatment with MTEP. 
These findings suggest that changes in mGlu5 receptors might lie at the core of the 
 absence-seizure prone phenotype of WAG/Rij rats, and that mGlu5 receptor enhancers 
are potential candidates to the treatment of absence epilepsy.
Keywords: Absence epilepsy, WAG/Rij rats, mGlu5 receptor, VU0360172-6
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1. Introduction
Typical absence epilepsy is a generalized non convulsive form of epilepsy characterized 
by bilaterally synchronous spike and wave discharges (SWDs) that spreads all-over the 
cortex as seen on the electroencephalogram (reviewed by Blumenfeld, 2005). SWDs are 
generated within a cortico-thalamo-cortical loop that comprises cortical pyramidal 
neurons and GABAergic interneurons, thalamic relay neurons, and inhibitory neurons of 
the reticular thalamic nucleus (nRT) and neurons of the nRT are also connected to each 
other via inhibitory GABAergic synapses as well as by gap junctions (reviewed by 
Blumenfeld, 2005; Meeren et al., 2002; Polack et al., 2009). The cortex (layer V and VI) send 
excitatory glutamatergic projections to the nRT and thalamic relay neurons send 
excitatory glutamatergic projections to cortical pyramidal neurons and nRT. The nRT 
neurons send inhibitory GABAergic connections to thalamic relay neurons but not to the 
cortex (Zhang and Jones, 2004; Blumenfeld, 2005; van Luijtelaar and Sitnikova, 2006). The 
nature of SWDs generated within the cortico-thalamo-cortical network has led to several 
debates on which anatomical area might be held as an initiation site and pioneer studies 
have tentatively put together the importance of the thalamus (Jasper and Kershman, 
1941) and the cerebral cortex (Avoli and Gloor, 1982) as key players. These studies have 
demonstrated that there is an aberrant function within the cortico-thalamo-cortical loop 
that contributes to the pathophysiology of absence seizure. In this loop the metabotropic 
glutamate (mGlu) receptors are particularly positioned to modulate rather than mediate 
synaptic transmission and are therefore potential targets for the management of SWDs 
(reviewed by Ngomba et al., 2011a). Group-I mGlu receptors (mGlu1 and mGlu5 receptors) 
are coupled to Gq/G11 proteins and are predominantly localized in the peripheral portion 
of postsynaptic densities. Their activation stimulates polyphosphoinositide hydrolysis 
with formation of inositol-1,4,5-trisphosphate and diacylglycerol, and also regulate the 
activity of different types of calcium and potassium channels (reviewed by Nicoletti et al., 
2011). mGlu1 and mGlu5 receptors show a different pattern of distribution in the cortico- 
thalamo-cortical network, which suggests distinct rather than complementary functions 
of these two receptor subtypes. High densities of mGlu1 receptors are found on dendrites 
of thalamic relay neurons that receive afferent input from cortical layer VI neurons 
(Ferraguti et al., 2008; reviewed by Ngomba et al., 2011a). In the cortex, mGlu1 receptors 
appear to be exclusively expressed postsynaptically on GABAergic interneurons 
(Stinehelfer et al., 2000). Moreover, it has been shown that activation of mGlu5 receptors 
has an excitatory effect similar to that mediated by mGlu1 receptors and that these 
receptors can participate in sensory responses of thalamic relay cells (Salt and Binns, 2000). 
Thalamic relay neurons also expressed mGlu5 receptors at dendrites postsynaptic to 
cortical inputs (Romano et al., 1995; Liu et al., 1998). Neurons of the nRT also show 
moderate- to-low expression of mGlu5 receptors (Romano et al., 1995; Lourenço Neto et 
al., 2000). In the cerebral cortex, mGlu5 receptors are expressed by pyramidal neurons 
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postsynaptic to thalamo-cortical projections (Wijetunge et al., 2008), as well as by 
interneurons (Romano et al., 1995; Sun et al., 2009). We have recently examined the role of 
mGlu1 receptors in absence seizures using Wistar Albino Glaxo/Rijswijk (WAG/Rij) rats as a 
genetic model of absence epilepsy. WAG/Rij rats develop spontaneous SWDs at >2 
months of age, and at 5-6 months of age they all have hundreds of SWDs per day (Coenen 
and van Luijtelaar, 1987; Schridde and van Luijtelaar, 2004). In these rats, generalized 
bilateral SWDs are characterized by a frequency of 7-9 Hz and duration of 1-30 sec, and are 
associated with behavioural manifestation mimicking those of absences in humans 
(Coenen and van Luijtelaar, 2003; van Luijtelaar and Sitnikova, 2006). SWDs in WAG/Rij rats 
are reduced by classical anti-absence drugs, such as ethosuximde and valproate, and are 
increased by vigabatrin and carbamazapine, which worsen absence seizures in humans 
(Bouwman et al., 2007; Coenen and van Luijtelaar, 2003; Peeters et al., 1989). Thus, WAG/Rij 
rats represent a model of absence epilepsy endowed with construct, face, and pharmaco-
logical validity. We have reported that mGlu1 receptors are down-regulated in the ventral 
basal thalamus of symptomatic WAG/Rij rats, and that pharmacological activation of mGlu1 
receptors reduces SWDs in these rats (Ngomba et al., 2011b). We have now extended the 
study to mGlu5 receptors, finding that receptor expression and function change in the 
thalamus and somatosensory cortex of both pre-symptomatic and symptomatic WAG/Rij 
rats, and that a selective mGlu5 receptor enhancer drastically reduce absence seizures.
2. Materials and methods
2.1. Drugs
VU0360172-6 (N-cyclobutyl-6-[2-(3-fluorophenyl)ethynyl]pyridine-3-carboxamide) was obtained 
from Vanderbilt University Medical Center, JNJ16259685 (( 3,4-dihydro-2H-pyranol [2,3-b] 
quinolin-7yl) (cis-4-ethoxycycloexyl)methanone),DHPG (3,5 dihydroxyphenylglycine), MTEP3- 
((2-Methyl-1,3-thiazol-4-yl) ethynyl) pyridine hydrochloride, and diazepam were purchased 
from Tocris Cookson Ltd. (Bristol, UK); VU0360172-6 was dissolved in 10% Tween 80, and 
injected s.c.. MTEP was dissolved in saline, and injected i.p..
2.2. Animals
Male WAG/Rij and ACI (Agouti Copenhagen Irish) rats were kept under environmentally 
controlled conditions (ambient temperature = 22 °C, humidity = 40%) in a room with 
reversed light-dark cycle (light on from 8:00 p.m. to 8:00 a.m.), with food and water ad 
libitum. Experiments were carried out during the dark phase of the cycle in which WAG/Rij 
rats have the largest amount of SWDs (van Luijtelaar and Coenen, 1988). All animals were 
handled prior to EEG registrations. For biochemical studies, age-matched ACI rats were 
used as controls. ACI rats have no or only very few SWDs and the lowest number of SWDs 
of all inbred strains investigated as was assessed in a 48 h EEG evaluation study (Inoue et 
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al., 1990) and in all cases they have much less SWDs than WAG/Rij rats of the same age 
(Schridde and van Luijtelaar, 2004). Therefore, ACI rats are commonly used as controls in 
experiments with WAG/Rij rats (Lasoń et al., 1992; Ngomba et al., 2008; van de Boven-
kamp-Janssen et al., 2006; van Rijn et al., 2010). We used rats of both strains at 2 and 8 
months of age. WAG/Rij rats of 2 months of age do not show SWDs as yet, and, therefore, 
are considered “pre-symptomatic”. All 8 months old WAG/Rij rats have about 16–20 SWDs 
per hour, which is a few hundred SWDs per day, and are thus defined as “symptomatic”. 
This study was performed in accordance with the guidelines of the European Community 
for the use of experimental animals and approved by the local ethics committee for 
animal studies (RU-DEC).
2.3  Immunoistochemisrty
Brains from WAG/Rij and ACI rats were fixed in Carnoy’s solution (60% ethanol, 10% acetic 
acid, and 30% chloroform), embedded in paraffin and cut into sections of 10 mm. 
Deparaffinised sections were pre-incubated for  1 h in normal goat serum for 1 h (vector 
laboratories, Burlingame, CA), then incubated overnight with polyclonal rabbit anti- 
mGluR5 (1:100; Millipore, Billerica, MA) antibody dissolved in 10% of PBS and then for  1 h 
with secondary biotin-coupled anti-rabbit antibody (1:200; Vector Laboratories, Burlingame, 
CA). 3,3-Diaminobenzidine tetrachloride (Sigma Aldrich, Milan, Italy) was used for detection. 
Control staining was carried out without the primary antibody. The  intensity of mGlu5 
immunoreactivity in cortical and thalamic regions (see Fig.1) was quantified by  measuring 
the relative optical densities. Brain coronal sections of 350 mm were sliced from bregma 
-1.3 mm to -4.8 mm. Images were acquired at low magnification (2.5x) and the 
densitometric anal- ysis was performed by assessing the intensity of the background 
values (i.e., the optical density measured in unlabelled areas present in the section, such 
as corpus callosum) by using Zeiss Axio Imager M1 microscope equipped with a motorized 
stage and focus control system (Zeta axis), and with a digital video camera.
2.4. Western blot analysis of mGlu5 receptors
Male WAG/Rij and matched control ACI rats, 2 or 8 month old, were anesthetized with 
ether, decapitated and brains were rapidly removed and frozen. Brains were coded and 
the codes were released after Western blot analysis. Whole brains were placed on a 
cryostat and tissue that comprises the principal area of the cortico-thalamo-cortical 
network were dissected out using the coronal diagrams (between coordinates from 
bregma -1.88 mm and - 3.80 mm) from Paxinos and Watson atlas (2005) as a guide. For 
cortical areas, we dissected out a part of the cortex that includes primary somatosensory 
cortex (S1) and another portion of the cortex that includes primary motor cortex (M1). 
Then,  the thalamus was dissected into two separate parts, one containing the reticular 
thalamic nucleus (nRT) and the second containing all other thalamic nuclei, as previously 
described (Ngomba et al., 2008, 2011b). Cortical areas 2 mm anterior and posterior from 
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the above mentioned cortical areas were dissected out and used as control regions. 
Moreover, the hippocampus, which is thought not to be involved in the pathogenesis of 
absence seizures was also dissected. The expression of mGlu5 receptor proteins was 
estimated by Western blot analysis, using a specific rabbit polyclonal antibody (1:1.000, 
Upstate Biotechnology, Lake Placid, NY) and a mouse monoclonal antibody to label 
β-actin (1:100.000, Sigma, St.Louis, MO). Brain tissues were homogenized at 4 °C in 50 mM 
Tris-HCl buffer, pH 7.4, containing 1 mM EDTA, 1% Triton X-100, 1 mM PMSF, 1 mg/ml 
aprotinin, 1 mg/ml pepstatin, and 1 mg/ml leupeptin. Proteins were resuspended in 
SDS-bromophenol blue reducing buffer with 40 mM DTT. Western blot analyses were 
carried out using 8% SDS polyacrylamide gels which were electroblotted on immunblot 
PVDF membranes (BioRad, Milano, Italy); filters were blocked overnight in TBS-T buffer 
containing 5% non fatty milk. Blots were incubated for 1 h with rabbit polyclonal anti- 
mGlu5 antibodies and mouse monoclonal antibody to label β-actin. Filters were washed 
with TBS-T buffer and then incubated for 1 h with secondary antibodies (peroxidase- 
coupled anti-rabbit or anti-mouse, Amersham, Piscataway, NJ) diluted 1:7000 with TBS-T 
buffer. Immunostaining was revealed by enhanced ECL.
2.5. Measurement of DHPG-stimulated polyphosphoinositide (PI) 
hydrolysis in living rats
ACI and WAG/Rij rats were anesthetized with ketamine (100 mg/kg) plus xylazine (10 mg/
kg) and injected with [myo-3H]inositol (2 μCi/5 μl/2 min, i.c.v.). Twenty-four hours later, rats 
were treated with lithium ions (administered as LiCl, 10 mmol/kg, s.c.) to inhibit the 
conversion of inositol monophosphate (InsP) into free inositol. The mGlu1/5 receptor 
agonist, DHPG (500 nmol/5 μl saline containing 50% dimethyl sulfoxide) was injected i.c.v., 
1 h after LiCl injection. Control rats were injected with the vehicle alone. The selective 
mGlu1 receptor antagonist JNJ16259685 (10 mg/kg) and diazepam (10 mg/kg) used as an 
anti-convulsant drug, were injected i.p. 30 min before DHPG. Rats were killed 1 h after 
treatment with DHPG or vehicle. The sensorymotor cortex and the thalamus were quickly 
removed and stored at −80 °C. On the day of the assay, tissue was sonicated in 1.25 ml of 
water containing 10 mM LiCl. After centrifugation at 10,000 g for 20 min, the [3H] InsP 
present in the supernatant was separated by anion exchange chromatography in 10 ml 
columns containing 1.5 ml of Dowex 1-X-8 resin (formate form, 100–200 mesh; Bio-Rad). 
Columns were washed twice with water, once with a solution of 5 mM sodium tetraborate 
and 40 mM sodium formate to elute cyclic InsP and glycerophosphoinositols, and then 
with 6.5 ml of 0.2 M ammonium formate and 0.1 M formic acid for the elution of InsP 
(Nicoletti et al., 1986). Total radioactivity in the brain regions was determined by counting 
a 100 μl aliquot of the whole homogenate.
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Figure 1  Immunohistochemical analysis of mGlu5 receptors in the cortico-thalamic- 
cortical network of ACI and WAG/Rij rats. Representative mGlu5 receptor immunostaining 
in the cortex (M1 and S1) and thalamus (nRT and VB) of ACI and WAG/Rij rats at 2 and 
8 months of age are shown in (A) and (D), respectively. The densitometric analysis was 
performed in M1, S1, nRT and VB (the areas are delineated with black discontinuous 
illustrative boxes in A, D). Data of densitometric analysis are shown in (B, C, E, F). Values are 
means ± S.E.M. and were calculated from the average of 5 coronal sections for each 
animal (n = 6 animals per group). *p < 0.05 vs the corresponding values obtained in the 
same strain at 2 months, #p < 0.05 vs. the corresponding values obtained in ACI rats at 
8 months.
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2.6. EEG recordings
Male WAG/Rij rats (8-month old) with a mean body weight of 390 ± 20 g, were used. 
Animals were individually housed in Macrolon cages in a room illuminated with white 
lights from 8:00 p.m. to 8:00 a.m. A permanent cortical tripolar electrode set was implanted 
under complete isoflurane anesthesia, one electrode into the frontal region (coordinates 
with the skull surface flat and from bregma zero–zero, AP +2.0; L −2.5), and the other in the 
parietal region (A −6.0; L −4.0) (Paxinos and Watson, 2005). The ground electrode was 
placed over the cerebellum. After the surgery, animals were allowed to recover for two 
weeks. Rats were put into transparent recording cages, connected to an EEG cable which 
allowed free movement, and habituated to the experimental conditions for 12 h. The EEG 
was filtered (only frequencies between 0.1 and 100 Hz, were allowed to pass, digitalized 
with a sample frequency of 512 Hz, and stored for off-line analysis using Windaq system 
(DATAQ Instruments, Akron, OH, USA). Baseline EEG was recorded during the dark period 
(9:00–11:00 a.m.) for 2 h prior to injection and thereafter, following the systemic injection 
of the selective mGlu5 receptor positive allosteric modulator, VU0360172-6 (3 or 10 mg/kg, 
s.c., dissolved in tween) and the mGlu5 receptor antagonist, MTEP (10 or 30 mg/kg, i.p., 
dissolved in saline), or vehicle in a volume of 1 ml. The post injection EEG was registered 
during the next 5 h. SWDs were marked at visual inspection based on commonly used 
criteria: trains of sharp spikes and slow waves lasting minimally 1 s, an amplitude of the 
spikes at least twice the background, frequency of the SWDs between 7 and 10 Hz and an 
asymmetric appearance of the SWDs (van Luijtelaar and Coenen, 1986).
2.7. Animal behaviour: recording of spontaneous motor activity
Spontaneous motor activity in symptomatic WAG/Rij rats was recorded with an analogic 
passive infrared detector (PIR) (Luna PR, Rokonet Electronics LTD, Rishon Le Tzion, Israel) 
(van Rijn et al., 2010) during the EEG recording session. The  analogue signal was digitalized 
simultaneously with the EEG signal. In order to check whether the drugs induced behavioural 
effects and whether the putative drug effects on SWDs could be ascribed to effects on 
behaviour considering the initmate relation- ship between the behavioural state of the 
animal and the occurrence of SWDs (Drinkenburg et al., 1991; Smyk et al., 2011), the amount 
of bodily movements in the baseline and after drug administration were quantified by 
calculating the mean of the PIR signal per hour.
2.8. Statistical analysis
Data are expressed as means ± SEM. Statistical analysis for Western blot and immunohis-
tochemistry was carried out by a two-way ANOVA, with the rat strain and age as 
independent factors, while Student’s t-test was used for the analysis of DHPG-stimulated 
PI hydrolysis. Statistical analysis of EEG and behavioural data was carried out by ANOVA for 
repeated measures followed by the Bonferroni’s test to isolate the differences.
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Figure 2  Immunoblot analysis of mGlu5 receptors in the ventrobasal thalamus and 
sensorymotor cortex of ACI and WAG/Rij rats. Representative immunoblot of mGlu5 
receptors in the ventrobasal thalamic nuclei (A), somatosensory cortex (C) and motor 
cortex (E) of 2- and 8-month old ACI or WAG/Rij rats are shown. Densitometric analysis is 
shown in (B), (D), and (F), respectively. Statistical analysis was carried out by two-way 
ANOVA, with the rat strain and age as variable factors. Values are means ± S.E.M. (n = 8 
animals per group). Post hoc analysis: *p < 0.05 vs. age-matched control ACI rats. In each 
individual blot, protein extracts from rats of each experimental group were loaded in 
order to obtain relative comparisons among the groups.
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3.  Results
3.1. Expression of mGlu5 receptors in the cortico-thalamo-cortical 
network of ACI and  WAG/Rij rats at  2 and  8 months of age
Immunohistochemical analysis of mGlu5 receptors in the sen- sorymotor cortex and 
thalamus of ACI and WAG/Rij rats at 2 and 8 months of age is shown in Fig. 1A and D, 
respectively. In the motor and somatosensory cortices of non-epileptic ACI rats, expression of 
mGlu5 receptors decreased with age, being lower at 8 than at 2 months of age. In contrast, 
expression of mGlu5 receptors in the motor and somatosensory cortices of WAG/Rij rats 
did  not change with age. Eight-month old symptomatic WAG/Rij rats showed a significant 
increase in mGlu5 receptor immunoreactivity in the motor and somatosensory cortices as 
compared to age-matched ACI rats (Fig. 1B and C). A trend to an increased immuno-
reactivity was also seen in 2-month old presynthomatic WAG/Rij rats with respect to 
age-matched ACI rats. However, this difference did not reach statistical significance (Fig. 
1B and C). In contrast, 8-month old WAG/Rij rats showed a reduction in mGlu5 receptor 
immuno- reactivity in both the nRT and ventrobasal thalamic nuclei (VB). In the nRT, 
mGlu5 receptor immunoreactivity was significantly lower in 8-month old WAG/Rij rats 
than in 2-month old WAG/Rij rats (Fig. 1E), In the VB, a significant reduction was found 
between 8- month old WAG/Rij rats and age-matched ACI rats (Fig. 1F). A nonsignificant 
trend to a reduction in mGlu5 receptor immunore- activity was also seen in  the VB of 
2-month old WAG/Rij rats, as compared to ACI rats of corresponding age (Fig. 1F).
 We also carried out immunoblot analysis of mGlu5 receptors on protein extracts 
from the motor cortex, somatosensory cortex, and VB of ACI and WAG/Rij rats. Immuno - 
blots showed a major band at about 130  kDa  corresponding to the mGlu5 receptor 
monomers. Data of Western blot  analysis were in line with those obtained by immuno-
histochemistry showing an increased mGlu5 receptor expression in the motor and 
somatosensory cortices, and a reduced expression in the VB of 8-month old  symptomatic 
WAG/Rij rats as compared to age-matched ACI rats (Fig. 2AeF). The only difference was 
that these changes reached statistical significance also in 2- month old  WAG/Rij  rats (vs. 
age-matched ACI rats) (Fig.  2AeF). Thus, at least immunoblot data suggest that  changes 
of mGlu5 receptors in the cortico-thalamic-cortical network of WAG/Rij  rats precede the 
onset of SWDs.
3.2. Changes in mGlu5 receptor-mediated PI hydrolysis in the 
cortex and thalamus of WAG/Rij rats
We used an in vivo metho to assess the mGlu5-receptor mediated PI hydrolysis in the 
sensorymotor cortex and thalamus of ACI and WAG/Rij rats (see Fig. 3A for experimental 
details). Rats were infused i.c.v. with the mixed mGlu1/5 receptor agonist, DHPG (500 
nmol/5 ml), and the component of PI hydrolysis mediated by mGlu5 receptors was isolated 
by co-injecting the rats with the mGlu1 receptor antagonist, JNJ16259685 (10 mg/kg, i.p.). 
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There was no significant change in DHPG-stimulated PI hydro- lysis in the sensorymotor 
cortex between WAG/Rij and ACI rats, although a trend to an increase was seen in WAG/
Rij rats (Fig. 3B). In contrast, a large reduction in DHPG-stimulated PI hydrolysis was seen in 
the thalamus of WAG/Rij rats (Fig. 3C), in close agreement with receptor expression data.
3.3. Pharmacological potentiation of mGlu5 receptors reduced 
spike and  wave  discharges (SWDs) in WAG/Rij rats
Acute treatment with MTEP (10 or 30 mg/kg, i.p.), a selective negative allosteric modulator 
(NAM) of mGlu5 receptors (Anderson et al., 2002; Cosford et al., 2003), did not change the 
incidence and mean duration of SWDs in symptomatic WAG/Rij rats (Fig. 4A and B). We 
next examined whether pharmacological potentiation of mGlu5 receptors could affect 
SWDs by injecting rats with the mGlu5 receptor enhancer, VU0360172. This drug was used 
Figure 3  Changes in mGlu5 receptor-mediated PI hydrolysis in the sensorymotor cortex 
and thalamus of WAG/Rij rats. In vivo measurements of PI hydrolysis in the sensorymotor 
cortex and thalamus of 8-month old WAG/Rij rats and age-matched controls (ACI rats) 
was carried out as outlined in (A). PtdIns-4,5,P2 = phosphatidylinositol-4,5-bisphosphate; 
Ins-1,4,5-P3 = inositol-1,4,5-trisphosphate; InsP = inositolmonophosphate. DHPG-stimu-
lated PI hydrolysis in the sensorymotor cortex (B) and in thalamus (C) of WAG/Rij rats (n = 
5 animals per group). *p < 0.05 (Student’s t test) vs. values obtained in controls rats. Basal 
values of [3H] InsP formation normalized by the amount of total radioactivity in each 
sample were 1.45 ± 0.17 and 1.40 ± 0.15 (means ± S.E.M.) in the sensorymotor cortex of ACI 
and WAG/Rij rats, respectively. Basal values of [3H] InsP  formation normalized by the 
amount of total radioactivity in each sample were 1.68 ± 0.08 and 1.72 ± 0.12 (means ± 
S.E.M.) in the thalamus of ACI and WAG/Rij rats, respectively.
A B
C
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at doses (3 or 10 mg/kg, s.c.) that are known to be centrally active (Rodriguez et al., 2010). 
Pharmacological enhancement of mGlu5 receptors signifi- cantly reduced the incidence 
of SWDs in a dose-dependent manner in the first 2 h after administration, and the effect 
of the highest dose lasted up to 4 h after drug injection (Fig. 4C). Treatment with 
VU0360172 also reduced the mean duration of SWDs to a similar extent as the incidence 
of SWDs (Fig. 4D). To exclude unknown off- target effects of VU0360172, the compound 
Figure 4  Pharmacological potentiation of mGlu5 receptors reduces spike and wave 
discharges (SWDs) in WAG/Rij rats. Pharmacological potentiation of mGlu5 receptors 
reduces both number and mean duration of SWDs in symptomatic WAG/Rij rats (C, D). 
No effect of MTEP alone (A, B) or combined with VU0360172 (E, F) on number and mean 
duration of SWDs. Values are means ± S.E.M. of 4/8 animals (MTEP 10 mg/kg = 4 rats, 
MTEP 30 mg/kg = 6 rats, VU0360172 3 or 10 mg/kg = 6 rats, MTEP þ VU0360172 = 8 rats). 
p < 0.05 (ANOVA for repeated measures followed by Bonferroni’s test) vs. the corresponding 
values at baseline (T0) (*) or vs. the corresponding values obtained in WAG/Rij rats treated 
with vehicle (#).
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was also injected at the dose of 3 mg/kg, s.c., in WAG/Rij rats pretreated with MTEP (10 
mg/ kg, i.p.) 15 min earlier. As shown in Fig. 4E and F, the  effect of VU0360172 was 
antagonized by MTEP, demonstrating that the drug reduced absence seizures by 
amplifying the endogenous activation of mGlu5 receptors. Spectral analysis of the EEG 
during SWDs after the highest dose of VU0360172 showed that the peak frequency of the 
SWDs was7.9 Hz, and did not differ from the peak frequency detected in WAG/ Rij rats 
treated with vehicle (data not shown).
3.4. Pharmacological potentiation of mGlu5  receptors did not 
affect motor behaviour
To exclude that changes in SWD induced by VU0360172 were secondary to changes in 
motor behaviour, we measured motor activity in 8-month old WAG/rij rats for 7 h 
following the injection of vehicle or VU0360172 (3 or 10 mg/kg, s.c.). ANOVA for repeated 
measures showed a significant effect of  time (F = 5.77, df 5,14, p < 0.001), with no drug 
effect and no drug x time interaction (Fig. 5).
4. Discussion
A major finding here was that pharmacological enhancement of mGlu5 receptor activity 
caused a robust and dose-dependent reduction in the incidence and mean duration of 
SWDs in WAG/Rij rats, which have pharmacological validity as a model for absence 
epilepsy. In contrast, pharmacological blockade of mGlu5 receptors did not affect absence 
seizures. A different scenario occurs in models of convulsive seizures, where pharmaco-
logical blockade of mGlu5 receptors is usually protective (Chapman et al., 2000; Lojková 
and Mares, 2005; Jesseet al.,  2008). WAG/Rij rats also showed a reduced expression and 
Figure 5  Assessment of motor behaviour in 8-month WAG/Rij rats treated with vehicle or 
VU0360172. Values are means þ S.E.M. (n = 6 rats per group). ANOVA for repeated measures 
showed a significant effect of time with no drug effect and no drug x time interaction.
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function of mGlu5 receptors in the thalamus and an increased receptor expression in the 
sensor- ymotor cortex. Immunoblot data show that in WAG/Rij rats changes in mGlu5 
receptor expression are antecedent to the onset of absence  seizures, and, therefore, are 
not secondary to seizure activity. This is peculiar because changes in the expression of 
mGlu1 receptors in the thalamus only occur in symptomatic WAG/ Rij rats (Ngomba et  al., 
2011b), whereas expression ofmGlu4 receptors show opposite modifications in  pre-symp-
tomatic and symptomatic WAG/Rij rats (Ngomba et al., 2008). We wish to highlight that 
the reduced function of mGlu5 receptors in  the thalamus was seen using an  in vivo 
method that allows the assessment of agonist-stimulated PI hydrolysis without the biases 
inherent to the conventional assay of PI hydrolysis in brain slices. We suggest that a 
reduced expression and function of mGlu5 receptors in the thalamus is a molecular 
determinant of the pathological phenotype of WAG/Rij rats, and that pharmacological 
amplification of thalamic receptors that are  still  present and func- tional is sufficient to 
significantly reduce absence seizures. If so, it is not surprising that MTEP had no effect on 
SWDs because thalamic mGlu5 receptors were already hypofunctional in WAG/Rij rats. It 
is worth mentioning that another mGlu5 receptor NAM, 2-methyl-6-(phenylethynyl)
pyridine (MPEP) inhibits SWDs in lethargic mice (Chapman et  al.,  2000), which represent 
an atypical model of absence epilepsy and bear a mutation in the b4 subunit of volt-
age-sensitive calcium channels (Burgess et al., 1999). However, MPEP is also a weak mGlu4 
receptor PAM (Mathiesen et al., 2003) and mGlu4 receptors are involved in the generation 
of absence seizures (Snead et al., 2000; Ngomba et al., 2008). MPEP had no effect on 
acutely induced SWDs by low doses of the GABAA receptor antagonist, pentylenetetrazol, 
in immature rats (Lojková and Mares, 2005). The logical conclusion is that the role of 
mGlu5 receptors in different seizure and epilepsy models is not uniform, and the effect of 
mGlu5 receptor NAMs critically depends on the genetic background of the animals, the 
age and/or the type of absence seizures (e.g., spontaneous vs. drug-induced). The mGlu5 
receptor is physically linked to the NR2 subunit of N-methyl-D-aspartate (NMDA) receptors 
through a  chain of scaf- folding proteins that include PSD95, Shunk, and Homer (Tu et al., 
1999). Furthermore, activation of mGlu5 receptors facilitates the activation of NMDA 
receptors, and vice versa  (Doherty et al., 1997; Ugolini et al., 1999; Awad et al., 2000; Attucci 
et al., 2001; Mannaioni et al., 2001; Pisani et al., 2001; Alagarsamy et al., 2005). This interaction 
cannot explain the protective effect of VU0360172 that we have observed here because it 
is the NMDA receptor blockade that reduces absence seizures in WAG/Rij rats (Peeters et 
al. 1990; Coenen and van Luijtelaar, 2003). Either neuronal mGlu5 receptors act 
independently of the NMDA receptors in regulating synaptic activity in the cortico-thala-
mo-cortical network, or glial  mGlu5 receptors (Liu et al., 1998) have a role in regulating 
the expression of high affinity glutamate transporters (Aronica et al., 2003) or signalling 
molecules that may affect the function of thalamic or cortical neurons. An attractive 
hypothesis is that activation of mGlu5 receptors in VB restrains GABA release and therefore 
protects against SWDs through a mechanism mediated by an enhanced formation of en-
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docannabinoids with ensuing activation of presynaptic CB1 cannabinoid receptors 
(Varma et al., 2001; Jung et al., 2005; Uchigashima et al., 2007; Won et al., 2009; Izumi and 
Zorumski, 2012). Interestingly, pharmacological activation of CB1 receptors reduces 
absence seizures in WAG/Rij rats (van Rijn et al., 2010). It is worth noting that systemic 
injection of drugs that enhance synaptic GABA levels, such as tiagabine and vigabatrin, 
enhance SWDs in GAERS and WAG/Rij rats (Coenen et al., 1995; Depaulis and van Luijtelaar, 
2006; Bouwman et al., 2007), and similar effects are seen following bilateral injections of 
g-vinyl GABA or the GABAA receptor agonist, muscimol, into the medial part of the ventral 
lateral thalamus containing thalamic relay nuclei (Liu et al., 1991). In contrast, injections of 
g-vinyl GABA or muscimol into the nRT suppress SWDs (Liu et al., 1991). Local injections 
with VU0360172 in the VB or nRT in combination with CB1 receptor antagonists and/or 
GABAergic drugs may help to clarify the precise mechanism whereby pharmacological 
enhancement of  mGlu5 receptors reduces absence seizures in WAG/Rij rats. We have also 
found an increased expression of mGlu5 recep- tors in the sensorymotor cortex of WAG/
Rij rats, although receptor function was not significantly enhanced. The significance of 
this finding is uncertain because pharmacological blockade of mGlu5receptors did not 
affect absence seizures.   
 We cannot exclude that an enhanced expression of  mGlu5 receptors in  the cerebral 
cortex represents a compensatory protective mechanism against SWDs  that was further 
amplified by VU0360172. Again, experiments in which drugs are microinfused in the main 
stations of the cortico-thalamic-cortical network ar necessary to disclose the precise role 
of mGlu5 receptors in  the regulation of absence seizures. The evidence that a selective 
mGlu5 receptor enhancer signifi- cantly reduced absence seizures in WAG/Rij rats without 
affecting motor behaviour is of great interest from a therapeutic standpoint. If activation 
of a single receptor type is warranted, receptor enhancers are advantageous over 
orthosteric agonists because they recruit exclusively those receptors that are 
endogenously activated (i.e., they act in an activity-dependent manner). This places 
mGlu5 receptor enhancers in the right position as novel anti-absence drugs, which might 
correct the abnormalities in mGlu5 receptor function without recruiting “silent” mGlu5 
receptors that could generate dose-related adverse effects. It should be highlighted that 
more than 20% of patients with absence epilepsy and those with atypical absence seizure 
are refractory to conventional medication (Mikati and Holmes, 1997; Panayiotopoulos, 
1999; Ollivier et al., 2009). Speculatively, mGlu5 receptor PAMs could be  developed for the 
treatment of patients with absence epilepsy refractory to conventional medications, since 
subtype selective ligands of mGlu receptors are now under Phase I and II clinical studies 
for the treatment of neurological and psychiatric disorders (Niswender and Conn,  2010).
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Abstract
Acute treatment with positive allosteric modulators (PAMs) of mGlu1 and mGlu5 
metabotropic glutamate receptors (RO0711401 and VU030172, respectively) reduces the 
incidence of spike-and-wave discharges in the WAG/Rij rat model of absence epilepsy. 
However, from a therapeutic standpoint, it is important to establish whether tolerance 
develops to this antiepileptic activity after chronic administration. We therefore injected 
either VU0360172 (3 mg/kg, s.c.) or RO0711401 (10 mg/kg, s.c.) into WAG/Rij rats twice daily 
for ten days. VU0360172, maintained most of its antiepileptic activity during the ten days 
of treatment, whereas rats developed tolerance to RO0711401 by the end of the 3rd day of 
treatment and remained refractive for two days after treatment withdrawal. Immunoblot 
analysis revealed that, in response to VU0360172, expression of mGlu5 receptors increased 
in the thalamus of WAG/Rij rats after 1 day of treatment, and remained elevated afterwards. 
VU0360172 also enhanced mGlu5 receptor expression in the cortex after 8 days of treatment 
without affecting the expression of mGlu1α receptors. Treatment with RO0711401 enhanced 
the expression of both mGlu1α and mGlu5 receptors in the thalamus and cortex of WAG/
Rij rats after 3-8 days of treatment. These data were different from those obtained in 
non-epileptic control rats, where repeated injections with VU0360172 and RO0711401 
down-regulated the expression of mGlu1α and mGlu5 receptors. Finally, brain levels of 
both compounds remained unaltered after repeated administration, although, there 
was a decrease of cortical levels of RO0711401 from day 3 to day 8. In conclusion, mGlu5 
receptors PAMs are suitable candidates for the development of novel anti-absence drugs 
in humans.
Key words: Absence Epilepsy; Spike-Wave Discharges; WAG/Rij rats; VU0360172; RO0711401; 
tolerance; chronic treatment; group I mGlu receptors.
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1. Introduction
About 20% of patients with absence epilepsy, particularly those with atypical absence 
seizures, are refractory to the currently used antiabsence drugs, such as ethosuximide, 
valproate, and clonazepam (Panayiotopoulos et al., 1999; Glauser et al., 2010). Moreover, in 
patients that are not refractory, antiepileptic drugs may cause class-related adverse 
effects, such as sedation, dizziness, amnesia and ataxia. Unfortunately, newer anti-absence 
drugs, such as lamotrigine and lacosemide, loose efficacy during chronic treatment 
(Glauser et al., 2010) or may have only marginal effects or paradoxically enhance absences 
seizures in animal models (van Rijn et al., 1994; van Luijtelaar et al., submitted). Therefore, 
more effective antiepilepsy drugs are still needed. 
 Metabotropic glutamate (mGlu) receptors are potential targets for novel anti-absence 
drugs. mGlu receptors form a family of eight, G-protein-coupled subtypes (mGlu1-8). 
mGlu1 and mGlu5  receptors are coupled to Gq/G11, whereas the rest are coupled to Gi/Go. 
These receptors are strategically distributed at synapses of the cortico-thalamo-cortical 
network, which is the anatomical site of origin of spike-wave discharges (SWDs) underlying 
absence epilepsy (Ngomba et al., 2011a; van Luijtelaar et al., 2011). For example, mGlu1 and 
mGlu5 receptors are localized postsynaptically on neurons of ventrobasal thalamic nuclei 
(VB) (Romano et al., 1995; Liu et al., 1998), whereas mGlu4 receptors are localized presyn-
aptically on cortical glutamatergic neurons afferent to the thalamic reticular nucleus (Ngomba 
et al., 2008). In the cerebral cortex, mGlu1 receptors are found on GABAergic interneurons 
(Stinehelfer et al., 2000), whereas mGlu5 receptors are expressed by pyramidal neurons 
postsynaptic to thalamo-cortical projections (Wijetunge et al., 2008), as well as by inter- 
neurons. The study of mGlu receptors in models of absence epilepsy has been facilitated 
by the recent availability of potent and systemically active subtype-selective ligands. 
Noteworthily, some of these drugs are now under clinical development for neurological 
and psychiatric disorders showing an overall good profile of safety and tolerability 
(reviewed by Nicoletti et al., 2011). 
 Ligands that bind to the glutamate recognition site of mGlu receptors behave as 
orthosteric agonists or antagonists. On the other hand, ligands that bind to an allosteric 
site typically localized on the seven-transmembrane domain, can act as either positive or 
negative allosteric modulators (PAMs and NAMs, respectively). By definition, PAMs amplify 
receptor function only in the presence of an orthosteric agonist, and therefore recruit 
only mGlu receptors activated by endogenous glutamate (reviewed Niswender and 
Conn, 2010). Acute systemic treatment with mGlu1 and mGlu5 receptor PAMs (RO0711401 
and VU030172, respectively) reduces the incidence of SWDs in the WAG/Rij rat model 
(Ngomba et al., 2011b; D’Amore et al. 2013), a genetic model of absence epilepsy with 
excellent predictive validity (Coenen and van Luijtelaar, 2003; van Luijtelaar and Sitnikova, 
2006). Because RO0711401 and VU030172 do not affect motor behavior, there are interesting 
for the development as anti-absence drugs for humans. However, from a therapeutic 
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standpoint it is important to establish whether the anti-absence activity of mGlu1 and 
mGlu5 receptors PAMs is retained or not in response to repeated drug administrations. In 
fact, the development of tolerance seriously limits the therapeutic use of clonazepam 
and other benzodiazepines currently used in the treatment of epilepsy (Peeters et al., 
1990).
2. Materials and Methods 
2.1. Drugs
VU0360172 (N-clyclobutyl-6-[2-3(fluorophenyl) ethynyl] pyridine-3-carboxamine), a selective 
mGlu5 receptor PAM, was obtained from Vanderbilt University Medical Center (Williams 
et al. 2011). RO0711401 (9H-xanthene-9-carboxylic acid (4-trifluoromethyl-oxazol-2-yl) 
amide, a selective mGlu1 receptor PAM, was kindly provided by F.Hoffmann -La Roche 
(Basel, Switzerland). VU0360172 was dissolved in 10% Tween 80 and injected subcutaneously 
(s.c.). RO0711401 was dissolved in arachis oil (Sigma-Aldrich, Italy) and also injected s.c. 
All drug solutions were prepared freshly daily. 
 Control animals received equal volumes of 10% Tween 80 or arachis oil, s.c. RO0711401 
was administered at 10 mg/kg because we previously found that this dose was effective 
at suppressing the number and mean duration of SWDs (Ngomba et al., 2011b). VU0360172 
was administered at the centrally active dose of 3 mg/kg (Rodriguez et al., 2010), which 
was also effective in reducing SWD number and mean duration (D’Amore et al. 2013), 
taken into consideration that very high doses (30 mg/kg and more) of mGlu5 PAMs [e.g. 
5PAM523 = (4-Fluorophenyl){(2R,5S)-5-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]-2-methyl-
piperidin-1-yl}methanone), has been reported to show neurotoxic and seizure side effects 
in Female Wistar Hannover rats (Parmentier-Batteur et al 2013).
2.2. Animals
Thirty-six male WAG/Rij and six male ACI (Agouti Copenhagen Irish) rats were used for 
combined EEG–behavioral studies. The rats were born and raised at Radboud University 
Nijmegen, The Netherlands, and had a mean body weight of 350 g at 9 months of age. 
They were defined as being “symptomatic” at 6 months of age, when they develop about 
16–20 SWDs per hour, or more than 200 SWDs per day (van Luijtelaar and Coenen, 1988). 
The animals were individually housed in Macrolon cages, kept under controlled conditions 
(20ºC, 60% humidity) in a room with a reversed light–dark cycle (white light on from 9 
p.m. to 9 a.m.), with food and drinking water always available. Animals were handled 
regularly a few days before starting EEG registrations.
 In addition, twelve 3-month-old male Wistar rats (mean body weight, 200–240 g; 
Charles River, Italy) and five 3 to 4-month-old male Wistar rats (mean body weight, 380 – 
420 g; Charles River, Italy) were used for Western blot analysis and EEG recording 
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respectively. These rats were housed in similar conditions of WAG/Rij and ACI rats in the 
animal facility at Neuromed Pozzilli, Italy. Male adult cervelet-4 (crv4) homozygous mutant 
mice lacking mGlu1 receptors (Conti et al.,  2006; kindly provided by  Prof. Alda Maria Puliti, 
University of Genoa, Italy) and male adult mGlu5-/- mice (breeded at Neuromed Institute) 
were used to test the specificity of  the antibodies used for the detection of  mGlu1α and 
mGlu5 receptors in Western blot experiments. The study was performed in accordance 
with the guidelines of the European Community for the use of experimental animals and 
was approved by local ethics committee for animal studies (RU-DEC). All efforts were 
made to reduce discomfort experienced by the animals and to keep the number of 
animals as low as acceptable.
2.3. Drug injection regimens
For EEG recordings and assessment of spontaneous motor activity, four separate groups 
of 8-9 WAG/Rij rats were treated twice daily (at 9 a.m. and 9 p.m.) for 10 days with 
RO0711401 (10 mg/kg, s.c.), VU0360172 (3 mg/kg, s.c.), or their respective vehicles (see 
above, s.c.). Drugs and vehicles were injected once more at 9 a.m. 2 days after withdrawal 
(day 13).  Additional groups of WAG/Rij rats (n = 16, 4 rats per group) or non-epileptic 
Wistar rats (n = 12, 3 rats per group) were treated twice daily for 8 days with drugs or 
vehicles, and used for immunoblot analysis of mGlu1α and mGlu5 receptors in the 
thalamus and cerebral cortex. The same WAG/Rij rats treated with RO0711401 or 
VU0360172 were also used for measurements of drug levels in the thalamus, and cerebral 
cortex. These Wistar and WAG/Rij rats were sacrificed 1 hour after the morning injection 
(i.e. at 10 a.m.). Additional groups of  non epileptic rats (Wistar or ACI rats) were injected 
with VU0360172, 3 mg/kg, s.c. or its vehicles.
2.4. In vivo Recordings
2.4.1. EEG
A cortical tripolar electrode set was implanted via stereotactic surgery under isoflurane 
anaesthesia supplemented with pre- and postoperative Rimadyl as analgesic and 
lidocaine as local anaesthetic. One active electrode was implanted in the frontal region 
(coordinates with the skull surface flat and from bregma zero-zero, AP +2, 0: L -3, 5) with a 
second one in the parietal region (A -6, 0: L -4, 0) (Paxinos and Watson, 2005). The ground 
electrode was placed over the cerebellum. After surgery the rats had two weeks to 
recover, after which, they were moved into transparent EEG recording cages supplied 
sawdust and cage enrichment and with water and food ad libitum. WAG/Rij and ACI rats 
were connected to an EEG cable with a preamplifier and a swivel, which allowed free 
movement. Before recording the rats were habituated to the leads for at least 12 hours. 
The differential recorded EEG was filtered (only frequencies between 1 and 100 Hz were 
allowed to pass) and were digitalized with a sample frequency of 512 Hz, and saved for an 
off-line analysis using Windaq system (DATAQ, Instruments, Akron, OH, USA). Wistar rats 
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were implanted with stainless-steel wire recording electrodes epidurally on the left and 
right parietal cortex under isofluorane anaesthesia supplemented with lidocaine local 
anaesthetic. EEG was recorded by means of Grass-Telefactor system and visually analysed 
to evaluate the occurrence of SWDs.
 Baseline EEG recordings (Day 0) were carried out at day 0 during the first two hours of 
the dark period (i.e. 9 a.m. 11 a.m.). EEG and behavioural recordigs were taken during the 
dark-phase, five hours post injection, because this is when WAG/Rij rats have the greatest 
incidence of SWDs (van Luijtelaar and Coenen, 1988; Smyk et al., 2012). SWDs were labelled 
visually using common criteria, regular trains of sharp spikes and slow waves lasting from 
of 1–10 s, spike-wave frequency of 7–10 Hz, a spikes amplitude at least twice the 
background signal and asymmetric appearance of the SWDs (van Luijtelaar and Coenen, 
1986; Ovchinnikov et al., 2010)
2.4.2. Spontaneous motor activity
Spontaneous motor activity was recorded as previously reported (van Rijn et al. 2010); an 
analogic passive infrared detector (PIR) (Luna PR, Rokonet Electronics LTD, Rishon Le Tzion, 
Israel) was fixed to a semi-open lid on top of the each rat’s EEG recording cage. The 
analogue signal was digitalized simultaneously with the EEG signal. Movements were 
quantified by calculating the mean of the absolute value of the PIR signal per hour. The 
values of each individual rat were analysed to investigate if there were any differences in 
motor activity between baseline- and post injection periods to see if there were any drug 
effects. 
Figure 1  Representative EEG recording from symptomaticWAG/Rij rats and age-matched 
Wistar rats. A typical SWDs in the EEG recording ofWAG/Rij rats is shown in (A). SWDs had 
a frequency of 7-10 Hz, an amplitude of at least twice the background, and a minimal 
duration of 1s. Note the absence of SWDs in control Wistar rats (B).
A
B
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2.5.  Detection of RO0711401 and VU0360172 in cortex and 
thalamus of WAG/Rij rats 
2.5.1. Sample Preparation
WAG/Rij rats treated with RO0711401 or VU0360172 were killed by decapitation on days 1, 
3 or 8 as described above. The brains were rapidly removed, and the left portion of the 
thalamus and cerebral cortex were dissected and immediately frozen at -80°C. Tissue 
samples were homogenized with 1 ml of 0, 1% aqueous formic acid. The weight of each 
sample was recorded. 30 µl of tissue homogenate was added to 150 µl of internal standard 
working solution (1mM Dansilnorvaline in 100% acetonitrile). After extensive vortex (60 
sec), samples were centrifuged at 14,000 rpm for 5 min. 40 µl of supernatant was then 
mixed with 160 µl of 0.1% aqueous formic acid and transferred to an autosampler vial for 
injection into the chromatographic system.
2.5.2 Liquid Chromatography–Tandem Mass Spectrometry Analysis
HPLC analysis was performed with an Agilent Liquid Chromatography System series 1100 
(Agilent Technologies, USA), with a binary pump, an autosampler, a solvent degasser and 
a column oven. Chromatographic separation was performed with a 50×2.0 mm, Luna 
C18, 5µm, 100 Å pore size column (Phenomenex, Torrance, CA, USA), equipped with a 
Security guard precolumn (Phenomenex, Torrance, CA, USA), containing the same packing 
material. The column was maintained at room temperature. The mobile phase was a solution of 
0.1% aqueous formic acid (eluent A) and 100% acetonitrile (eluent B). The injection volume 
was 20 µl; elution was performed at a flow rate of 300 µl/min, using 10% solvent B for 1 
minute, linear gradient to 90% solvent B for 3 min, 90% solvent B for 2 min and afterwards 
re-equilibrating with 90% solvent A for 4 min. The total analysis run time was 10 min.
 Mass spectrometry was performed with a 3200 Triple Quadrupole system, equipped 
with a Turbo Ion Spray source (Applied Biosystems, Foster City, CA). Data were acquired and 
processed with Analyst 1.4.2 software. The detector was set in the positive ion mode. The ion 
spray voltage was set at 5000 V and the source temperature was 300°C. The collision activation 
dissociation (CAD) gas was set at medium value and nitrogen was used as the collision gas. 
The Q1 and Q3  quadrupoles were tuned for the unit mass resolution. The transitions of the 
precursor ions to the product ions were monitored with a dwell time of 100 ms for each 
analyte. The instrument was set in the multiple reaction monitoring (MRM) modes and 
mass spectrometer parameters were optimized to maximize sensitivity for all transitions.
 Data analysis were carried out using a calibration curve with established known 
concentrations (0, 6.25, 12.5, 25, 50, 100, 250, 500, and 1000 ng/ml) of RO0711401 and 
VU0360172 dissolved in 0.1% aqueous formic acid and processed in the same way as of tissue 
samples. The equation of linear regression obtained for this value range was y = 0.000204x 
+ 0.0033 (r = 0.9982).  Mass spectrometer parameters were optimized to maximize 
sensitivity for each transition of both drugs (internal standard) and the instrument was set 
in the multiple-reaction monitoring mode.
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2.6 Western blot analysis of mGlu1α and mGlu5 receptors
This analysis was carried out in the right portions of the thalamus and cerebral cortex 
dissected from WAG/Rij and Wistar rats treated for 1, 3 or 8 days with RO0711401, VU0360172, 
or their respective vehicles. Tissue samples were homogenized at 4°C in 50 mM Tris-HCl 
buffer, pH 7.4, containing 1 mM EDTA, 1% Triton X-100, 1 mM PMSF, 1 µg/ml aprotinin, 
1 µg/ml pepstatin, and 1 µg/ml leupeptin. Proteins were resuspended in SDS-bromophenol 
blue reducing buffer with 40 mM DTT. Western blot analyses were carried out using 8% 
SDS polyacrylamide gels, which were electroblotted onto immunoblot PVDF membranes 
(BioRad, Milano, Italy); filters were blocked overnight in TTBS buffer containing 5% non- 
fatty milk.
 Specific rabbit polyclonal antibodies for mGlu1α or mGlu5 receptor were used (1:500 
and 1:1,000, respectively, Upstate Biotechnology, Lake Placid, NY, USA). Blots were incubated 
for 1 h with primary polyclonal antibodies or a mouse monoclonal antibody to label 
b-actin (1:100,000, Sigma, St.Louis, MO, USA) and then incubated for 1 hour with secondary 
antibodies (peroxidase-coupled anti-rabbit or anti-mouse, Amersham, Piscataway, NJ, USA) 
diluted 1:7000 with TTBS. Immunostaining was revealed by enhanced ECL (Amersham, 
Piscataway,NJ,USA).
2.7. Statistical analysis
It was first tested whether the two vehicles differed from each other or were associated 
with hourly or daily EEG or behavioural parameters. Since this was not the case, it was 
decided to pool the data of the two control groups. The effects of chronic administration 
of VU0360172 or RO0711401 on incidence and mean duration of SWDs as a percentage of 
the base-line data as well as the behavioral activity of animals were tested in three 
separate repeated-measures mixed-design ANOVA with incidence and mean duration of 
SWDs or amplitude of the PIR as dependent variables. For all three analyses, the time of 
EEG recording (5 hours) and day of experiment (day 1, day 10, day 13) were used as the 
within-subjects factors, the administered compound (vehicle(s), VU0360172 and 
RO0711401) was used as the between-subjects factors. Bonferroni’s test was used to 
isolate the differences between drugs, days and hours. Two-way mixed-design ANOVA 
was used for the analyses of the day effect across all injection days (1-10 and 13) in order to 
establish more clearly the development of tolerance and the effects of interruption of 
treatment. The incidence in the first hour post-drug was the dependent variable.  
 Statistical analysis of HPLC and Western blot data for thalamus and cortex separately 
were evaluated using a one-way ANOVA with drug treatment between days (day 1, day 3, 
day 8) as within-subjects factor, followed by the post-hoc analysis (Bonferroni’s multiple 
comparison test). Data are expressed as means ± SEM. Where values are means ± S.E.M. of 
3 determinations per group with *p<0.05 vs. Control and # p<0.05 vs. day 1 or § p<0.05 vs. 
day 3 treatment.
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3. Results
3.1.  Acute and chronic administration of mGlu1 and mGlu5 
receptor PAMs in WAG/Rij rats: effects on SWDs
Symptomatic 6-7 months old WAG/Rij rats were treated twice daily for 10 days with 
RO0711401 (10 mg/kg, s.c.), VU0360172 (3 mg/kg, s.c.) or their respective vehicles. SWDs 
were analysed every day during the treatment and then after 3 days of withdrawal in 
response to drug rechallenge. Sample records of EEG activities from a representative 
WAG/Rij rat and a non epileptic Wistar rat are shown in Fig. 1A,B. 
 The analysis of the incidence of SWDs during the first 5 hours post injection (data on 
incidence and duration for day 1 and 10 are shown in Fig. 2) showed a drug effect (F=14.12, 
df 1,24, p<.001, η2=.54; VU0360172 and RO0711401 groups had less SWDs than vehicle), 
an “hour” effect (F=22.40, df 4,96, p<.001, η2=.48; hour 1 < hours 2-5) and interactions 
between hour x drug (F=7.13, df 8,96, p<.001; η2=.38) and between day x drug (F=10,20, df 
4,48, p<.001, η2=.46). Post hoc analysis on day 1 showed that RO0711401 and VU0360172 
reduced the incidence of SWDs in the 1st post injection hour (Fig. 2A), with VU0360172 
being more effective than RO0711401. WAG/Rij rats treated with VU0360172 (but not with 
RO0711401) also showed a trend to a reduction in the incidence of SWDs at the 2nd hour 
post injection (p>0.05). Post-hoc analyses on the incidence of SWDs on day 10 showed 
that VU0360172 retained its anti-absence activity at the 1st hour post injection whereas 
RO0711401 became inactive. Fig. 2B shows the incidence of SWDs on day 10 of treatment. 
Post hoc analyses on day 13 showed exactly the same group differences as on day 10, 
with VU0360172, but not RO0711401, being effective as an anti-absence drug in the 1st 
hour post-injection. However, RO0711401 significantly reduced the incidence of SWDs in 
the second hour post injection on day 13 as compared to VU0360172 and vehicle (p<0.05; 
not shown), suggesting that RO0711401 had regained some of its effects after 3 days of 
withdrawal.  
 Analysis of mean duration of SWDs at days 1, 10, and 13 showed a day effect (F=9.39, 
df=2,46, p <.000, η2 =.290) and a significant second-order interaction between day x hour 
x drug (F=3.54, df=16,184, p<0.000, η2=.235). Post hoc tests on day 1 showed that mean 
duration of SWDs was reduced by VU0360172 at the 2nd hour post injection (see Fig. 2C) 
compared to all other groups. VU0360172 had lost its effect on the mean duration of SWD 
at day 10 and 13. Mean duration was not affected by treatment with RO0711401 (Fig. 2C,D).
To exclude that SWDs data could be biased by a potential behavioural effect of the two 
drugs, motor behaviour was measured with PIR at day 1, 10 and 13 during the first 5 hours 
post injection. Statistical analysis showed neither drug effect nor interactions effects 
between drug and any other independent variable (Fig. 2E,F).
 The incidence of SWDs and their mean duration were exclusively analysed at 1 hour 
post injection on all treatment days in order to inspect the changes in drug efficacy over 
time. Two-way ANOVA analysis showed a drug effect (F=591,90, df 2,15, p<0.001, η2=.99; 
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VU0360172<RO0711401<vehicle), a day effect (F=7.63, df 10,150, p<0.001, η2 =.34) and an 
interaction between day x drug (F=9.80, df 20,150, p<0.001, η2 =.57). Post hoc analysis 
showed that VU0360172 retained its anti-absence action across all 10 days of treatment, 
and kept also its antiabsence action at the re challenge day after 2 withdrawal days. In 
contrast, RO0711401 showed its antiabsence effect only during the first 2 days of 
treatment, after that, the antiabsence action was completely and immediately lost and at 
day 3 the incidence of SWDs was no longer different from solvent. The anti-absence 
activity of RO0711401 was not restored after 2 days of drug withdrawal (p>0.05; Fig. 3). 
Figure 2  Differential effects of RO0711401 and VU0360172 on the incidence of SWDs on 
days 1 and 10 of treatment in WAG/Rij rats. Rats were treated s.c. twice daily with 
RO0711401 (10 mg/kg), VU0360172 (3 mg/kg) or their respective vehicles. SWD incidence 
measured at baseline (time 0) and in the first 5 h post injection on day 1 and 10 of 
treatment are shown in (A) and (B), respectively. Mean duration of SWDs is shown in (C) 
and (D); spontaneous motor activity is shown in (E) and (F). Values are means + S.E.M. P < 
0.05 vs. The respective vehicles (*) or vs. VU0360172 (#). Statistical analysis is detailed in the 
Results session.
A
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F
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There was no effect of the two drugs on the mean duration of SWDs at 1 hour post 
injection at any day of the treatment (not shown).
3.2  Measurements of thalamic and cortical drug levels during 
repeated administrations of RO0711401 or VU0360172
To examine whether the development of tolerance to RO0711401 was associated with 
time-dependent changes in central bioavailability of the drug, we measured RO0711401 
levels in the thalamus and cortex in three separate groups of WAG/Rij rats treated with the 
drug as mentioned above and killed at day 1, 3 or 8 at one hour after the morning 
injection. One-way ANOVA did not reveal any significant effect of day of treatment in the 
thalamus (Fig.4B, p > 0.05) while a significant day effect was observed in the cortex (Fig.4A, 
F=1,501, df= 1,4, p<0.05, η2=.273), with levels of RO0711401 being reduced on day 8 of 
treatment. However, RO0711401 levels were unchanged on day 3 of treatment, when 
tolerance to the anti-absence effect begun to develop (Fig.4A). We also measured 
VU0360172 levels and found no significant day effect, neither in cortex nor in thalamus 
(Fig. 4C,D, p >0.05). 
Figure 3  Development of tolerance to the anti-absence activity of  RO0711401 after the 
first 3 days of treatment. WAG/Rij rats were treated s.c. twice daily for 10 days with 
RO0711401 (10 mg/kg), VU0360172 (3 mg/kg), or the respective vehicles. A rechallenge 
with each of the two drugs was performed after 3 days of withdrawal. The incidence of 
SWDs at 1 h after the morning injection is shown. Values are means + S.E.M. P < 0.05 vs. 
the respective vehicles (*) or vs. VU0360172 (#).
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3.3  Measurements of mGlu1α and mGlu5 expression in the 
thalamus and somatosensory cortex after treatment with 
RO0711401 or VU0360172  
Next it was examined whether repeated administrations of RO0711401 or VU0360172 
induced any adaptive changes in the expression of mGlu1α and mGlu5 receptors in WAG/
Rij rats that could correlate with the temporal profile of drug response on SWD incidence. 
 Immunoblot analysis revealed bands at 140kDa and 130 kDa, which, that correspond 
to the deduced molecular sizes of the receptor’s monomers (arrowheads in the 
representative immunoblots). A faint higher molecular weight band corresponding to 
dimers of mGlu1α and mGlu5 receptors was also visible in some of the immunoblots (not 
shown) but was not included in our densitometric analysis. The specificity of the 
antibodies was confirmed using the cerebellum of crv4 mutant mice hypomorphic for 
mGlu1 receptors (Conti et al., 2006) or the cerebral cortex of mGlu5 receptor knockout 
mice as negative controls. The lower band present in the repre-sentative mGlu1a and 
mGlu5 immunoblots was non-specific because it was still visible in samples from crv4 
and mGlu5-/- mice, respectively (Fig. 5). Treatment of WAG/Rij rats with vehicle twice daily 
for 8 days did not change the expression of mGlu1α and or mGlu5 receptors in the 
Figure 4  Drug levels in the thalamus and cortex during 8-day treatment with RO0711401 
or VU0360172 in WAG/Rij rats. Rats were treated s.c. twice daily for 8 days with RO0711401 
(10 mg/kg) or VU0360172 (3 mg/kg). Values are means + S.E.M. #P < 0.05 vs. the respective 
values on day 1 or 3 of treatment.
A
C
B
D
503055-L-bw-DAmore
Head-to head comparison of mGluR1 and mGluR5 PAMs in a chronic treatment study  |  101
4
thalamus or cortex (only values at day 8 are shown and indicated as “controls”). Treatment 
with RO0711401 caused an increase in both mGlu1α and mGlu5 receptor protein levels on 
day 8. The drug also enhanced mGlu1α receptor levels on day 3 in the cortex [Fig. 6A-D; 
mGlu1α ( F = 10.36, P = 0.0039 and F = 15.50, P = 0.011; for the thalamus and cortex 
respectively) and mGlu5] (F = 7.33, P = 0.011 and F = 6.15, P = 0.018; for the thalamus and 
cortex respectively). In contrast, treatment with VU0360172 in WAG/Rij rats caused an 
early and persistent increase in mGlu5 receptor expression in the thalamus (Fig. 7A: F = 
7.56, P = 0.0042) a late increase of mGlu5 receptor expression in the cortex (Fig. 7B: F = 9.17, 
P = 0.0057) and no changes in mGlu1α receptor levels in any of the two brain regions (Fig. 
7C,D).
 To examine whether these adaptive changes in receptor expression represented a 
general response to mGlu1 and mGlu5 receptor PAMs or were peculiar to epileptic WAG/
Rij rats, the analysis was extended to non-epileptic age-matched Wistar rats treated with 
vehicles, RO0711401 or VU0360172 for 1, 3 and 8 days. It was confirmed in these rats that 
treatment with RO0711401 caused changes in both mGlu1α and mGlu5 receptors whereas 
treatment with VU0360172 caused selective changes in mGlu5 receptors. However, the 
direction of these changes was opposite to that observed in WAG/Rij rats. Wistar rats 
treated with RO0711401 showed an early and persistent down-regulation of mGlu1α and 
mGlu5 receptors in the thalamus and cortex [Fig. 8A-D; mGlu1α (F = 18.51, P = 0.0020 
and F = 46.19, P = 0.0001; for the thalamus and cortex respectively) and mGlu5 (F = 10.76, 
Figure 5  Specificity of the antibodies used for immunoblot analysis of mGlu1a and mGlu5 
receptors. Western blot analysis was performed in protein extracts from the cerebellum of 
crv4 mutant mice (left) and the cerebral cortex of mGlu5_/_ mice (right) to verify the 
identity of the bands corresponding to mGlu1α and mGlu5 receptors, respectively. 
mGlu1a and mGlu5 receptor labelling are also shown in the cortex and thalamus of Wistar 
rats, respectively, for comparison. The upper band at 140 and 130 kDa corresponds to 
mGlu1a and mGlu5 receptor monomers, respectively. The lower band was non-specific 
because it was still present in crv4 and mGlu5_/_ mice.
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P = 0.0035 and F = 21.00, P = 0.0026; for the thalamus and cortex respectively)]. In contrast, 
Wistar rats treated with VU0360172 showed a late reduction in mGlu5 receptor expression 
in the thalamus (F = 10.75, P = 0.0035) and an early and persistent reduction of mGlu5 
receptor expression in the cortex (F = 14.82, P = 0.0012) with no changes in the expression of 
Figure 6  Adaptive changes in the expression of mGlu1a and mGlu5 receptors caused by 
8-day treatment with RO0711401 inWAG/Rij rats. Rats were treated s.c. twice daily for 
8 days with RO0711401 (10 mg/kg) or the respective vehicle. Values are means + S.E.M. 
P < 0.05 (One-way ANOVA + Bonferroni’s test) vs. the respective control (*), day 1 (#) or day 3 
(x) values.
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mGlu1α receptors (Fig. 9A-D). Thus, interestingly, epileptic WAG/Rij rats and non-epileptic 
Wistar rats showed opposite manifestations of receptor adaptation in response to prolonged 
mGlu1 and mGlu5 receptor enhancement. A synopsis on the effect of chronic treatment 
with RO0711401 or VU0360172 on the thalamic/cortical expression of mGlu1α and mGlu5 
receptors is shown in Fig. 10.
Figure 7  Adaptive changes in the expression of mGlu5 receptors caused by 8-day 
treatment with VU0360172 in WAG/Rij rats. Rats were treated s.c. twice daily for 8 days 
with VU0360172 (3 mg/kg) or the respective vehicle. Values are means + S.E.M. P < 0.05 
(One-way ANOVA + Bonferroni’s test) vs. the respective control (*) or day 1 (#) values.
A C
B D
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 Finally, we examined whether chronic treatment with VU0360172 in Wistar rats could 
induce the appearance of SWDs as a result of the down-regulation of mGlu5 receptors in 
the thalamus (see D’Amore et al., 2013). No SWDs were recorded in Wistar rats treated for 
8 days with VU0360172 (3 mg/kg, s.c. twice daily; EEG recorded at day 1, 3 and 8 of 
Figure 8  Adaptive changes in the expression of mGlu1a and mGlu5 receptors caused by 
8-day treatment with RO0711401 in non-epileptic Wistar rats. Rats were treated s.c. twice 
daily for 8 days with RO0711401 (10 mg/kg) or the respective vehicle. Values are means + 
S.E.M. P < 0.05 (One-way ANOVA + Bonferroni’s test) vs. the respective control (*) or day 1 
(#) values.
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treatment). Similarly, no SWDs were induced by chronic VU0360172 (3 mg/kg, s.c., twice 
daily for 10 days; EEG recorded at days 1, 5, and 10) in non-epileptic ACI rats, used as 
additional controls (representative EEG recordings shown in Fig. 11). 
Figure 9  Adaptive changes in the expression of mGlu5 receptors caused by 8-day 
treatment with VU0360172 in non-epileptic Wistar rats. Rats were treated s.c. twice daily 
for 8 days with VU0360172 (3 mg/kg) or the respective vehicle. Values are means + S.E.M. 
P < 0.05 (One-way ANOVA + Bonferroni’s test) vs. the respective control (*) or day 1 (#) 
values.
A C
B D
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Figure 10  Schematic diagram illustrating mGlu1/mGlu5 receptor responses in symptomatic 
WAG/Rij and non-epileptic control Wistar rats following chronic treatment with either 
mGlu1 or mGlu5 receptor PAMs. Detailed results of western blot analysis of mGlu1 and 
mGlu5 receptors are provided in Figs. 6-9.
Figure 11  EEG records showing no SWDs in Wistar or ACI rats treated chronically with 
VU0360172. Wistar or ACI rats (n = 3- 6 per group) were treated with VU0360172 (3 mg/kg s.c.) 
or vehicle twice daily for 8- 10 days, and recorded at baseline (day 0) and at the indicated 
days of treatment. These treatments did not cause the appearance of SWDs in the two 
strains of rats. Representative EEG recordings of rats treated with VU0360172 are shown.
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4. Discussion
The main objective of the study was to establish whether tolerance develops to the 
SWD-suppressing activity of mGlu1 and mGlu5 receptor PAMs and to unravel the 
molecular nature of tolerance (if any). This is a necessary step for the preclinical and clinical 
development of mGlu receptor PAMs for the treatment of absence epilepsy in humans. 
As expected (Ngomba et al., 2011b, D’Amore et al., 2013), both mGlu1 and mGlu5 receptor 
PAMs were able to suppress SWDs in WAG/Rij rats in the early phases of the treatment. 
However, a large difference between the two drugs was apparent when the response was 
monitored on a daily basis during chronic administration. The anti-absence effect of the 
mGlu5 receptor PAM, VU0360172, on the incidence of SWDs largely persisted over time, 
with only small signs of tolerance. More precisely, treatment with VU0360172 caused a 
significant reduction in the incidence of SWDs at the 1st hour and a reduction trend at the 
2nd hour on day 1. The effect at the 1st hour was fully maintained on day 10. On the other 
hand, the mean duration of SWDs was reduced at the 2nd hour post injection on day 1 but 
not on day 10. In contrast, the mGlu1 receptor PAM, RO0711401, lost its anti-absence 
effects on the incidence of SWDs on day 10. In order to disclose when precisely tolerance 
to RO0711401 began to develop, we analysed the incidence of SWDs in the first hour of 
injection of all ten consecutive days of treatment. The outcomes showed that the 
anti-absence action of RO0711401 remained unchanged from day 1 to day 2, diminished 
on day 3, and completely disappeared on day 4, remaining absent throughout the rest of 
the experiment. Therefore, tolerance to RO0711401 began to develop after relatively short 
time, i.e., after only four injections and was complete after two additional injections. The 
small and incomplete tolerance to the mGlu5 receptor PAM, VU0360172, is somehow 
consistent with data obtained with CDPPB another mGlu5 receptor PAM, in a mouse 
model of audiogenic seizures (Pacey et al., 2011). Therefore, it seems that the two drugs 
differ with respect to the development of tolerance, with VU0360172 retaining most of 
the “therapeutic” effect when repeatedly administered to WAG/Rij rats, and RO0711401 
inducing fast and complete tolerance to the anti-absence effect. We have collected only 
few pharmacokinetic data on the two PAMs in this study. VU0360172 shows high plasma 
protein-binding and little or no first-pass metabolism (Rodriguez et al., 2010). R00711401 
has a short elimination half-life (< 2 hours), but no data on liver metabolism are available 
(Vieira et al., 2009). Whether or not the two drugs may inhibit or accelerate their own 
metabolism with time is unknown. We found that thalamic levels of the two drugs 
remained stable during eight consecutive days of treatment in WAG/Rij rats, while a 
decrease over the days (day 3 vs. day 8) found in the cortex might indicate a contribution 
of pharmacokinetic tolerance to the loss of effects of RO0711401 on day 8 (but not on day 
3). We next measured the expression of mGlu1a and mGlu5 receptors in the thalamus and 
cortex of WAG/Rij rats on different days of drug treatment, as compared to treatments 
with the respective vehicles. This analysis was also carried out on non epileptic Wistar rats 
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treated with the two drugs. We were surprised to find that adaptive changes in receptor 
expression induced by the two PAMs were highly divergent between WAG/Rij and Wistar 
rats. In Wistar rats, both drugs substantially reduced the expression of the respective 
mGlu receptor subtype particularly in the cerebral cortex. Interestingly, repeated adminis-
trations of RO0711401 also reduced the expression of the mGlu5 receptors whereas 
VU0360172 has no effect on the expression of the mGlu1a receptors. This particular type 
of receptor regulation was completely disrupted in WAG/Rij rats, where the two PAMs 
rather enhanced the expression of the respective subtype, although with different 
temporal and regional profile. However, also in this case, RO0711401 changed the 
expression of both the mGlu1a and the mGlu5 receptors, whereas VU0360172 selectively 
changed the expression of the mGlu5 receptors only.
 In an attempt to explain the different receptor selectivity in the adaptive changes 
induced by the two PAMs, we wish to highlight that mGlu receptor subtypes can form 
both homodimers (e.g., either mGlu1-mGlu1 or mGlu5-mGlu5 dimers) and intra-group 
heterodimers (e.g., mGlu1-mGlu5 heterodimers), at least in heterologous expression 
systems (Doumazane et al., 2010). In addition, only one PAM molecule per dimer is 
sufficient to fully amplify receptor activity (Kniazeff et al., 2004). We speculate that in the 
thalamus and cortex of both WAG/Rij and Wistar rats there is a prevalence of mGlu1-mGlu1 
homodimers and mGlu1-mGlu5 heterodimers over mGlu5-mGlu5 homodimers. This 
explains why the mGlu1 receptor PAM, RO0711401, induced adaptive changes in both 
mGlu1 and mGlu5 receptors, whereas the mGlu5 receptor PAM, VU0360172, selectively 
induced changes in mGlu5 receptors. The reason why receptor regulation caused by 
chronic PAM treatment is qualitatively different in WAG/Rij rats is unknown. Under normal 
conditions, prolonged agonist exposure causes mGlu receptor desensitization (i.e., 
uncoupling from G proteins), followed by receptor internalization that may lead to 
reducing receptor expression (i.e., receptor down-regulation) if de novo synthesis of 
receptor protein does not compensate for receptor degradation (for reviews, see Reiter 
amd Lefkowitz, 2006; Whalen et al., 2011). It is possible that mechanisms that lie at the core 
of receptor desensitization and down-regulation are distorted in WAG/Rij rats because of 
the hypersynchronous activity of the cortico-thalamic-cortical network. This encourages 
the study of molecules involved in desensitization and internalization of mGlu1 and 
mGlu5 receptors, such as G-protein coupled receptor kinases and b-arrestin (reviewed by 
Iacovelli et al., 2013) in WAG/Rij rats and other animal models of absence epilepsy.  
 In conclusion, our data support the development of mGlu5 receptor PAMs as 
potential symptomatic drugs for the chronic treatment of absence epilepsy. These drugs 
may not cause pharmacodynamic tolerance perhaps because they fail to induce adaptive 
changes in the cognate mGlu1 receptor. We wish to highlight that VU0360172 (and also 
the mGlu1 PAM, RO0711401) did not affect motor behaviour and did not cause gross signs 
of toxicity in either WAG/Rij or Wistar rats. mGlu5 receptor PAMs are already under 
development for the treatment of schizophrenia with the only concern of neurotoxicity 
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and convulsive seizures induced by very high doses of these compounds (Parmenti-
er-Batteur et al., 2013). It remains to be established whether mGlu5 receptor PAMs can be 
safely associated with other drugs used in the treatment of absence epilepsy in patients 
that are resistant to conventional antiepileptic medication.
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Summary
Objective: Glutamate and GABA are the key neurotransmitter systems in the cortico-thal-
amo-cortical network, involved in normal and pathological oscillations such as spike-wave 
discharges (SWDs) characterizing different forms of absence epilepsy. Metabotropic 
glutamate (mGlu) and GABA receptors are widely expressed within this network. Here, we 
examined the effects of two selective positive allosteric modulators (PAMs) of mGlu1 and 
mGlu5 receptors, the GABA reuptake inhibitor, tiagabine, and their interaction in the 
somatosensory cortex and thalamus on SWDs in WAG/Rij rats. 
Methods: Male WAG/Rij rats were equipped with bilateral cannulas in the somatosensory 
cortex (S1po) or the ventral basal complex of the thalamus (VB), and with cortical EEG 
electrodes. Rats received a single dose of the mGlu1 receptor PAM, RO0711401, or the 
mGlu5 receptor PAM, VU0360172, various doses of tiagabine, or VU0360172 combined 
with tiagabine. 
Results: Both PAMs suppressed SWDs regardless of the site of injection. Tiagabine 
enhanced SWDs when injected in the thalamus, but, unexpectedly, suppressed SWDs in 
a dose-dependent manner when injected in the cortex. Intracortical co-injection of 
VU0360172 and tiagabine produced slightly larger effects as compared to either VU0360172 
or tiagabine alone. Intrathalamic co-injections of VU0360172 and sub-threshold doses of 
tiagabine caused an anti-absence effect similar to that exhibited by VU0360172 alone in 
the first 10 min. At 30 min, however, the anti-absence-effect of VU0360172 was prevented 
by sub-threshold doses of tiagabine, and the combination produced a paradoxical 
pro-absence effect at 40 and 50 min. 
Significance: These data (i) show that mGlu1 and mGlu5 receptor PAMs reduce absence 
seizures acting at both thalamic and cortical levels; (ii) demonstrate for the first time that 
tiagabine, in spite of its established absence-enhancing effect, reduces SWDs when 
injected in the somatosensory cortex; (iii) indicate that the efficacy of VU0360172 in the 
thalamus may be critically affected by the availability of (extra)synaptic GABA.  
Key words: Glutamate, GABA; Absence Epilepsy; WAG/Rij rats; mGlu PAM 
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Introduction 
Dysfunction in either glutamatergic or GABAergic neurotrasmission is known to be one of 
the causes responsible for the initiation and spread of seizures, including absence epilepsy. 
Known as the electroencephalographic hallmark of absence seizures, the archetypical 
spike-wave discharges (SWDs) are initiated in the deep layers of the somatosensory cortex 
and quickly spread to the cortico-thalamo-cortical (C-T-C) network.1,2 This network consists 
of glutamatergic projections from the deep layer cortical neurons to ventrobasal (VB) 
thalamic nuclei including the PO, and to the reticular thalamic nucleus (nRT); glutamatergic 
projections from VB thalamic nuclei to the cortex and nRT; and GABAergic projection 
from the nRT to VB thalami nuclei.2,3 Several mGlu receptor subtypes appear strategically 
distributed at the synapses of the C-T-C loop. In the cortex, group-I mGlu receptors (namely 
mGlu1 and mGlu5 receptors) are expressed post-synaptically on GABAergic interneurons.4,5,6 
At thalamic level, group I mGlu receptors are present post-synaptically on glutamatergic 
neurons of the VB complex reviewed by Ngomba et al., 2011.7 These neurons express 
moderate levels of mGlu5 receptor immunoreactivity,8 while the mGlu1 receptors mainly 
reside in the perisynaptic area.9,10,11,12 Modulatory effects of individual mGlu receptor 
subtypes on both excitatory and inhibitory synaptic transmissions in the C-T-C circuit have 
been found, and subtype-selective mGlu receptor ligands were proposed as potential 
candidates for novel antiabsence drugs.7 
 Studies with mGlu receptor ligands have been conducted in WAG/Rij rats, which develop 
spontaneous absence seizures after 2-3 months of age.7 Systemic administration of compounds 
RO0711401 and VU0360172, which behave as selective positive allosteric modulators (PAMs) 
of mGlu1 and mGlu5 receptors, respectively, decrease the incidence of SWDs in symptomatic 
WAG/Rij rats.13,14 No tolerance develops to the anti-absence activity of VU0360172, whereas 
the activity of RO0711401 declines after the first three days of repeated administrations.15 
Where precisely within the C-T-C circuit activation of mGlu1 or mGlu5 receptors reduces SWDs 
is unknown. Here, we have addressed this question by locally injecting either VU0360172 or 
RO0711401 in the VB part of the thalamus or in the somatosensory cortex. 
 Next to the role of glutamate, GABA also holds a key position in the control of SWDs. 
It is well known that systemically administered GABA-mimetics, such as tiagabine, acting 
by blocking the reuptake of GABA via the high affinity GABA transporter, GAT-1,16 aggravate 
the incidence  of SWDs.17 Here, we also investigated whether GABAergic regulation of 
absence seizures differs in the thalamus and cerebral cortex. WAG/Rij rats represent an 
appropriate model to examine this issue because in these rats as well as in GAERS (genetic 
absence epileptic rats of Strasbourg, 18 a high excitability of S1po is a prerequisite for the 
initiation of SWDs 1,2  that are then sustained by an enhanced tonic GABAergic inhibition in 
the thalamus.19,20 Finally, using tiagabine, we examined whether, and in which direction, 
an increased availability of (extra)synaptic GABA influences responses to the mGlu5 
receptor PAM, VU0360172, in the thalamus and somatosensory cortex.
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Materials and Methods
Animals
One hundred and thirty one male WAG/Rij rats were used for all experiments. Of these, 
eight animals were excluded because of a wrong position of the cannulas either in the 
cortex or in the thalamus. All rats were born and raised at Radboud University Nijmegen, 
The Netherlands, and had a mean body weight of about 350 g at 9 months of age. Rats 
of this age have about 16–20 SWDs per hour, adding several hundred SWDs per day.21 
The animals were housed in pairs in Macrolon cages, kept under controlled conditions 
(20ºC, 60% humidity) in a room with a reversed light–dark cycle (white light on from 
9 p.m. to 9 a.m.), with food and drinking water always available. After surgery, rats were 
kept individually. Animals were handled regularly before starting EEG registrations to 
reduce handling stress imposed by  the local injections. The study was performed in 
accordance with the guidelines of the European Community for the use of experimental 
animals and was approved by local ethics committee for animal studies (RU-DEC). All 
efforts were made to reduce discomfort experienced by the animals and to keep the 
number of animals as low as possible. 
Drugs and experimental protocol
VU0360172 (N-clyclobutyl-6-[2-3(fluorophenyl) ethynyl] pyridine-3-carboxamine), a selective 
mGlu5 receptor PAM, was obtained from Vanderbilt University Medical Center.22 RO0711401 
(9H-xanthene-9-carboxylic acid (4-trifluoromethyl-oxazol-2-yl) amide, a selective mGlu1 
receptor PAM, was kindly provided by Hoffmann-La Roche (Basel, Switzerland). Tiagabine 
(Hydrochloride, monohydrate), a GABA-reuptake inhibitor, was purchased from Siegfried 
Chemie AG.
 In all 3 experiments (Table 1), bilateral microinfusions in the peri-oral region of the 
somatosensory cortex (S1po) or in the VB  thalamic nuclei were performed using artificial 
cerebro spinal fluid (ACSF) as vehicle. Drugs were soluble in ACSF at concentrations of 
1 mg/ml (VU0360172, RO0711401) or 2 mg/ml (tiagabine). In experiments with single 
injections, drugs were always microinfused in a volume of 1 μl. Doses were 1 μg for 
VU0360172 and RO0711401, and 0.5, 1 or 2 μg for tiagabine. In experiments in which 
VU0360172 and tiagabine were co-administered, the two drugs were infused with a 3 min 
interval. In the S1po, both VU0360172 and tiagabine were infused at doses of 1 μg in a 
volume of 1 μl (i.e., 1 μl + 1 μl with 3 min of interval). In the thalamus, VU0360172 was 
infused at the dose of 1 μg whereas tiagabine was infused at the dose of 0.5 μg (always in 
a volume of 1 μl). ACSF was infused twice with 3 min  interval in control animals. Infusions 
were performed by means of a Hamilton syringe at a flow rate of 1 µl per min and the 
injection needle remained in the cannula after each single injection for 2 min to prevent 
backflow. The needle necessary for doing local injections did not protrude from the guide 
cannulas in order to avoid a spreading depression induced by the local injection.23
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In all experiments, cortical EEG was recorded and motor behavior was quantified as 
detailed in the Supporting Information. Surgical procedures, coordinates used for the 
implantation of guide cannulas, and the procedure we have used to determine the 
position of the guide cannulas are  described in detail in the Supporting Information. 
Statistical analysis
The effects of intracortical or intrathalamic drug injections on the incidence and mean 
duration of SWDs, and locomotor activity were tested in separate repeated-measures 
ANOVAs with incidence and mean duration of SWDs or amplitude of the PIR as dependent 
variables. The hourly incidence (number) and mean of SWDs in the 2 hours before 
injection were determined and differences between groups were analyses with a simple 
one-factor ANOVA (groups) for all three experiments. For all post-injection analyses, the 
time of EEG recording (6x10 minutes blocks post injection) was used as the within subjects 
factor, group (either site of injection of different drugs) was used as between subjects 
factor. In Experiment 2 and 3 repeated measures were conducted as well, but now 
Table 1   Overview of the three local injection experiments with drugs, doses, and side of 
drug application.
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different doses of tiagabine in cortex and thalamus (Experiment 2), or the different groups 
(Experiment 3 co-injection group, ACSF + ACSF), were used as between subjects factors, 
all followed by post-hoc tests, if appropriate. One way ANOVAs and Duncan post-hoc 
tests were used to isolate differences between the locations, doses or different drug 
treated groups at the different 10 minute episodes. Results are expressed as mean ± SEM 
and calculations were obtained using SPSS 19 software. The level of statistical significance 
was set at p < .05.
Results
Effects of microinfusion of VU0360172, RO0711401 or ACSF in  
the S1po cortex and ventrobasal thalamus on absence seizures  
in WAG/Rij rats
EEG was recorded in symptomatic WAG/Rij rats at baseline and following bilateral 
microinfusion of VU0360172 (1 μg/μl), RO0711401 (1 μg/μl) or vehicle (ACSF, 1 μl) in the 
S1po region of the somatosensory cortex or in the VB  thalamus. A representative trace of 
a typical SWDs recorded by EEG is shown in Fig. 1A. No significant differences were found 
in the two hours preceding drug injections among the 6 groups of animals receiving each 
of the two drugs or vehicle in either the S1po or the VB  thalamus with respect to the 
incidence  of SWDs (F=2.048, df 5,45, p =.086, η2=.16), mean duration of SWDs (F=0.460, df 
5,45, p =.804, η2=.04), and locomotor activity (measured as the amplitude of the PIR) 
(F=1.607, df 5,45,  p =.174, η2=.13). 
 EEG was recorded for two more hours post  drug or vehicle injections in the S1po or 
the VB thalamus, and the incidence  and mean duration of SWDs was measured in blocks 
of 10 min. Two-way ANOVA for repeated measures applied to the analysis of the incidence 
of SWDs in blocks of 10 min after bilateral injections of VU0360172 (n = 8), RO0711401 (n = 8), 
or vehicle (n = 9) in the S1po showed a time effect (F= 69.25, df 5,155, p< .001, η2= .691), 
a drug effect (F=29.56, df 2, 31, p < .001, η2=.656) and a significant interaction between 
time and drugs (F=10.28, df 10,155 p <.001, η2=.399). Post-hoc tests revealed that both 
VU0360172 and RO0711401 reduced SWD incidence in the first 40 min post-injection with 
no difference between the two drugs at all time-points (Figure 1B). 
 The same analysis on SWD incidence after injections of VU0360172 (n = 9), RO0711401 
(n = 8) or vehicle (n = 9) in the VB  thalamus revealed a time effect (F=39.48, df 5,224, p< 
.001, η2= .552), a drug effect (F=44.61, df 2,32, p< .001, η2=.736), and a significant interaction 
effect between time and drugs (F=5.48 df 14,224 p< .001, η2=.255), (Figure 1C). Post-hoc 
analyses across the six 10-min blocks showed varying differences across time. VU0360172 
was more (p<.001) effective than RO0711401 in suppressing the incidence of SWD in the 
first 10 min post-injections, with both drugs showing significant effects as compared to 
the ACSF control group. Between 10-20 and 20-30 min post-injections, RO0711401 and 
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Figure 1  Pharmacologic enhancement of mGlu or mGlu5 receptors in the somatosensory 
(S1po) cortex or ventrobasal (VB) thalamus inhibits absence seizures in WAG/Rij rats. 
A representative EEG recording of a typical SWD episode is shown in (A). The incidence of 
SWDs (in blocks of 10 min) in WAG/Rij rats locally infused in the somatosensory (S1po) 
cortex with VU0360172 (1 µg; n = 8), RO071140 (1 µg; n = 8), or ACSF (n = 9) is shown in (B). 
The incidence of SWDs after infusion of VU0360172 (1 µg; n = 9), RO071140 (1 µg; n = 8), 
or ACSF (n = 9) in the VB thalamus is shown in (C). The injection volume was always 1 µl. 
Values are means + SEM. p < 0.05 (two-way ANOVA + Duncan’s t-test) compared to 
the corresponding  ACSF values (*), or the corresponding VU0360172 values (#). The corre- 
sponding values of mean duration of SWDs and locomotor activity (means + SEM) are 
shown in (D, E) and (F, G), respectively.
A
B
D
F
C
E
G
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VU0360172 were equally effective in suppressing SWDs. Between 30 and 50 min post 
injection RO0711401 lost its activity whereas VU0360172 still significantly reduced the 
incidence of SWDs. 
 Differences in the efficacy of VU0360172 injected in the cortex and thalamus were 
found only after 50 min post-injection (F=14,205, df 2,32, p < .001, η2=.470), when the 
SWD-suppressing effects of VU0360172 were larger in the thalamus. This difference was 
no longer observed at 60 min post-injection. No statistical difference was found between 
intrathalamic and intracortical injection of RO0711401 with respect to the incidence of 
SWD.  
 None of the treatments caused significant differences in the mean duration of SWDs 
(Fig. 1D,E) and in locomotor activity (Fig. 1F,G).
Intracortical and intrathalamic injections of tiagabine produced 
opposite effects on absence seizures in WAG/Rij rats
Tiagabine was injected at doses of 1 or 2 μg in the S1po (n = 8 in both groups), and 0.5, 
1, or 2 μg in the VB thalamus (n = 4, 5, and 5, respectively). Control rats received ACSF (n = 8 
in both S1po and thalamus). There were no differences between the groups before drug 
administration. Intracortical injection of tiagabine reduced the incidence of absence 
seizures. Two-way ANOVA for repeated measures applied to the analysis of the incidence 
of SWDs after cortical injections of tiagabine or vehicle showed a time effect (F=107.93, df 
5,105, p< .001, η2=.837), with a large reduction of SWDs  in the first 40 minutes post 
injection (Fig. 2A). There was also a dose effect (F=164.69, df 2, 21, p< .001, η2=.940), and an 
interaction between time and dose (F=42.77, df 10,105, p< .001, η2=.803). Post-hoc analyses 
showed various differences across the six 10-min blocks:  Between 10-40 minutes post-
injection, the high dose of tiagabine was more effective in suppressing SWDs compared 
to the low dose of tiagabine and to ACSF. The low dose also suppressed SWDs during the 
first 30 min, as compared to ACSF. The low and high doses of tiagabine lost their 
anti-absence effect at 40 and 50 min post-injections, respectively.
 The increase in the incidence of SWDs was obtained after intrathalamic injection of 
tiagabine. Two-way ANOVA for repeated measures showed a time effect (F= 73.643, df 5, 
80, p< .001, η2= .822), with an increase in the incidence of SWDs being present in the first 
40 minutes after injection of tiagabine (Fig. 2B). There was also a dose effect (F= 656.218, 
df 3, 16, p< .001, η2=.992) and an interaction between time and dose (F=45.84, df 15, 80 p< 
.001, η2=.896). Post-hoc analysis across the six 10-min blocks showed that, between 10 
and 30 min post-injection, the highest dose of tiagabine (2 μg) increased the incidence of 
SWDs to a greater extent than the mid dose (1 μg). The lowest dose of tiagabine (0.5 μg) 
was inactive. At 40 min post injection, only the highest dose of tiagabine was still effective 
in reducing the incidence of SWDs. 
 Treatment with tiagabine did neither  change the mean duration of SWDs (Fig. 2C,D) 
nor  locomotor activity scores (Fig. 2E,F).
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Figure 2  Effect of tiagabine locally infused in the somatosensory (S1po) cortex or 
ventrobasal (VB) thalamus on absence seizures in WAG/Rij rats. The effects of two doses of 
tiagabine (1 µg; n = 8; or 2 µg; n = 8) or ACSF (n = 8) infused in the S1po cortex, and the 
effects of three doses of tiagabine (0.5 µg/µl; n = 4; 1 µg/µl; n = 5; 2 µg/µl; n = 5) or ACSF 
(1 µl; n = 8) infused in the VB thalamus are shown in (A) and (B), respectively. The injection 
volume was always 1 µl. Values are means + SEM. p < 0.05 (two-way ANOVA + Duncan’s 
t-test) compared to the corresponding ACSF values (*), to the corresponding values 
obtained with 1 lg tiagabine (#) in (A), or to the corresponding values obtained with 0.5 µg 
tiagabine (§) in (B). In (B), the same symbol (either * or §) is referred to the overlapping 
values obtained inrats treated with 1 or 2 lg of tiagabine. The corresponding values of 
mean duration of SWDs and locomotor activity (means + SEM) are shown in (C,D) and (E, F), 
respectively.
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Effects of combined injections of VU0360172 and tiagabine in the 
cortex and thalamus
In all experiments, injection of VU0360172 (1 μg in both S1po and VB thalamus) preceded 
by 3 min the injection of tiagabine (1 μg in the S1po, and 0.5 μg in the VB thalamus; n = 8 
and 9, respectively). Control rats received two sequential injections of ACSF in the S1po or 
in the VB thalamus (n = 8 and 9, respectively). There were no differences between the 
groups before drug administration. Data obtained after intracortical injections are shown 
in Fig. 3A. Two-way ANOVA for repeated measures after injections of VU0360172 + 
tiagabine and ACSF + ACSF showed a time (F= 14.132, df 5,70, p< .001, η2= .502), and a 
group effect (F= 102.86, df 1,14,  p< .001, η2= .880). In the first 10-40 min post injection, the 
combination of VU0360172 and tiagabine substantially reduced the incidence of SWDs 
with respect to the control group. In the first 20 min post-injection the reduction in the 
incidence of SWDs was greater than that previously observed with VU0360172 alone 
(-67% and -72% with VU0360172 plus tiagabine at 10 and 20 min post-injection, 
respectively, in Fig. 3A vs. -57% and -60% with VU0360172 alone at 10 and 20 min post-
injection, respectively, in Fig. 1B). At 50 and 60 min there was a slight reduction in the 
incidence of SWDs, with no significant difference from the control group.
 Data obtained after intrathalamic injections of VU0360172 (1 µg/µl) and tiagabine 
(0.5 µg/µl) are shown in Fig. 3B. Here, there was also a time effect (blocks) (F= 5.23, df 5,80, 
p< .001, η2= .231), and an interaction between time and group (F=2.90, df 5,80 p<.001, 
η2=.154). Post-hoc analysis across the six 10-min blocks showed that in the first 10 min 
post-injection, the combination between VU0360172 and tiagabine reduced the 
incidence of SWDs compared to 2 x ACSF. Combination of the two drugs was ineffective 
at 20 min and caused a significant increase in the incidence of SWDs at 30 and 40 min 
post injection, again in comparison with 2 x ACSF. 
 None of these treatments had any effect on the mean duration of SWDs (Fig. 3C,D) 
and locomotor activity (Fig. 3E,F).
Discussion 
Our experiments were a follow-up from the evidence that systemic administration of 
group-I mGlu receptor PAMs reduces the incidence of SWDs in WAG/Rij rats.7,13,14 Here, we 
showed that this effect could be induced by injecting mGlu1 or mGlu5 receptor PAMs in 
both the S1po and ventrobasal thalamic nuclei. There was a difference in the thalamic 
and cortical response to RO0711401 and VU0360172. The two drugs were equally effective 
in reducing SWDs when injected in the cortex; in contrast, the mGlu5 PAM, VU036012, 
displayed a greater efficacy than the mGlu1 PAM, RO0711401, when injected in the 
thalamus. The somatosensory cortex is the main site of origin of SWDs in WAG/Rij and 
GAERS rats,1 and this region is highly excitable. 2  In the somatosensory cortex, mGlu1α 
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Figure 3  Combined effect of VU0360172 and tiagabine on the incidence of absence 
seizures in WAG/Rij rats. The effects of intracortical injections of VU0360172 (1 µg) plus 
tiagabine (1 µg) (n = 8) or ACSF + ACSF (n = 8) on the incidence of SWDs are shown in (A); 
the effects of intrathalamic injections of VU0360172 (1 lg) plus tiagabine (0.5 µg) (n = 9) or 
ACSF + ACSF (n = 9) are shown in (B). Values are means + SEM. Values are means + SEM. 
*p < 0.05 (two-way ANOVA + Duncan’s t-test) versus the corresponding ACSF values. 
The corresponding values of mean duration of SWDs and locomotor activity (means + 
SEM) are shown in (C, D) and (E, F), respectively. VU0360172 and tiagabine were 
microinfused with 3 min of interval. Control rats received two injections of ACSF with 
3 min of interval.
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receptors are expressed by somatostatin-positive, calretinin-positive, and calbindin-posi-
tive, but not by fast-spiking parvalbumin-positive, GABAergic interneurons.4,5,6 mGlu5 
receptors are found in both somatostatin-positive and parvalbumin-positive GABAergic 
interneurons,5,6 as well as in pyramidal neurons.24 Because the efficacy of intracortically 
injected VU0360172 and RO0711401 was identical, it is possible that a cell type expressing 
both mGlu1 and mGlu5 receptors is a common target for the two PAMs. We hypothesize 
therefore that activation of either mGlu1 or mGlu5 receptors expressed by somatosta-
tin-sensitive and other types of regular spiking GABAergic interneurons suppresses SWDs 
by enhancing GABAergic inhibition onto pyramidal neurons. This hypothesis is consistent 
with the finding that intracortical injection of tiagabine, which inhibits the high affinity 
GABA transporter, GAT-1, reduced SWDs. This leaves us with the suggestion that enhancing 
mGlu1/5-mediated activation of cortical GABAergic interneurons or inhibiting GABA 
reuptake would produce the same effect. Hence, it is  not surprising that intracortical 
injection of VU0360172 plus tiagabine reduced SWDs to a slightly larger extent than 
injection of VU0360172 alone. 
 Both mGlu1 and mGlu5 receptors are present postsynaptically on VB thalamic neurons, 
and only mGlu5 receptors are found at moderate levels in GABAergic neurons of the reticular 
thalamic nuclei (reviewed by Ngomba et al., 2011)7. Both mGlu1 and Glu5 receptors are 
coupled to Gq/11, and their activation stimulates phospholipase-Cβ4(PLC-β) with ensuing 
hydrolysis of phosphatidylinositol-4,5-bisphosphate and formation of inositol-1,4,5- 
trisphosphate and diacylglycerol (reviewed by Nicoletti et al., 2011). 25  Mutations of PLC-β4 
at thalamic level have been shown to enhance bursting of thalamo-cortical projection 
neurons in a T-type Ca2+ channel-dependent fashion, resulting in absence epilepsy.26 
Thus, activation of either mGlu1 or mGlu5 receptors present in VB  thalamic neurons 
might restrain the occurrence of absence seizures by negatively regulating the activity of 
T-type Ca2+ channels on thalamo-cortical cells. However, intrathalamic injection of 
VU036172 caused a more robust and prolonged suppression of SWDs as compared to 
intrathalamic injection of RO0711401, suggesting that an additional mechanism that is 
peculiar to mGlu5 receptors contributes to restrain the occurrence of SWDs. A major 
difference between mGlu1 and mGlu5 receptors is that only the latter are found on 
astrocytes, both in the thalamus and cerebral cortex.27,28 Astrocytes are key players in the 
regulation of thalamic oscillations because they clear extracellular glutamate and GABA, 
thereby limiting the activation of extrasynaptic glutamate and GABA receptors.
 An increased inhibitory GABAergic transmission at the synapses between reticular 
thalamic neurons and VB thalamic neurons sustains the occurrence of SWDs (reviewed by 
Blumenfeld, 2005)2, and this explains the pro-absence effect seen after systemic 
administration of drugs that enhance GABAergic transmission, such as tiagabine, 
vigabatrin, and the neurosteroid allopregnanolone in both GAERS and WAG/Rij rats.16,29,18,30 
Intrathalamic injections of the GABA-transaminase inhibitor, γ-vinyl GABA, the GABAA 
receptor agonist, muscimol, or the neurosteroids, allopregnanolone or ganaxolone also 
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increase the incidence of SWDs.31,32  Tiagabine enhances tonic inhibition of thalamic relay 
neurons by inhibiting GABA re-uptake, and, therefore, facilitating the endogenous 
activation of extrasynaptic GABA receptors.33,19,34 Hence, the enhanced incidence of SWDs 
found after intrathalamic injection of tiagabine was fully expected and suggests that the 
pro-absence activity in the thalamus prevails over the anti-absence activity in the cortex 
after systemic injection of tiagabine. 
 Experiments in which the mGlu5 receptor PAM, VU036172 was co-injected with 
sub-threshold doses of tiagabine in the VB thalamus produced interesting results. 
If combined with tiagabine, VU036172 was still effective in reducing the incidence of 
SWDs in the early post-injection time (10 min), but then lost this effect at 20 min, and 
displayed a paradoxical pro-absence effect at 30 and 40 min. This suggests that the 
regulation of thalamic oscillations by mGlu5 receptors is shaped by extracellular GABA, or, 
alternatively, that the mGlu5 receptor controls the activity of the GABA transporter, GAT-1, 
in astrocytes or in GABAergic fibers afferent to VB thalamic nuclei. Activation of glial 
mGlu5 receptors is known to regulate the expression of the glial glutamate transporters, 
GLT-1 and GLAST.35 If this regulation extends to GAT-1, we may suggest the following 
scenario. Pharmacological enhancement of mGlu5 receptors produces pleiotropic effects 
in the VB thalamus, including an enhanced clearance of extracellular GABA, which might 
be critical for the suppression of SWDs. In the presence of a GAT-1 inhibitor (e.g., tiagabine) 
activation of mGlu5 receptors will not stimulate GABA reuptake, and the progressive 
increase in extracellular GABA will block the anti-absence action mediated by mGlu5 
receptor stimulation. Studies on GABA uptake in cultured astrocytes or studies on tonic 
inhibition in thalamic slices in epileptic and non-epileptic rats are needed to verify this 
hypothesis. 
 In conclusion, group I metabotropic receptors are involved in the control of absence 
seizures through the entire C-T-C  network that is responsible for the pathological oscillations 
associated with SWDs. However, the consequences of stimulation are site dependent: 
stimulating group I mGlu receptors in the cortex may enhance GABA-ergic inhibition onto 
pyramidal neurons and reduces SWDs. Stimulation of group I mGlu receptors in thalamic 
relay neurons might reduce tonic inhibition thereby reducing SWDs. In the presence of 
tiagabine, activation of thalamic mGlu5 receptors will not stimulate GABA reuptake, and the 
progressive increase in extracellular GABA will abolish the anti-absence effect mediated 
by mGlu5 receptor stimulation. A schematic diagram illustrating our hypothesis on the 
regulation of absence seizures by cortical and thalamic group-I mGlu receptors and the 
potential interaction with GABAergic transmission is shown in Fig. 4.
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Figure 4  Mechanistic hypothesis of the role played by cortical (A) or thalamic (B) mGlu1 
and mGlu5 receptors in the modulation of absence seizures. The diffusion of either GABA 
(rounded dots and arrows in green) or glutamate (rounded dots and arrows in red) within 
and out of the synaptic terminals and glial cells are depicted. In the S1po cortex, 
pharmacologic enhancement of mGlu1 or mGlu5 receptors might reduce absence 
seizures by activating somatostatin (SST)–positive GABAergic interneurons, and tiagabine 
might produce the same effect by enhancing GABA levels at the synapses between SST+ 
interneurons and pyramidal neurons. In the ventrobasal thalamus, tiagabine enhances 
absence seizures by increasing synaptic and extrasynaptic GABA levels, thereby facilitating 
the activity of T-type voltage-sensitive Ca2+ channels. mGlu1 and mGlu5 receptors 
might protect against absence seizures by directing modulating T-type Ca2+ channels 
(modulation of T-type channels by phospholipase C has been reported26) or through a 
blockade of the glial glutamate transporter.35 Tiagabine might act via blockade of the 
presynaptic and glial GABA transporter. Data on the interaction between VU0360172 and 
tiagabine raise the possibility that mGlu5 receptors regulate the expression or activity of 
GAT-1 in GABAergic terminals and/or astrocytes.
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Abstract 
Ethosuximide is the drug of choice in the treatment of various types of absence seizures. 
However, there is room for other anti absence drugs considering that not all subjects 
(57%–74%) become seizure free and in about 47% of subjects ethosuximide therapy 
failed. New anti-absence drugs may target or modulate glutamatergic and or GABA-ergic 
neurotransmission, the key players in the circuitry involved in the cortico-thalamo-cortical 
oscillations responsible for the highly stereotyped spike-wave discharges (SWDs). The rat’s 
somatosensory cortex contains a highly excitable focal region while tonic inhibition is 
dominant in the thalamus. Biochemical studies have shown that symptomatic WAG/Rij 
rats differ from age matched controls regarding increased mGlu5R expression in the 
somatosensory cortex and decreased mGlu1R and mGlu5R expression and function in the 
thalamus. Two group I positive allosteric modulators VU0360172 and RO0711401 dose-de-
pendently suppressed SWDs in acute pharmacological studies, and both compound 
were effective in cortex and thalamus. Interestingly, the GABA reuptake blocker tiagabine 
reduced SWDs only in cortex, while the efficacy of ethosuximide is much higher in the 
highly excitable cortex than in the thalamus. It is therefore proposed that VU0360172 
stimulates cortical GABA interneurons, which inhibit the highly excitable cortical neurons 
in the focal area and that in the thalamus, VU0360172 may reduce tonic inhibition. Group 
I PAMs might be further develop as an anti-absence drugs, while their preclinical profile in 
mesial temporal epilepsy models, another focal type of epilepsy, needs to be determined.
Key words: Group I mGluR; Positive allosteric modulators; absence epilepsy; genetic 
models; WAG/Rij rats; focal epilepsy; GABA; somatosensory cortex; antiepileptic drug 
development; 
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Introduction
Childhood absence epilepsy (CAE) is the most common form of pediatric epilepsy, 
accounting for 10% to 17% of all cases. It typically begins between 4 and 8 years of age 
and is characterized by daily, frequent, brief staring spells, often with the eyes fluttering 
and the child being unresponsive to external stimuli. Children may experience dozens to 
hundreds of these episodes per day. Ethosuximide (ETX), dating back to the 1950s, and 
valproic acid (VPA) have been and still are the drug of choice in absence seizures for many 
decades, while a relative newly developed lamotrigine, was proposed and approved in 
the mid nineties [2]. It was only recently that the efficacy, safety and tolerability of the 
three compounds were compared in a large multi center study. A 2010 double-blind 
randomized, comparative controlled, including 446 patients, examined the efficacy and 
tolerability of ETX, valproic acid, and lamotrigine. At the week 16–20 visit, subjects on ETX 
(53%) and valproic acid (58%) had significantly higher freedom from failure rates than 
subjects on lamotrigine. Next, subjects on ETX had significantly less attention dysfunction 
compared to subjects on [3]. This combination of findings implied that ETX is the optimal 
initial monotherapy for CAE. Despite these rather favorable outcomes and ETX being the 
“winner” at week 16–20, ETX therapy failed in 47% of subjects: 14% due to seizures, 24% 
due to intolerable side effects, 13% withdrew from study. Epidemiologic cohort studies 
showed only freedom in the range from 21%–74%. In five prospective cohort studies, the 
proportion of seizure free subjects was 57%–74%. Although labeled a “benign” syndrome, 
the clinical course of CAE is variable and remission rates are far lower than in other classic 
benign idiopathic epilepsies such as Benign Rolandic Epilepsy [4]. Although a complete 
discussion of the adverse effects is beyond the scope of discussion, the reader is referred 
to a recent review of Gören and Onat [5], the usage of ETX has been associated with 
commonly observed dose-dependent side effects related to the gastrointestinal tract, 
central nervous system and hematopoietic adverse effects. Nausea, abdominal discomfort, 
vomiting, diarrhea, and anorexia are common at the onset of ETX therapy. Central nervous 
system effects include drowsiness, dizziness, hiccups, fatigue, insomnia, tiredness, 
headache, and psychotic behaviors. ETX has been also associated with a wide variety of 
idiosyncratic reactions, including allergic dermatitis, rash, Stevens-Johnson syndrome, 
systemic lupus erythematosus, lupus-like syndrome, serum sickness reaction, agranulocy-
tosis, and aplastic anemia [3,6]. The hematopoietic effects include leukopenia, eosinophilia, 
and pancytopenia [7]. A new dimension to the treatment of absence epilepsy has been 
added by the proposal that ETX, first in WAG/Rij rats, subsequently also in GAERS, has 
besides antiabsence effects [8] also antiepileptogenic effects when treatment started 
early and lasted 4 months [9,10,11,12] and that the comorbidity of absence epilepsy with a 
mild form of depression-like behavior, typically for the WAG/Rij strain [13] did not occur as 
a consequence of anti epileptogenesis by ETX [14]. Most relevant, from a theoretical but 
also from a translational point of view is that remission is more than likely in high 
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compliance absence patients that were treated with ETX [15]. It can be concluded that 
ETX is the most precious tool in the treatment of absence epilepsy, that it is certainly not 
without problems, including the relative high failure rate, and its putative adverse effects 
suggests that there must be room for a new and better anti-absence drugs. Moreover, 
ETX is the drug of choice, new and better antiabsence drugs must be compared with ETX. 
The assumed working mechanisms of ETX
It has long been thought that the action of ETX is blocking It currents in thalamic-cortical 
(TC) relay cells and, consequently, the burst firing mode of TC relay cells. The burst firing of 
TC cells was assumed to be the neurophysiologic substrate of SWD activity in cortico- 
thalamo-cortical pathways. These ideas were developed in the beginning of the nineties 
of the previous century based on in vitro neurophysiological studies using voltage-clamp 
techniques in acutely isolated neurons of the ventrobasal complex from rats and guinea 
pigs. Therapeutically relevant concentrations ETX induced a reduction of the low 
threshold Ca2+ current which was most pronounced at more-hyperpolarized potentials 
first in the relay nuclei with no change in its kinetics or steady-state properties [16,17,18], 
later this was also found for the reticular thalamic nucleus (RTN) [19]. It was generally felt 
that virtually all thalamic neurons are endowed with a prominent low-threshold Ca2+ 
conductance that is of sufficient magnitude to generate a low-threshold Ca2+ spike and 
the accompanying burst firing mode of thalamo-cortical cells [20,21,22]. This conductance 
is crucial in the generation of normal thalamo-cortical oscillations such as sleep spindles 
[23], and in the occurrence of delta waves, typical for deep slow sleep [24,25]. The 
possibility was raised that it may also play a key role in the development of pathological 
SWDs and this idea was thought to be a sufficient explanation for the working mechanism 
of ETX in reducing SWDs in absence epilepsy patients. However, ETX also decreases 
persistent Na+ and Ca2+-activated K+ currents in thalamic and layer V cortical pyramidal 
neurons [26,27] which may explain also the decrease in burst and the increase in tonic 
firing. These results cast doubts on the hypothesis that a reduction of IT in thalamic 
neurons underlies the therapeutic action of this anti-absence medicine [26]. In addition, 
there is evidence that in a genetic absence epilepsy rat model ETX reduces cortical 
γ-aminobutyric acid (GABA) levels. Also, elevated glutamate levels in the primary motor 
cortex of rats with absence epilepsy (but not in normal animals) are reduced by ETX. In 
addition, whole-cell patch-clamp studies revealed an increase in spontaneous GABA 
release by ETX concurrent with no change in glutamate release at synapses in the rat 
entorhinal cortex in vitro [28]. This was reflected in a substantial rise in the ratio of network 
inhibition to excitation, and a concurrent decrease in excitability of neurons embedded in 
this network. These authors concluded that ETX directly elevates synaptic inhibition in 
the cortex next to its well established effects on ion channels, and that both factors 
contribute to its well known anti-absence effects. Interestingly, an increase in synaptic 
inhibition of cortical cells was also found after tiagabine by the same authors. 
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 This notion is relevant considering that there is now good evidence that generalized 
absence seizures in the genetic models, but also in a by systemic administration of a low 
dose of PTZ induced absence-like seizures, are initiated at a cortical focus in the deep 
layers of the somatosensory cortex [29,30]. Subsequent studies revealed that ETX exerted 
an immediate and strong anti-absence action when injected in the somatosensory cortex 
and not the cortex in general [31,32]. Moreover, In vivo studies showed that the majority 
(60%) of cat TC neurons are completely silent during SWDs [33] and in GAERS, a well 
characterized and validated rat genetic model of absence epilepsy, no low threshold 
Ca2+ spikes (LTSs) are recorded in TC neurons during the majority (90%) of SWDs [34,35]. 
However, hyperpolarized mediated LTSs and the burst firing mode were seen in RTN 
during SWDs in GAERS [35]. Microinfusion of ETX into VB produced only a weak and 
delayed anti-absence effect while the effects in the RTN were of a larger magnitude. In all, 
the outcomes of also these studies questioned the notion that ETX exerts its therapeutic 
effect for a large extent at the thalamic level [36]. 
 Monotherapy often fails and seizure control can be only achieved with the administration 
of polytherapy. Valproic acid and ETX were singly and also co administered in rats of the 
WAG/Rij strain. The incidence of SWDs in the electroencephalogram (EEG) was the 
read-out variable. The median effective doses (ED50 values) of the two drugs in this 
model were 121 and 21.5 mg/kg for valproic acid and ETX, respectively [37]. When both 
agents were administered together, the interaction between the two agents was shown 
to be infraadditive: the combination was less effective in diminishing the incidence of 
SWDs in WAG/Rij rats than could be anticipated and based on the net effect of the drugs 
administered alone. This is indirect evidence that the two anti absence drugs share some 
common cellular or molecular mechanism, perhaps blocking Na+ channels. 
New anti-absence drugs 
The search for new anti-absence drugs has been concentrated on drugs that target the 
circuitry in which the for absence epilepsy characteristic SWDs are elicited, maintained and 
aborted. For typical absence epilepsy is undoubtedly the reciprocally interconnected cortico- 
thalamo-cortical network including the RTN [38,39,40,41], for atypical absence epilepsy it is 
more likely a hippocampal, thalamo-cortical circuit [42]. GABA and glutamate are the major 
neurotransmitter systems within the interconnected cortex and thalamus. Therefore, it 
seems logic to investigate the role of these neurotransmitter systems on the incidence of 
SWDs. Our group has done most of the experiments in a well characterized and validated 5 
model of absence epilepsy, rats of the WAG/Rij strain [43]. The model has construct, face, 
and pharmacological validity [39,44,45]. In the mid nineties, drugs affecting ionotropic 
glutamate receptors were in the focus of interest and all subclasses of antagonists reduced 
SWD while agonists enhanced SWD in our genetic absence model [45,46,47,48]. However, 
many of the ionotropic receptor antagonists had toxic effects and their role in seizure control 
has not led to the successful development of new antiabsence or anticonvulsant drugs. 
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 Since targeting mGluRs might be less toxic than targeting ionotropic glutamate 
receptors, we decided to focus on the role of mGluRs, also considering that drugs 
targeting mGluR have been shown to exert pro or antiepileptic effects in various seizure 
and epilepsy models [49]. More specifically: orthosteric antagonists of Group I mGluR 
reduce motor seizures induced by sound stimulation in DBA mice as well as non-convulsive 
(absence) seizures in the lethargic mice model [50,51], the latter is a genetic absence 
model with ataxia and hypoactivity, while the non-selective orthosteric agonist DHPG 
targeting both type 1 and 5 receptors, enhances convulsions [52,53]. The role of orthosteric 
agonists on non-convulsive epilepsy has not been investigated. Interestingly, besides 
orthosteric agonists and antagonists also more selective allosteric modulators (PAMs and 
NAMs) are currently developed and available, which might be even more subtle in 
inducing changes. A second reason was that the mGluRs are widely distributed in the 
cortico-thalamo-cortical networks [54], the brain circuitry in which SWD originate, are 
maintained, and end [40]. This network consists of a large number of subtypes of mGluR, 
and they are selectively present in different parts of the circuitry, offering possibilities for 
selective targeting disease modified (sub)systems. Here we focus on specifically the role 
of Group I mGluRs receptor with its two subtypes (I and 5) in the pathogenesis of absence 
epilepsy and whether drugs affecting this system might be putative anti-absence drugs. 
It is known that Group I mGluRs are involved in absence epilepsy because thalamo-corti-
cal -limited knockdown as well as whole-animal knockout of PLCβ4, a protein involved in 
the Group I signaling pathway, induced spontaneous SWDs in mice with simultaneous 
behavioral arrests. In addition, the susceptibility to drug-induced SWDs was increased in 
these knock-out mice, indicating that the deletion of thalamic PLCβ4 leads to the genesis 
of absence seizures [55]. Interestingly, PLCβ4 co localizes with mGlu1 receptors, and 
mediates mGlu1 receptor signaling in thalamic nuclei [56,57]. Moreover, also the studies 
by Chapman et al. [50,51] suggest a role of these receptors in non-convulsive seizures.
Neurochemical studies 
As mentioned above, mGluRs are widely distributed in the cortico-thalamo-cortical 
network [54]. In the thalamus, group I mGluRs are located on relay neurons in the 
ventrobasal thalamus postsynaptic to the cortical inputs [58,59,60]. Moderate-to-low 
mGlu5 receptor mRNA and protein levels are expressed in RTN neurons [59,61], whereas 
these neurons do not express mGlu1 receptor mRNA [62]. mGlu1 receptors in the cortex 
are located 6 postsynaptically on GABAergic interneurons [63], and mGlu5 receptors are 
expressed by pyramidal neurons postsynaptic to thalamo-cortical projections [64], as well 
as by interneurons [59,65]. Group I mGluRs are coupled to Gq/G11 proteins and their 
activation stimulates polyphosphoinositide hydrolysis with formation of inositol-1,4,5-tris-
phosphate and diacylglycerol, and also regulate the activity of different types of Ca2+ and 
K+ channels [66]. 
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 Several studies of both expression and function were performed in the WAG/Rij in 
order to assess the biochemical role of mGluRs receptors in the pathophysiology of 
non-convulsive epilepsy. Relevant is that in the WAG/Rij rat absence model the SWDs start 
to become present in the cortical EEG from 2-3 months of age onwards. The analysis of 
expression of mGluRs was carried out by using symptomatic WAG/Rij rats (minimally 6 
months of age) and pre-symptomatic WAG/Rij rats (not more than 2 months of age) 
which were compared with age-matched control non epileptic ACI rats. Various part of 
the cortico-thalamo-cortical network, such as RTN, ventrobasal thalamic nuclei, somato -
sensory cortex and motor cortex were inspected [67,68]. The functional activity of Group I 
mGluRs receptors was examined by using an in vivo method that allows measurements of 
agonist-stimulated PI hydrolysis after incorporation of [3H]inositol into the phospholipids of 
living rats [69]. mGlu1 or mGlu5 receptor function was evaluated in the thalamus and or 
in the somatosensory cortex of symptomatic WAG/Rij rats as compared to age matched 
controls.
 Both the expression and function of mGlu1 and mGlu5 receptors were reduced in 
the thalamus of symptomatic WAG/Rij rats compared to age-matched non-epileptic ACI 
rats. Lower levels of Group I subtype protein receptors in the thalamus of the symptomatic 
WAG/Rij rats were confirmed by immunohistochemical analysis [67]. Moreover, these data 
showed that the reduced expression of mGlu1 receptors found in symptomatic WAG/Rij 
rats was observed in the ventrobasal complex, that correspond to dorsal and medial 
nucleus, but not in the ventroposterolateral thalamus. Furthermore, no mGlu1 receptor 
mRNA was observed in the RTN of the rats. No change in mGlu1 receptor signaling was 
detected in the somatosensory cortex of symptomatic WAG/Rij rats compared to age- 
matched control ACI rats. In contrast, the expression of mGlu5 receptors was increased 
either in the somatosensory and motor cortex of symptomatic WAG/Rij rats, as assessed 
by immunohistochemical and western blot analysis [68]. 
 In all, these neurochemical data demonstrate that absence epilepsy in this genetic 
model is accompanied by significant changes in expression and function of group I 
mGluR in for absence epilepsy relevant parts of the SWD generating circuit. 
Acute and subchronic Pharmacological studies 
Considering our aim to evaluate putative new treatments for absence epilepsy, first the 
effects of a selective mGluR group I subtype 1 PAM on the occurrence of spontaneous 
absence seizures were investigated. Adult symptomatic rats of the WAG/Rij strain were 
treated systemically with the compound RO0711401 (3, 10 or 30 mg/kg, s.c.), a selective 
PAM at mGlu1 receptors [70]. The outcomes indicated that the dose of 3 mg/kg of 
RO0711401 could only abolish the early stress-related increase in the incidence of SWDs; a 
dose of 10 mg/kg was required for a substantial reduction in the incidence of SWDs; and 
a dose of 30 mg/kg could reduce the incidence as well as the mean duration of trains of 
SWDs. To further demonstrate a protective role for mGlu1 receptors against SWDs, the 
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same rats were systemically injected with compound JNJ16259685 (2.5 or 5 mg/kg, i.p.), 
which behaves as a selective NAM of mGlu1 receptors. Treatment with JNJ16259685 
increased the incidence of SWDs in a dose-dependent manner [67]. 
 Group I (mGluR1 and mGluR5) receptors show a different pattern of distribution in 
the C-T-C network, which suggests a distinct rather than complementary functions of 
these two receptor subtypes. Therefore our pharmacological investigation was extended 
to mGlu5 receptors. The pharmacological enhancement of mGluR5 activity with the PAM 
VU0360172 at doses 3 and 10 mg/kg, s.c., known to be centrally active [71], caused a 
robust and dose-dependent reduction in the incidence and mean duration of SWDs. The 
acute treatment with MTEP (10 or 30 mg/kg, i.p.), a selective NAM of mGlu5 receptors 
[72,73], did not change the incidence and mean duration [68]. 
 From a therapeutic standpoint it is important to establish whether tolerance 
developed to the action of these putative anti absence drugs. Effective doses of 
VU0360172 (3 mg/kg, s.c.) and RO0711401 (10 mg/kg, s.c.) were administered in rats twice 
daily for ten days and the incidence of SWD was daily determined. As expected [67,68] 
both mGlu1 and mGlu5 receptor PAMs suppressed the incidence of SWDs in the first 2 
days of the treatment. While the anti-absence effect of the mGlu5 receptor PAM 
(VU0360172), persisted largely over the 10 day administration period with only a small sign 
of tolerance. In contrast, rats quickly developed complete tolerance to RO0711401 since 
the 3rd day of treatment. The results are presented in Figure 1. 
Figure 1  Tolerance towards twice daily s.c. administration of VU360172 (3 mg/kg) and 
RO711401 (10 mg/kg) on incidence of spike-wave discharges (SWDs) in adult (> 6 month) 
WAG/Rij rats during baseline (hour 0) and during first hour post injection at Day 1-10 and 
Day 13 (rechallenge), control rats were given vehicle. Rats injected with VU0360172 
showed an antiabsence effect throughout all injection days without clear signs of 
tolerance; in contrast, RO711401 was effective on Day 1 and 2 only and it lost completely 
its antiabsence action at Day 3. This lack of effects persisted throughout the remainder of 
the study, including during the rechallenge after 2 days of withdrawal. Depicted are 
means ± S.E.M. of incidence of SWDs, 8-9 animals per group (Adapted After [74]).
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Next it was wondered whether chronic treatment with RO0711401 or VU0360172 would 
cause desensitization of mGlu1 and mGlu5 receptors both in symptomatic WAG/Rij rats 
and in non-epileptic age matched Wistar control rats [74]. Chronic administrations of 
VU0360172 increased the expression of mGlu5 receptors in the thalamus and in the cortex 
in WAG/Rij rats without changing the expression of mGlu1a receptors. Treatment with 
RO0711401 enhanced the expression of both mGlu1a and mGlu5 receptors in thalamus 
and cortex in WAG/Rij rats. Opposite data were obtained in non-epileptic Wistar rats, in 
which repeated injections of the two PAMs down-regulated the expression of mGlu1a 
and mGlu5 receptors. RO0711401 changed the expression of both the mGlu1a and the 
mGlu5 receptors in WAG/Rij and Wistar rats, whereas VU0360172 selectively changed the 
expression of mGlu5 receptors only [74]. 
 All these outcomes contribute to highlight the key role of the Group I mGluRs in 
the pathophysiology of absences seizures, at least in the spontaneous absence seizures 
model WAG/Rij rats. Moreover, they suggest that chronic administration of group I PAMs 
may change the expression of mGlu1a and mGlu5 in cortex and thalamus, that these 
changes might be different for the two different PAMs and that the genetic context may 
also be crucial for the changes in receptor function after repeated administration.
Local injection studies 
The next step was a C-T-C circuit demarcation strategy adopted by independent bilateral 
intra-cortex or intra-thalamus (ventral basal complex) micro-infusions to investigate 
site-specific effects on the regulation of SWDs WAG/Rij rats received micro-infusion with 
RO0711401 or VU030172. The two drugs were equally effective in reducing the incidence 
of SWDs when injected into the cortex. Both drugs were also effective in reducing SWDs 
incidence when they were infused in the thalamus, although the mGlu5 PAM VU036012 
displayed a somewhat larger efficacy than the mGlu1 PAM RO0711401, when injected into 
the thalamus [75]. It is well known that not only a dysfunction in glutamatergic neuro-
transmission is known to be one of the causes responsible for the initiation and spread of 
seizures, but also GABAergic neurotransmission. Moreover, glutamate and GABA interact 
at many locations within the T-C-T network. Therefore first the effects of tiagabine alone, a 
GABA reuptake inhibitor at the neuronal or glial GAT-1 transporter, micro-injected in 
cortex and thalamus were investigated. Cortical administration of tiagabine resulted in a 
dose-dependent decrease in the incidence of SWDs, an effect similar to the effects of the 
PAMs of mGluR. In contrast: intra-thalamic injections showed a dose-dependent increase 
in the incidence of SWDs, an effect opposite to that obtained with the PAMs. 
 Next, the interaction between GABA and glutamate was investigated. More precisely, 
it was established whether and in which direction an increased availability of (extra)
synaptic GABA influences responses to VU0360172 in the thalamus and cortex. Combined 
micro injections of VU0360172 and tiagabine were carried out. Co-administration of 
VU0360172 and tiagabine reduced the incidence in the SWDs when injected in the cortex 
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and some indications were obtained for subadditive effects. In contrast, complete 
opposite effects were observed after the same co-administration in the thalamus: first a 
decrease, which was followed by an increase in the incidence of SWD, suggesting that the 
effects of VU0360172 were completely blocked in the presence of increased GABA [75]. 
In all the above mentioned experiments the behavior of the rats was quantified with the aid of 
a calibrated infrared movement detector; it allowed the quantification of the amount of 
bodily activity during the EEG recording session. In none of the experiments described 
above, VU0360172 affected the behavior of the rats. 
 It can be concluded that these pharmacological studies demonstrate dose dependent 
SWD decreasing effects of both PAMs, minimal tolerance in a twice daily 10 day administration 
protocol of VU0360172 and the quick development of tolerance to RO0711401. Local 
injections of both PAMs demonstrated that both compounds are effective in cortex and 
thalamus. Effects on behavior were not noticed. In all, VU0360172 has a good preclinical 
profile in the WAG/Rij absence model. 
Discussion 
The preclinical profile of VU0360172 as an antiabsence drug, as described here, seems 
promising, although only a few studies have investigated its effects. ETX has a much 
longer tradition, it has the best clinical profile of all anti absence drugs, although recent 
reviews also emphasize the need for other and newer treatment options. Many earlier in 
vivo and in vitro neurophysiologic studies in mostly healthy individuals of different species 
such as rats, cats, and ferrets, e.g. [19,20,76,77] have found that ETX acts in the thalamus by 
blocking Ca2+ channels, both in the relay nuclei and in the RTN. The comparative cor-
tex-thalamus local injection studies with ETX in the GAERS absence model have yielded a 
somewhat different pattern since they have shown that ETX is more effective in the 
somatosensory cortex than in the thalamus. Moreover, this cortical effect of ETX was 
restricted to the focal region in the somatosensory cortex, while in the thalamus ETX 
showed a less large effect in both the VB nuclei and in the RTN [31,36]. A compilation of 
the WAG/Rij and GAERS data regarding the local administration of ETX and VU0360172 in 
cortex and thalamus is presented in Figure 2. 
 Next to blocking pyramidal cortical cells within layer V–VI of the facial somatosensory 
cortex in GAERS [32], most likely via a specific attenuation of the noninactivating Na+ and 
Ca2+-activated K+ currents [26,27], ETX might also facilitate GABA-ergic neurotransmission 
[28]. Interestingly, VU0360172 and RO0711401 were two drugs that were equally effective 
in suppressing SWDs in the somatosensory cortex and ventral basal part of the thalamus, 
and this was now found in the WAG/Rij model. This suggests that VU0360172 and 
RO0711401 may target both locations equally effective and therefore we propose that this 
factor may contribute to successful seizure suppression of both of both mGluR Group I 
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PAMs. At first glance the SWD reducing effects of VU0360172 and RO0711401 seems 
puzzling considering that group I agonists and PAMS enhance glutamatergic neurotrans-
mission [78] and that at least the glutamatergic (ionotropic) agonists have proabsence 
effects [46,47,48], as was established in the WAG/Rij model. Our local injections of the 
PAMs in cortex and thalamus and the comparative study with tiagabine also in WAG/Rij 
rats showed two interesting facts. The first was that both PAMs suppressed SWD when 
injected in the thalamus. It was thought that the SWD inhibiting effects of the PAMS in 
the thalamus were due to an increased glutamatergic excitation which inhibited the tonic 
inhibition, one of the assumed causes for the occurrence of SWD [79]. Second, cortical 
injections with the PAMs also suppressed SWDs, but here the cause of epilepsy is an 
increased local excitation, a second reason for SWD occurrence [30,39,80]. Both tiagabine 
and VU0360172 showed the same SWD reducing effect after local cortical microinjections, 
which were ascribed to the stimulating effects of VU0360172 on cortical GABA-interneurons, 
which released GABA when stimulated by VU0360172, mimicking the net effects of the 
cortical microinfusion of the GABA reuptake blocker tiagabine itself [75]. 
 It needs to be added that the results, as obtained regarding the direction of the 
effects of the Group I PAMs and NAMs as described here, were opposite to what has been 
described in the lethargic mice model [50,51]. It is obvious that the effects could be 
dependent on the genotype (WAG/Rij rats versus lethargic mice). More specifically, our 
biochemical studies have clearly revealed that absence epilepsy in WAG/Rij rats is 
Figure 2  Local cortical and thalamic injections of ethosuximide and VU360172 on 
incidence of spike-wave discharges (SWDs) in 30 min after local administration in facial 
area of somatosensory cortex and the ventral basal complex of the thalamus (data from 
[31,75]).
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accompanied by, among others [39,48,81], significant changes in expression and function 
of group I mGluR in cortex and thalamus [67,68],so in the for absence epilepsy most 
relevant parts of the SWD generating circuit and it is by no means clear that the same 
SWD reducing effects of group I PAMs will be obtained in other genetic absence models. 
On the other hand, the WAG/Rij model has predictive validity and until now there are no 
false positive or false negatives [45]. The lethargic mice has a rather complex phenotype 
(absence seizures, chronic ataxia, hypoactivity and transients attacks of severe dyskinetic 
motor behaviour) and also in this model in situ hybridization and Western blot analyses 
have indicated large increase in GAD(67) expression (mRNA and protein) in thalamic cells 
and disturbances of the GABAB receptor system with an involvement of T-type voltage 
gated Ca2+ channels [82]. 
 From a drug developmental perspective it is important that in none of our studies 
with VU0360172 and RO0711401 qualitative and quantitative changes in motor behaviour 
of the animals were found, although in each of them the spontaneous behaviour was 
quantified with an infrared movement detector. Moreover, the lack of behavioural 
changes suggest also that the anti-absence effects of the PAMs are not secondary to 
changes in wake behavior, or can be explained by sleep related variables, as far as the 
latter could be inferred from our quantitative behavioral measurements. Interestingly, 
VU0360172 did not affect spontaneous motor activity in an open field but it did attenuate 
dose-dependently hyperlocomotion induced by the psychotomimetic amphetamine 
[83]. Tolerance towards the antiabsence action to a ten day twice daily drug regime was 
minimal with VU0360172, in contrast to RO0711401. With the latter drug tolerance was 
absent on the first 2 days (in fact the acute antiabsence action lasted up to 6 hours) and 
was complete after 3 days. 
 Neurotoxic studies with higher doses of VU0360172, such as the measurement of 
stereotyped motor coordination tasks, such as balancing on a rotarod, but also towards 
sedative and analgesic effects obviously need to be done. More challenging is to establish 
effects on cognition. Fortunate is that Group I PAM’s were already proposed for the 
treatment of psychosis and cognitive disturbances in schizophrenia patients, also since 
Group I PAMs enhance certain forms of synaptic plasticity via LTD and LPT and learning 
and memory processes [84]. These latter properties were ascribed to the ability of PAMs 
to indirectly potentiate the function of NMDA receptors; our cortical injection studies 
suggest that the action group I PAMs might in addition to this well known effect, also 
facilitate cortical GABA-ergic neurotransmission. 
 Antiepileptic drugs are often given in combination considering than monotherapy 
might often be insufficient for obtaining full seizure control. However, many antiepileptic 
drugs are enzyme inducing and substantially lower the efficacy of other medications. ETX 
showed infraadditive effects with valproic acid in WAG/Rij rats. Combination studies of 
PAMs with ETX and valproic acid are indicated. Considering that antiepileptogenesis can 
be achieved with ETX and levitiracetam in the genetic absence models, it is also indicated 
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that it important to investigate whether antiepileptogenesis is also possible with Group I 
PAMs. 
 The local cortical injection studies with Group I PAMS strongly suggest that these 
PAMs deserve to be investigated in other types of epilepsy models, in which seizures have 
their origin in a brain region in which glutamate and GABA interact, such as in various 
types of mesial Temporal Lobe epilepsy models and in which local increases glutamatergic 
activity cannot be sufficiently inhibited. Also in these models VU0360172 may enhance 
the diminished GABA mediated inhibitory neurotransmission. 
 VU0360172 does not fully interact in fully competitive manner wi with a prototypic 
allosteric binding site, in contrast to some other recently synthetized mGlu5 PAMs (Rook 
et al., 2015); however whether this is crucial or not for its actions in vivo, in our case its 
anti-absence action, remains to be elucidated.
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Abstract
Purpose: Ethosuximide (ETX) is the drug of choice for the treatment of patients with 
absence seizures – taking into account both its efficacy, tolerability and antiepileptogenic 
properties. However, 47% of subjects failed in ETX-therapy, and most antiepileptic drugs 
have cognitive side effects. VU0360172, a positive allosteric modulator (PAM) of mGluR5, 
has been proposed as a new anti-absence drug. Here it is investigated whether anti-epi-
leptogenesis induced by ETX alters the sensitivity of VU0360172, and whether cognition is 
affected during and after chronic ETX treatment. 
Method: EEG’s were recorded before and after a challenge with VU0360172 in chronic 
ETX and in control WAG/Rij rats during and after treatment. Rats were also exposed to a 
cue discrimination learning task in a Y-maze both during and after treatment. At the end 
of the experiment, mGlu5 receptors were quantified by Western Blot analysis.
Results: Antiepileptogenesis was successfully induced by ETX and VU0360172 showed a 
time and dose dependent anti-absence action in the control group. VU0360172 kept its 
anti-absence action in chronic ETX treated rats both during and after treatment, without 
time and dose dependency. This anti-absence effect of VU0360172 in both groups 
matched the lack of differences in mGluR5 expression. Chronic ETX enhanced the number 
of completed trials, the number of correct choices in the Y-maze and the number of 
consumed sucrose pallets. 
Significance: VU0360172 maintains its anti-absence effects after chronic treatment; as 
such, VU0360172 can also be used as a adjunctive therapy in patients with absence 
epilepsy. The enhanced motivation and cognitive performance by ETX might be mediated 
by the antidepressant action of ETX as expressed by an increase in the rewarding 
properties of sucrose pallets. 
Key words: antiepileptogenesis, mGluR5, Electroencephalography, absence epilepsy, 
WAG/Rij rats, Ethosuximide, Western Blots, Y-maze learning
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Introduction
Childhood absence epilepsy (CAE), a neurological disorder which can be found in about 
10% of children with epilepsy, usually occurs around the ages of 4 to 12 years [1]. During 
an absence, ongoing activity is halted and a person’s responsiveness is usually briefly 
impaired [2]. Furthermore, typical absence epileptic seizures are electrophysiologically 
characterized by a pattern of bilateral synchronized spike wave discharges (SWDs) [3]. 
SWDs in the genetic rodent models such as rats of the WAG/Rij strain and GAERS are 
initiated in the deep layers of the somatosensory cortex and quickly spread to the cortico- 
thalamo-cortical (C-T-C) network [4,5,6]. Current medical therapies for epilepsy sympto-
matically suppress seizure activity, but they are not disease modifying, and therefore have 
no effect on the underlying propensity of the brain to generate seizures. One exception 
may be that of chronic treatment with ethosuximide (ETX). This may interfere with 
epilepto genesis, as was suggested by the outcomes of several experimental studies in 
the genetic models [7,8,9]. A prospective cohort study in children with CAE showed that 
long-lasting ETX treatment resulted in a higher rate of complete remission, and in more 
occurrences of five and ten-year remission, suggesting an anti-epileptogenic effect [10]. 
 Evidence has emerged that metabotropic glutamate receptors (mGluR) are good 
candidates for the treatment of absence epilepsy [11,12,13]. We demonstrated that the 
potentiation of mGlu5 receptors with the positive allosteric modulator (PAM), VU0360172, 
reduces SWDs dose dependently and the outcomes of a ten-day chronic administration 
study showed no loss, or only a very small loss of efficacy with respect to its anti-absence 
action [14,15]. Next, it was found that VU0360172 reduces the occurrence of SWDs when 
locally micro-infused in the main areas of the absence network (cortex and thalamus) [16]. 
This demonstrates that VU0360172 is equally effective in targeting both locations, and this 
may contribute to successful seizure suppression of mGluR Group I PAMs. 
 Considering that seizure control cannot often be achieved with monotherapy, drug 
interaction studies are imperative. The interaction between acutely administrated ETX 
and valproic acid (VPA) showed infra-additive effects in the WAG/Rij model, suggesting 
that these two antiepileptic drugs (AED) share a common mode of action [17]. No 
interactions between acutely administered ETX and non-selective orthosteric agonist/
antagonist mGlu5 receptors were found in pentetrazole-induced convulsions in mice 
[18,19]. However, no drug interaction studies were done on the genetic absence models 
during chronic ETX treatment aimed at antiepileptogenesis; it was only found that the 
sensitivity of levetiracetam (LEV) was lost one month following the end of its chronic 
treatment [20]. Here the (inter)action of VU0360172 with ETX will be investigated in our 
genetic absence model, both during and after ETX treatment has stopped. 
 Most AED such as VPA, ETX, and lamotrigine (LTG) have a negative impact on 
cognition [21,22]. On the other hand, the antiepileptogenic effects of chronic ETX were 
accompanied by a decrease in depressive-like behavior in WAG/Rij rats [23,24]. Considering 
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that epileptogenesis and chronic ETX treatment induce antiepileptogenesis, this could 
have an affect on mood and cognitive processes, such as learning and memory. These 
latter processes were additionally investigated in a cue discrimination learning task in an 
Y-maze (problem solving task) and in a sucrose motivation task during and after chronic 
treatment. This learning task has been found sensitive for the effects of e.g. VPA [25]. 
 The expression of mGlu5 receptors in the thalamus and cortex after chronic treatment 
with ETX and challenged by VU0360172 was also evaluated in order to investigate whether 
chronic treatment affects the expression of mGluR5, with respect to changes that could 
correlate to the temporal profile of the drug’s response to the incidence of SWDs. 
Materials and Methods
Drugs and experimental protocol
ETX (Ethymal 250 mg/4 ml ethosuximide), a blocker of T-type Ca2+ currents in thalamic 
neurons [26], was obtained from Apotex Europe BV, Leiden. VU0360172 (N-clyclobutyl- 6-
[2-3(fluorophenyl)ethynyl]pyridine-3-carboxamine), a selective mGlu5 receptor PAM, was 
obtained from Vanderbilt University Medical Center [27]. ETX was administered orally 
through the drinking water. VU0360172 was dissolved in 10% Tween 80, and injected s.c. 
Animals
The study consisted of 26 male inbred WAG/Rij rats, born and raised at the Donders 
Centre for Cognition in Nijmegen, The Netherlands. The 26 rats, after weaning, at 
post-natal day 28 (PND 28), were housed in standard macrolon type III cages in groups of 
four and five for the first two weeks, then they were housed in pairs. All rats had free 
access to food and water throughout the whole experiment, and were maintained on a 
12:12 h light/dark cycle (lights on at 8:30 am) under controlled conditions (20ºC, 60% 
humidity). Four rats in this group died during surgery, and the rest of the animals (n=22) 
were decapitated immediately after the last behavioral test, following the last EEG 
recording session. All experimental procedures and animal care were carried out in 
compliance with the Animal Experiments Committee of Radboud University (RU-DEC 
2013-269). All efforts were made to minimize animal suffering and to reduce the number 
of animals used.
Chronic drug administration protocol and pharmacological 
challenges with mGluR5 PAM
For the chronic treatment studies, animals from a single litter were divided and allocated 
as either ETX-treated (n=13) or control (n=13) (tap water)–treated animals in a paired 
fashion. At four weeks of age when the study began, all animals were able to drink 
independently, and ETX treatment was initiated in young WAG/Rijs to achieve a palatable 
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dose of 250 mg/kg/day in the drinking water [7, 24]. Young animals drink more due to fast 
growth, therefore until day 45 we used 150 mg of ETX per 100 ml. After 45 days, the rate of 
growth decreased and we used 250 mg ETX per 100 ml water. The doses, including the 
changes, were identical to those used by other authors [7, 8, 24]. This means that the rats 
received a dose of 300 mg/kg/day (see Figure 1). Volumes consumed and animal weights 
were measured daily for the first week, and then weekly thereafter, and the drug dosage 
administered (mg/kg/day) was recorded. The concentration of drug in the water bottles 
was updated weekly to maintain the appropriate dosage in an iterative fashion. Control- 
treated rats received tap water ad libitum for the duration of the study. Due to the 
light-sensitive nature of ETX, drinking bottles were wrapped with black tape.
 To assess the effects of ETX treatment on seizures, the EEG was recorded continuously 
for 24 hours, two times: once at week 16, and following drug cessation at week 17. EEGs 
were conducted during treatment at week 16 to check the antiepileptic action of ETX and 
1 week post treatment at week 17 to check the putative anti-epileptogenic action of ETX. 
The drug effects on behavior were determined via Y-maze tests after 6 weeks of treatment, 
and at weeks 16 and 17 as well. Conducting this at different points in time could help us to 
discover during which time of treatment they may develop behavioral disturbances. 
Interestingly, the first week of behavioral tests coincided with the period in which WAG/
Rij rats began developing the SWDs (28). In this sense, the rats were at the border of being 
symptomatic and we were speculating whether the effects of the drug could already be 
manifesting at this stage. In particular, the reason for scheduling the behavioral tests 
during weeks 16 and 17 was because we felt it necessary to test the rat’s behavior during 
the end of the chronic treatment, and one week later, when ETX was no longer detectable 
in the plasma (24). The sucrose motivation tests were scheduled on exactly the same 
weeks (6, 16 and 17) as the Y-maze tests in order to test our hypothesis that chronic ETX 
enhances motivation to consume sugar pallets. The outcome of these tests could be 
considered evidence for the reduction in anhedonia as a consequence of chronic ETX 
treatment.
 A pharmacological challenge with 2 injections of VU0360172, both during treatment 
and one week after treatment, was performed to establish the efficacy of the compound 
on seizure activity as measured in the EEG. It is imperative to check the antiepileptic 
action (week 16: the last week of treatment) of ETX as well as its (ETX) anti-epileptogenic 
action (week 17).
 The pharmacological challenge was scheduled with two single injections of 
VU0360172 (1 mg/kg, s.c. and 3 mg/kg, s.c.) at 9:00 am and at 11:00 pm, respectively, in 
both ETX treated and the control group at two different times: during the last few days of 
the chronic ETX treatment and 6 days after the treatment had stopped. We chose to 
utilize a more commonly used design, which was a cumulative dose design. In this case, 
two doses are given on the same day, 2 hours apart, which is sufficient considering our 
previous pharmacokinetic data. From two of our previous studies, it was concluded that a 
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dosage of 3 mg/kg was able to reduce SWDs significantly (14,15), and that the effects had 
disappeared within 2 hours. We wanted to see if a lower dose of VU0360172 would also be 
effective and/or interact differently than a higher dose did with ETX. Therefore, we also 
used 1 mg/kg. It was (accurately) expected that the effects of 1 mg/kg (if any) would 
disappear within 2 hours. Therefore, the second injection was completed 2 hours after 
the first. In order to ensure that there would be enough time to reach base-line levels after 
the second injection, we recorded and analyzed 3 more hours of EEGs. Considering that 
we wanted to compare the same drug both during and after ETX treatment, the above 
mentioned procedure was also repeated one week later.
 The EEGs and the behavior of the rats were recorded (see Figure 1).
In vivo recordings; EEG recordings 
After 3 months of treatment, at the age of 4 months, the WAG/Rij rats were chronically 
equipped with a cortical EEG electrode set. A cortical tripolar electrode set (Plastics One®, 
Roanoke, VA, USA, MS333/1-A) was implanted via stereotactic surgery under isoflurane 
anesthesia supplemented with pre-and postoperative Rimadyl as analgesic and lidocaïne 
as local anesthetic.
 The first electrode was implanted in the frontal region (coordinates with the skull 
surface flat and from bregma zero–zero, AP+2, 0: L −3, 5) with a second one in the parietal 
region (A −6, 0: L −4, 0) [29]. The ground electrode was placed over the cerebellum. After 
surgery the rats had two weeks to recover, after which, they were moved into transparent 
EEG recording cages supplied sawdust and cage enrichment and with water and food ad 
libitum. WAG/Rij rats were connected to an EEG cable with a preamplifier and a swivel, 
which allowed free movement. 
 Before recording the rats were habituated to the leads for at least 24h. Each EEG 
session in order to check the anti-epileptogenic effect induced with ETX lasted 24 h for 
the treated group and control group as well. The next day after the effects of ETX during 
Figure 1  Schematic diagram illustrating the experimental procedures.
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and after treatment were established, the rats were challenged with VU0360172. The EEG 
session for the pharmacological challenge study with VU0360172 lasted 7h (2 h 
pre-injection (baseline); 2 h post the first injection; 3 h post the second injection). The 
differential recorded EEG was filtered (only frequencies between 1 and 100 Hz were 
allowed to pass) and were digitalized with a sample frequency of 512 Hz, and saved for an 
off-line analysis using Windaq system (DATAQ, Instruments, Akron, OH, USA). SWDs were 
labeled visually using common criteria, regular trains of sharp spikes and slow waves 
lasting from of 1–10 s, spike–wave frequency of 7–10 Hz, a spikes amplitude at least twice 
the background signal and asymmetric appearance of the SWDs [30,31].
Spontaneous motor activity
Spontaneous motor activity was recorded as previously reported [32]; an analogic passive 
infrared detector (PIR) (Luna PR, Rokonet Electronics LTD, Rishon Le Tzion, Israel) was fixed 
to a semi-open lid on top of the each rat’s EEG recording cage. The analogue signal was 
digitalized simultaneously with the EEG signal. Movements were quantified by calculating 
the mean of the absolute value of the PIR signal per hour. The values of each individual rat 
were analyzed to investigate if there were any differences in motor activity between 
baseline and post injection periods to see if there were any drug effects.
Western blot analysis of mGlu5 receptors
Twenty two rats were decapitated at the end of the experiment and brains were rapidly 
removed and frozen. Brains were coded and the codes were only released after the data 
of the Western blot were secured. Brains were coded and the codes were only released 
after the data of the Western blot were secured. Brains were cut coronally on a cryostat, 
and the primary motor cortex (M1), primary somatosensory cortex (S1), reticular thalamic 
nucleus (RTN) and ventrobasal thalamic nuclei (VB) were manually dissected between 
bregma -1.88 mm and -3.80 mm under the guide of the Paxinos and Watson atlas (2005).
The expression of mGlu5 receptor proteins was estimated by Western blot analysis, using 
a highly specific polyclonal antibody (1:5000, Abcam, Cambridge, UK) and a mouse 
monoclonal antibody to label β-actin (1:100.000, Sigma, St. Louis, MO). Anti-mGlu5 
receptor antibodies recognized a band of ~130 kDa. Specificity of anti-mGlu5 receptor 
antibodies was verified using brain protein extracts obtained from mGlu5 receptor 
knockout mice.
 Brain tissues were homogenized at 4 °C in 50 mM Tris-HCl buffer, pH 7.4, containing 1 
mM EDTA, 1% Triton X-100, 1 mM PMSF, 1 μg/ml aprotinin, 1 μg/ml pepstatin, and 1 μg/ml 
leupeptin. After sonication, 2 μl of total extracts were used for protein determinations. 
One hundred micrograms of protein extract were resuspended in sodium dodecyl sulfate 
(SDS)-bromophenol blue reducing buffer with 40 mM dithiothreitol (DTT). Western blot 
analyses were carried out by loading 35 μg of total proteins per lane into 8% SDS 
polyacrylamide gels, which were electroblotted on immunoblot polyvinylidene difluoride 
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(PVDF) membranes (BioRad, Milano, Italy). The PVDF membranes were blocked overnight 
in TBS-T buffer containing 5% non-fat dry milk. Blots were then incubated for 1 h at room 
temperature with rabbit polyclonal anti-mGlu5 antibodies and mouse monoclonal 
antibody to label β-actin. Filters were washed with TBS-T buffer and then incubated for 1 
h with secondary antibodies (peroxidase-coupled anti-rabbit or antimouse; 1:7000; 
Amersham, Piscataway, NJ). Immunoreactivity was revealed by enhanced chemilumines-
cence (ECL). Immunoreactive protein bands were quantified using the densitometry 
method (Scion image software, http://rsb.info.nih.gov/nihimage/). Values were obtained 
by calculating the ratio between the area under the curve (AUC) of the optical density of 
mGlu5 signal and the AUC of the house keeping protein β-actin for each lane.
Learning in the Y-maze
Problem solving has been analyzed in a Y-maze [33,34,35,36]. The Y-maze components 
were a starting box (0.10 m) in a starting arm (0.50 m) which was made with Plexiglas. Two 
identical arms were placed in a 90 degree angle on the starting arm and another 90 
degree angle was made after 0.20 m. At the beginning of the left and right arm the cues 
(width 0.10 m, length 0.15 m) were presented, Plexiglas and sandpaper [34]. The terminus 
of the identical arms were 0.20 m and in the termini food trays (0.03 m tall, 0.03 m 
diameter) were located in which sucrose pallets (Campden, sucrose pallets, 45 mg) could 
be placed. The Y-maze is 0.10 m in width, 0.10 m high and was covered with Plexiglas. 
Procedure Y-maze
Problem solving was subsequently measured at 6 weeks into treatment, 4 months into 
treatment and 1 week (for 3 days) after treatment had stopped. First, rats were given a 
habituation period of 15 minutes 5 days before the beginning testing phase to familiarize 
them with the Y-maze [33]. 15 pallets were placed in the left and right arm, if the rat ate all 
the pallets new ones were provided. After the habituation period the rats were randomly 
split into two groups. The location of the cues for each rat were switched in the different 
testing phases (example: phase 1 left, phase 2 right, phase 3 left), the cues (whether the 
sandpaper was associated with food, or Plexiglas) were kept consistent over the different 
testing phases. The first testing phase consisted of 5 days of testing with 5 learning trials 
per day per rat. A learning trial took 4 minutes, the rat was placed in the closed starting 
box, time started running at the moment the rat left the starting box. At the side of the 
relevant cue 2 sucrose pallets were placed, when the rat ate the sucrose pallets (one or 
two) he was picked up and placed back into the starting box [34]. The second testing 
phase (again 5 days and five trials per day) was the same as the first one except a time-out 
procedure was added after the animal made an incorrect choice. The rats were kept for 10 
seconds in the arm of the incorrect cue. The third testing phase was the same as the 
second but only lasted 3 days. The Y-maze was cleaned after each learning trial with a 
70% alcohol solution in water.
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 The measured variables were the percentage of correct choices and the total number 
of completed tasks. A task is completed by eating the sucrose pallets, next the rat was 
placed in the starting box again, until 4 minutes had elapsed. The criterion for making a 
choice was front paws and the head above/on the cue [37,38]. 
Sucrose pallet consumption (SPC) test
The assessment of the SPC test took place in a cage exactly resembling the rat’s home 
cage. A sucrose tray was placed against the wall of a shorter side. Rats were placed on the 
same location within the cage facing the sucrose tray, which contained a total of 100 
sucrose pallets (Campden, 45 mg). They were allowed to explore and eat for a total of 10 
minutes after which they were removed and placed back in their home cages. Rats were 
adapted to the food pallets 2 weeks prior to the test session and not food or water 
deprived. Dependent variables measured were the number of approaches the rats made 
towards the sucrose tray and the total amount of sucrose pallets consumed. The SPC test 
was done 1.5 months of treatment, 4 months of treatment, and 1 week after the discon-
tinuation of treatment.
Statistical analysis
All statistical procedures were performed using SPSS Version 22.0 (IBM Corp, 2013). EEG 
recordings lasted 5 hours starting at 9:00 a.m. for establishing the antiepileptic and antie-
pileptogenic effects of ETX and the vehicle group during and after one week of treatment. 
The behavioural and EEG part of the study were done with the two groups and the effects 
of chronic ETX on incidence and mean duration of SWDs, as well as the behavioural 
activity of animals (PIR) were tested in separate repeated-measures ANOVAs.
 The incidence and mean duration of SWDs for the VU0360172 in the water group 
during and after treatment and for the VU0360172 challenges during and after the chronic 
ETX treatment was done in four separate repeated measure analysis, in an EEG time-frame 
of 15 -min epochs. The time of EEG recording (7 h and 10 x 15 minutes blocks post 
injection) was used as the within-subjects factor. In case of significant main effect (time), a 
simple contrast analysis was used to isolate differences across time.
 Considering that the pre-VU0360172 incidence was rather different for the chronic 
ETX and water treated group both during and after the chronic treatment, the relative 
decrease in SWD incidence induced by VU0360172 was compared between the two 
groups with two repeated measures analyses in the EEG time-frame of 15–min epochs 
with all values expressed in % of 2 hour pre-injection (baseline), followed by unpaired 
T-test to establish difference across each time point.
 Repeated measures MANOVA were also used to analyze the Y-maze data. This data 
set was divided across the 3 phases in which Y-maze learning occurred since there were 
intervals with varying length between the learning sessions. Our within-subjects factor 
was day (day 1 to 5, day 6 to 10, day 11-13) and the between-subjects factor was drug (ETX, 
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control). As mentioned, the dependent variables were the percentage correct choices 
made in the Y-maze and the amount of completed trials. 
 Unpaired T-tests were used to establish differences in the SPC test, the dependent 
variable was the number total consumed pallets. 
 The experimental groups used for the Western blot were the rats chronically treated 
with ETX + VU0360172 or vehicle + VU0360172. Student’s t-test was used for the statistical 
analysis of each brain region.
Results
The analysis of the incidence of SWDs in the first 5 h post injection during and after 
treatment showed that there was no time of day effect, or interaction with time of day 
with time or group (p= >.05). Instead a very large group effect was present (F= 91.955, df 3, 
44 , p< .000, η2 =.862). This data confirmed the successful anti-absence and anti-epilepto-
genic effect induced by ETX without any difference in terms of SWD incidence between 
the ETX during and/or after the end of treatment. Both ETX groups showed less SWD’s 
compared with the vehicle groups (the data are presented in Figure 2A).
 No statistical difference was found in the mean duration of SWDs and in locomotor 
activity during and after chronic ETX treatment.
Figure 2A  Incidence of SWDs during and after ETX treatment (4 months treatment). A 
significant reduction of the incidence of SWDs was found during (antiepileptic) and one 
week after the end treatment (antiepileptogenesis). Values are means ± S.E.M of 22 
animals. *p< 0.05 (repeated-measures ANOVAs) vs. the corresponding value obtained in 
control rats.
A
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 The analysis of incidence of SWD in the water group, during treatment, after the first 
and second injection of VU0360172 (1/3 mg/kg), revealed a large time effect (blocks) 
(F= 54,74, df 22,242, p< .001, η2 = .83). A simple contrast analysis revealed that, the water 
group treated with VU0360172, showed clear time (the low dose of the drug was effective 
for about one hour, the higher dose for more than 1.5 hr) and dose dependent effects 
compared to the 2 hr pre-injection control period (the data are presented in Figure 2B).
 The same analysis in the water group treated with VU0360172, one week after 
treatment showed, again a large time effects (block) (F= 57,28, df 22,220, p<.001, η2 =.85); 
again the simple contrast analysis showed time and dose (the higher dose was longer 
and more effective) dependent effects (Figure 2C).
Figure 2B-C  The effect of two injections of VU0360172 in the water group during and 
after treatment. Notice the time and dose dependent effects of VU036172 on SWD 
incidence both during and treatment and after 1 week.
C
B
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 The analysis of incidence of SWD in the ETX group treated with VU0360172 during 
treatment showed, a medium sized time effect (F= 3.07, df 22,242, p<.001, η2=.22). A simple 
contrast analysis showed that all data points indicated the same lower SWD incidence 
compared to the baseline value (average of 2 hours).  This implies a lack of pharmacoki-
netic effects as were seen in the water + VU0360172 group. The decrease in SWD 
incidence after VU0360172 administration in the ETX group suggest that the compound 
still has some effect on SWD incidence, the data are presented in Figure 2D.
 Next, the same analyses on the SWD, one week after treatment, showed again a 
medium sized time effect (blocks) (F= 3.44, df 22,220, p< .001, η2 = .26); again the simple 
Figure 2D-E  The pharmacological challenge with VU0360172 (1 mg/kg and 3 mg/kg) 
with respect the SWD incidence during and after chronic treatment with ETX. Values are 
means ± S.E.M. of 22 animals. (p < 0.05, ANOVA for repeated measures followed by 
Bonferroni’s test) vs. the corresponding values at baseline (T0) (*) or vs.
E
D
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value and again without clear signs of pharmacokinetic and -dynamic effects (Figure 2E). 
None of the injections with VU0360172 caused significant effects between or within 
groups in the mean duration of SWDs and in locomotor activity.
 The comparison of the efficacy of VU0360172 between the chronic ETX and water 
group (the percentages of the incidence of SWD) after the first and second injection of 
VU0360172 (1/3 mg/kg) showed a time effect (F= 14,12, df 22,484, p< .001, η2 = .39), a time 
x group effect (F= 10,83, df 22,484, p< .001, η2 =.33), while, no group effect was found. This 
Figure 2F-G  Comparison of the efficacy of VU0360172 between the chronic ETX and 
water group (the percentages of the incidence of SWD) after the first and second injection 
of VU0360172 during treatment and after treatment. Values are means ± S.E.M. of 22 
animals. (p < 0.05, ANOVA for repeated measures followed by unpaired T-test) vs. the 
corresponding values at baseline (T0) (*) or vs.
G
F
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implies that overall; VU0360172 had the same anti-absence effect in terms of SWD reduction 
in the ETX and water group. The post-hoc t-tests showed in addition, that the incidence 
was lower in the control group between 125 and 215 min post injection. At other time 
points the ETX group was more effective mention the time periods. The data are 
presented in Figure 2F.
 The same analysis of incidence of SWD, one week after treatment, showed again a 
time effect (F= 18,09, df 22,440, p< .001, η2 =.47), a time x group effect (F= 14,08, df 22,440, 
p< .001, η2 =.41), again, no group effect was found. This suggests that over the 6 hrs post 
drug injection the efficacy of VU0360172 was the same for both groups. Outcomes of 
post-hoc analyses showed that VU0360172 was more effective in the control versus the 
chronic ETX group at mention the time episode, at other time points the ETX group was 
more effective. The data are presented in Figure 2G.
Expression of mGlu5 receptors in the cortico-thalamo-cortical network of 
symptomatic WAG/Rij rats after chronic treatment with ethosuximide
Western blot analysis of mGlu5 receptors was carried out on protein extracts from the 
motor cortex, somatosensory cortex, RTN and VB of symptomatic WAG/Rij rats after 
chronic treatment with ethosuximide + VU0360172 or vehicle + VU0360172. Immunoblots 
showed a major band at 130 kDa corresponding to the mGlu5 receptor monomers. There 
was no significant difference in mGlu5 receptors expression in cortex and thalamus in 
symptomatic WAG/Rij rats after chronic treatment with ETX or vehicle (Figure 3).
Y-maze: Completed trials 
1,5 months into treatment. The univariate analysis revealed a day effect (F= 12.72, df 2,34, 
p < .001, η2 = .401), a drug effect (F= 5.85, df 1,19, p> .026, η2 = .235) and a drug x day 
interaction (F= 5.75, df 2,44, p> .004, η2 = .232). The total number of completed tasks 
increased across days, the EXT group completed more tasks and the two groups differed 
in their changes across days. The ETX group were more eager to complete the task, and 
showed a bigger improvement over days than the control group (see Figure 4A, block 1).
4 months into treatment. The ANOVA revealed a small day effect (F= 3.40, df 2,34, 
p < .050, η2 = .152) and a medial strong drug effect (F= 6.90, df 1,19, p< .017, η2 = .266). 
There was no drug x day interaction. The total completed trials differed across days and 
the groups differed in the amount of completed tasks: the ETX group performed better 
than the control group (see Figure 4A, block 2).
1 week after discontinuation of treatment. The univariate analysis revealed no day effect. 
A drug effect was found (F= 13.453, df 1,19, p< .002, η2 = .415): the ETX group completed 
more trials than the control group (see Figure 4A, block 3). There was no drug x day 
interaction.
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Figure 3  Immunoblot analysis of mGlu5 receptors in the somatosensory cortex, motor 
cortex, ventrobasal thalamus and reticular thalamic nucleus of symptomatic WAG/Rij rats 
after chronic treatment with ethosuximide or vehicle. Densitometric analysis of mGlu5 
receptors for each brain region is shown in figure. Values are means ± S.E.M.
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Y-maze. Percentage correct
1,5 months into treatment. The ANOVA revealed no day effect, no drug effect, and there 
was no drug x day interaction. Both groups performed similarly and the total average 
correct choices did not differ across days (see Figure 4B, block 1).
4 months into treatment. The ANOVA revealed a day effect (F= 3.692, df 3,57, p< .017, 
η2 = .163). A marginal drug effect was found (F= 3.393, df 1,19, p< .081, η2 = .152). There was 
no drug x day interaction. In this phase the correct choices differed across days, there is 
Figure 4  (Completed task): Number (mean) of completed trials in 3 periods (day 1-5 
after 1.5 month of  treatment; day 6-10 after 4 month of treatment; day 11-13, 1 week after 
discontinuation of treatment (n = 13) and control (n = 13).
(Percentage correct): Percentage of correct choices  (mean) in 3 periods (day 1-5, 1.5 
month of  treatment, day 6-10, 4 months into treatment, day 11-13, 1 week after discontin-
uation of treatment), ETX (n = 13) and control (n = 13), with standard error of measurement 
bars.
(Pellets): Number of consumed pallets (mean) on 3 testing phases (1: 1.5 month of 
treatment, 2: 4 months into treatment, 3: 1 week after discontinuation of treatment), ETX 
(n = 13) and control (n = 13).
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a trend indicating that the two groups differed in their correct choices but the differences 
between groups did not differ across days. The data showed that the ETX group 
performed slightly better than the control group and that the total average correct 
choices differed across days (see Figure 4B, block 2).
1 week after discontinuation of treatment. The ANOVA revealed a drug effect (F= 7.198, 
df 1,19, p< .015, η2 = .275), no day effect and no drug x day interaction. The data showed 
that the ETX group performed better than the control group (see Figure 4B, block 3).
Sucrose Pallet Consumption (SPC) test 
The first SPC test has been done at 1.5 months into treatment. A large and significant 
effect of drug on the total consumed sucrose intake (F= 18.89, df 1,24, p< .001, η2= .440) 
has been found: the ETX group consumed more pallets than the control group (see 
Figure 5).
 The SPC test has been done a second time, at 4 months into treatment. The data 
showed again a drug effect on the total consumed sucrose pallets (F= 8.41, df 1,21, p< .009, 
η2= .286). The ETX group consumed more pallets than the control group (see Figure 5).
 The third SPC test has been done after treatment with ETX had stopped. The analysis 
revealed a marginal trend for more sucrose pallets in the ETX group (F= 3.06, df 1,19, 
p<.096).  
Discussion 
The first aim of the study was to investigate if the antiepileptogenic effect induced by ETX 
and administered via the drinking water altered the sensitivity of group I mGlu receptors. 
The antiabsence and antiepileptogenic effects were successfully induced by ETX without 
any differences in terms of SWD occurrence during the treatment, as well as one week 
after the treatment, as is in line with the outcomes of earlier studies [7,8,9,39,40]. Moreover, 
chronic ETX treatment has similar disease-modifying effects in GAERS – another genetic 
model of absence epilepsy [41] . 
 Our second interest was concerning the interaction between classical ant-epileptic 
drugs and mGlu modulating compounds with antiepileptic actions. It has been shown 
that e.g. the non-competitive antagonist mGlu5, SIB 1893, with pro- and anti-convulsant 
pharmacological activity against electroconvulsive threshold-induced seizures in mice, 
did not influence the protective action of either ETX, VPA, phenobarbital or clonazepam 
[19]. Furthermore, the combination of the mGluR5 antagonist with AED did not result in 
adverse effects [41]. A lack of interaction was also found between a selective Group II 
agonist, ETX and VPA on PTZ induced convulsions [18]. Here, the sensitivity of group I 
mGluR in chronic ETX treated rats was evaluated by the administration of VU0360172. As 
expected [14,15], pharmacological enhancement of mGlu5 receptor activity caused a 
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robust time and dose-dependent reduction with respect to the incidence of SWD in the 
control group. This was found two times within a six-day interval, without obvious 
changes in the sensitivity of the mGlu5 receptor. The effects of the same doses of 
VU0360172 in the chronic treated ETX rats and water-treated rats during and after 
treatment also showed the same (percentage-wise) overall anti-absence effects in terms 
of SWD reduction. This could be clinically relevant because seizure control is not always 
achieved by a single drug. However, the effects of VU0360172 in the chronic treated ETX 
rats showed rather striking results: VU0360172 decreased the incidence without any sign 
of time and dose-dependency. A possible explanation for the lack of dose dependency 
could be a threshold effect; it might be difficult to reduce an already low number of 
SWDs. However, the lack of a clear pharmacokinetic effect in the ETX treated rats effect 
cannot be explained by a threshold effect. In fact, the SWD incidences were reduced by 
about 40-60% and remained low throughout the entire recording session, without 
returning to the baseline. It can be speculated that the lack of time dependency may be 
due to a slowing down of the metabolism of VU0360172 after 4 months of ETX.
 The comparable overall efficacy of VU0360172 in the two groups is in agreement 
with a lack of differentiation in mGlu5R expression between the two groups in the cortex 
and thalamus. No down- or up-regulation of this receptor was found for the chronic 
treated group when compared to the age-matched and non-treated control group, 
suggesting that the system is not modified and VU0360172 does indeed show its 
anti-absence effect. 
 Although the overall efficacy of VU0360172 was comparable in the two groups, at 
many points the efficacy of VU0360172 was higher in the control than in the ETX treated 
groups. This suggests that chronic ETX influenced the pathways in which VU0360172 
exerted its anti-absence action. First of all, as for the ETX mechanisms, a reduction in 
burst-firing by ETX led to a reduction in SWDs by decreasing the strength of synchroniza-
tion within the cortico-thalamo-cortical loop during paroxysmal activity [42]. Acute ETX, 
in addition to its well established success in blocking T-type Ca2+ channels, directly 
reduced excitability by increasing spontaneous GABA release in cortical slices [43]. 
Moreover, G protein-activated inwardly rectifying K+ channels (GIRK (type GIRK1/2 and 
GIRK2)) have been shown to play an important role in regulating neuronal excitability, and 
those channels are activated by various G
i
 protein-coupled receptors [44,45]. It was found 
that ETX—but not other antiepileptic drugs—inhibited GIRK1/2 and GIRK2 channels at 
clinically relevant concentrations in cells of cerebellar slices of mouse brain, suggesting 
that the inhibitory effects of ETX on GIRK channels may affect the G protein signaling 
pathways [46]. It is obvious that G-protein signaling pathways are involved in the patho-
physiology of absence epilepsy and in SWD control [11,47]. Furthermore, the early and 
chronic treatment with ETX prevented the commonly reported changes in the expression 
of Na+ and HCN1 channels in the cortical focal region, as well the local excitability [24,48].
 More recent research has been focused on the identification of primary cell signaling 
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pathways that initially trigger various downstream mechanisms mediating epileptogene-
sis and, ultimately, a permanent increase in neuronal excitability [49,50]. One signal 
transduction system that has recently gained interest as an important regulator of cellular 
changes involved in epileptogenesis is the rapamycin (mTOR) pathway [51,52,53]. In 
particular, mTOR complex 1 (mTORC1) is involved in a variety of functions and has also 
been implicated in epileptogenesis (54). Rapamycin had anti-absence properties in acute 
and sub-chronic treatments of WAG/Rij rats. Conversely, early chronic treatment for 17 
weeks had clear antiepileptogeneic effects in the same animal models. These chronic 
treatment effects could be explained by the ability of rapamycin, through mTOR inhibition, 
to affect a variety of cellular and molecular processes, such as ion channel expression and 
neurotransmitter receptors, apoptosis, neurogenesis and synaptic plasticity, all of which 
are known to influence neuronal excitability and epileptogenesis [55,56,57]. The same 
kinds of both antiepileptogenic and inhibitions of the mTOR pathway were also found for 
Vigabatrin (VGB), which is known to cause an increase in GABA levels in the brain and to 
enhance SWDs in WAG/Rij rats when acutely administered [58]. However, when chronically 
administered, it had antiepileptogenic effects [38]. VGB inhibited seizures in a mouse 
model and partially inhibited mTOR pathway activity and glial proliferation in mice, and 
also reduced mTOR pathway activation in cultured astrocytes from mice [59]. It is known 
that the mGluR5 agonist, CHPG, activated the mTOR pathway [60]. It is therefore possible 
to speculate that the PAM VU0360172 also plays a role through the mTOR pathway. This 
suggests that chronic ETX treatment causes an inhibition in the activity of the mTOR 
pathway, and VU0360172 may interfere with the mTOR signaling pathway (activation/
inhibition) as well. So it could be postulated that VU0360172—although it to some extent 
maintained its anti-absence effect during and after ETX treatment—lost its common 
dose-dependency effect due to the already inhibited mTOR signaling by chronic ETX 
treatment. Further studies into the mTOR pathway after chronic ETX treatment could be a 
meaningful and interesting follow-up study to elucidate on the involvement of mTOR 
signaling pathways in anti-absence and epileptogenesis. 
 The results from the SC test showed that WAG/Rij rats after being treated with ETX for 
one month are more inclined to consume sucrose pallets than untreated rats, and this 
was replicated before the end of the chronic treatment. Although this version of sugar 
consumption has not been validated as a test of anhedonia, a characteristic of depres-
sion-like behavior in WAG/Rij rats [61,62], the outcomes do suggest an early anti-anhedonia 
or antidepressant-like response of ETX already at an early age and early in the treatment 
regime. 
 The Y-maze also revealed differences between both groups. Before differences in 
learning and memory emerged (better cue discrimination was only found at the end of 
treatment), the treated and untreated groups differed already in the number of completed 
trials after one month of ETX treatment. At this young age, the treated rats seemed more 
motivated to run in the Y-maze and they also displayed this above-mentioned increased 
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interest or appetite for sucrose pallets. Perhaps this caused these rats to be able to learn to 
discriminate between the cued and non-cued arm of the Y-maze. The positive effects of 
chronic ETX treatment and the results found were surprising, since most commonly used 
antiepileptic drugs such as VPA, LTG, and LEV all have a negative impact on cognition 
[63,34,22,35]. It is proposed that early and chronic ETX treatment has positive motivational 
effects and this might have facilitated their performance when presented a problem-solv-
ing task. Whether the favorable outcome on motivation is due to the effects of ETX perse, 
or to antiepiletogenesis, still needs to be established. Moreover, it could be possible that 
the absence of early differences on percentage correct choices in the Y-maze may be 
explained either by the duration of the treatment (too short) to induce antiepileptogene-
sis [39], or due to the fact that the number of trials in the learning task was insufficient to 
detect any effect. The differences found in the test for problem resolution can be 
attributed to depressive symptoms that were suppressed in the experimental group by 
ETX. Further research needs to establish whether or not ETX is sufficient enough to reduce 
depressive-like symptoms in humans as well, in which case additional drug treatments 
such as anti-depressives should perhaps be considered. 
 VU0360172 did not affect motor behavior, a beneficial property of an anti-absence 
drug.  Moreover, mGlu5 receptor PAMs are already in development for the treatment of 
schizophrenia, with the only concern being neurotoxicity and the possibility of convulsive 
seizures that can be induced by very high doses of these compounds [64]. Additionally, 
the Phase II clinical trials have now demonstrated promising effects of mGluR5 NAMs in 
treating anxiety and affective disorders, Parkinsons’s disease and fragile X syndrome 
[65,66], and suggest that the drug can be safely applied. 
 In conclusion, antiepileptogenesis was successfully induced by ETX, and in the 
chronically treated rats the anti-absence action of VU0360172, both during and after 
chronic ETX treatment, was preserved. The lack of pharmacokinetic effects remains 
enigmatic. The decrease in SWDs during and after ETX treatment was not accompanied 
by a change in mGluR5 expression. Chronic ETX has minor positive effects on the 
behavioral performance in the Y-maze, which may be mediated by an increased 
motivation to obtain sucrose pallets. The combined chronic ETX and acute VU0360172 
treatment did not result in any adverse effects, which emphasizes the potential of mGlu 
receptor ligands to act as adjuncts to current antiepileptic drugs. 
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General discussion
There is presently sufficient amount of evidence supporting our understanding of 
individual roles of mGlu receptor subtypes in the control of SWDs elicited in the corti-
co-thalamo-cortical (C-T-C) network. As discussed in Chapter 1, many of the ionotropic 
glutamate receptors agonists/antagonists had toxic effects and their function in seizure 
control has not led to the successful development of new antiabsence or anticonvulsant 
drugs (Bruno et al., 2001; Barton et al., 2003; Alexander et al., 2006). There is however 
extensive support for the statement that we are starting to gain significant knowledge 
about the individual roles of mGlu receptors in the control of SWDs elicited in the cortico- 
thalamo-cortical (C-T-C) network. Remarkably, the modulatory role of individual mGlu 
receptor subtypes on excitatory and inhibitory synaptic transmission in the C-T-C network 
makes subtype-selective mGlu receptor ligands possible candidates as novel antiabsence 
drugs. Evidence of phase I and phase II clinical trials with mGlu2/3, mGlu4, or mGlu5 
receptor compounds support that these types of ligands might be securely given to 
humans. This thesis aims to investigate the pharmacological effects of group I mGlu 
receptor modulation (mGluR1 and mGluR5) in an animal model of absence epilepsy, 
WAG/Rij rats, their role in SWD occurrence in cortex and thalamus, and their interactions 
with the clinically commonly used most AED ethosuximide chronically administered.
The role of mGluR1 and mGluR5 in SWD activity
In Chapter 2, the function, expression, and pharmacological manipulation of mGlu1 
receptors was examined in WAG/Rij rats. The main result was that pharmacological 
manipulation with the mGluR1 PAM, RO0711401 (3, 10 and 30 mg/kg), showed a dose- 
dependent reduction in the number and mean duration of SWDs. Treatment with the 
selective mGlu1 receptor NAM, JNJ16259685 (2.5 and 5 mg/kg), enhanced the number of 
SWDs in a dose dependent way.  Moreover, RO0711401 slightly increased spontaneous 
motor activity. 
 The results of the experiment investigating mGlu1 receptor signaling displayed a 
decrease in the function of this receptor in the thalamus of symptomatic WAG/Rij rats 
compared to age-matched control ACI rats. This decreased mGlu1 function in the 
thalamus is in agreement with the outcomes that the deletion of phospholipase-C β4 
(PLCβ4) in thalamic relay nuclei leads to absence seizures (Cheong et al., 2009). PLCβ4 is an 
enzyme activated by mGlu1 receptors and is found in thalamo-cortical neurons, where it 
functions as downstream signaling for the mGlu1 receptor to mediate cortico-thalamic 
excitatory inputs. The expression of PLCβ4 corresponds to that of the mGlu1 receptors 
(Watanabe et al., 1998; Miyata et al., 2003). Thereby, interruption of the group 1 signaling 
pathway (i.e. deletion of PLCβ4 in thalamus) causes SWDs. The reduction in mGlu1 
receptor expression that we found did occur in the VPM and PO, areas involved in the 
SWD network (Lüttjohann and van Luijtelaar, 2012). As discussed in Chapter 1, SWD occur 
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in the peri-oral region of the somatosensory cortex (Meeren et al., 2002), and the 
comparable somatotopic region in the thalamus is the lateral region of the thalamus 
(Polack et al., 2009). Therefore, we proposed that in WAG/Rij rats a reduced excitation in 
relay neurons due to a decrease in mGlu1 receptor expression found in the VPM and PO 
might be also responsible for the SWD occurrence.
 Pharmacological manipulation of mGlu1 receptors had a robust influence on SWD in 
WAG/Rij rats. Interestingly, mGlu1 and mGlu5 receptors have a different distribution 
pattern in the C-T-C circuitry, which suggests distinct rather than complementary roles of 
these two receptor subtypes. Therefore, in order to have a more detailed understanding 
of both group I receptors in this absence model, the role of mGlu5 receptors was 
addressed in Chapter 3. Pharmacological potentiation of this receptor with VU0360172 
(3 and 10 mg/kg) decreased numbers and mean durations of SWDs, without affecting 
motor behavior. The results of pharmacological blockade of mGlu5 receptors with the 
antagonist MTEP (10 and 30 mg/kg) did not influence SWDs. In order to prove that mGlu5 
PAM is selective for this receptor, VU0360172 was injected at a dosage of 3 mg/kg in WAG/ 
Rij rats, pre-treated with the selective antagonist MTEP (10 and 30 mg/kg). The effect of 
VU0360172 was successfully antagonized by MTEP, demonstrating that the drug reduced 
absence seizures by amplifying the endogenous activation of mGlu5 receptors. 
A decrease in both the mGlu5 receptor protein levels and mGlu5-receptor function in 
the thalamus was found when compared to the age matched non-epileptic ACI rats. 
Conversely, the expression of mGlu5 receptors was enhanced in the motor cortex and in 
the somatosensory cortex without an accompanying change in mGlu5-receptor function 
when compared to ACI rats as well. Interestingly, these changes in the expression come 
first the onset of the epileptic phenotype, because they were previously visible in 
pre-symptomatic WAG/Rij rats when compared to the ACI rats. Consequently, the mGlu5 
receptor expression in the cortex and thalamus is preceding  the origin of SWDs and, for 
this reason, is not dependent of  seizure activity. This is weird because modification in the 
mGlu1 receptors expression in the thalamus arises in symptomatic WAG/Rij rats (see 
Chapter 2). All in all, adaptive changes regarding the mGlu5 receptors might lay at the 
core of the absence-seizure prone phenotype of WAG/Rij rats, and mGlu5 receptor 
enhancers could be develop for the treatment of absence epilepsy.
Benefits of the acute studies 
The consistent outcomes of the pharmacological studies as described in Chapters 2 and 3 
permitted us to cover the until now missed role of group I PAM in non-convulsive epilepsy 
(see Chapter 1, pg. 36, Table 4). Now, a complete overview of both mGlu1-mGlu5 agonists/
antagonist and PAMs/NAMs in convulsive and non-convulsive epilepsy can be given 
(Table 5). The direction of the effects of group I PAM/NAM in terms of increase/decrease of 
absence epilepsy was predicted based on the available data as were presented in Table 3: 
where, orthosteric agonist of group I were pro-convulsive agents, while all orthosteric 
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antagonist were both anti-convulsive as well as anti-absence drugs. Thus, a group I NAM 
should decrease absence seizures and a group I PAM should increase absence seizures. A 
complete opposite effect emerged regarding the direction of the effects. As described in 
Chapters 2 and 3, the mGlu1 NAM, JNJ16259685, increased SWDs. The increase in SWDs 
may be due to mGlu1 receptors being hypofunctional in the thalamus. Nevertheless, the 
same NAM, JNJ16259685, had no effect in terms of SWD reduction/ enhancement in 
non-epileptic ACI rats. The unsuccessful mGlu1 receptor blockage in ACI rats indicates 
that a decreased function of mGlu1 receptors is not enough to originate absence seizures, 
and that an exact genotype is needed to generate the effects. 
Thereby, according to Table 5, at least 2 different conclusions might be extrapolated from 
the data obtained from Chapter 2 and 3 regarding group I PAMs/NAMs:
• Orthosteric antagonists are good anticonvulsant agents, but in non-convulsive absence 
epilepsy, PAM’s are suited for blocking SWDs. 
• Orthosteric agonists are proconvulsant, while NAMs have either no effect of enhance 
non-convulsive absence seizures.  
The differences regarding how group I drugs react towards convulsive epilepsy on the 
one hand and non-convulsive epilepsy on the other, is reminiscent to the effects found 
with GABA mimetics. They are generally very efficient regarding convulsive epilepsy, but 
they aggravate absence epilepsy (Coenen and van Luijtelaar, 2003). This may suggest that 
our PAMS and perhaps also our NAM (JNJ162599685), in vivo, are activating GABA 
receptors or blocking GABA receptors respectively.
mGlu compounds in two absence models: lh/lh mice vs. WAG/Rij rats
As described in Chapter 2, the hypothesis that an impaired mGlu1 receptor signaling in 
the thalamus and systemic administration of a group I NAM facilitates the occurrence of 
SWDs is not in agreement with data found in lethargic mice (see Table 4, Table 5, and 
Table 6), since treatment with orthosteric mGlu1 receptor antagonists reduced the 
occurrence of SWDs in these mice (Chapman et al., 1999). Also the results, as described in 
Chapter 3, that pharmacological potentiation of mGlu5 receptor provoked a sturdy 
dose-dependent decrease in the number and mean duration of SWDs in WAG/Rij rats, 
while the antagonist of this group MTEP did not increase/decrease SWDs (Table 6), is 
opposite to what was reported in lethargic mice. 
 A deducible outcome might be that the function of mGlu1 and mGlu5 receptors in 
the two genetic absence models is not similar, and the role of mGlu5 receptor PAMs/
NAMs is dependent on the genetic background of the animals. However, there are 
obvious differences between the two models. First of all, lh/lh mice are monogenic 
models when compared to WAG/Rij rats, which are polygenic models. Secondly, lh/lh 
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mice, develop ataxia when the cerebellum is also involved, motor disturbances are lacking 
in the WAG/Rij model. Thirdly, as is shown in Table 6, the same compound LY379268, has 
been tested in lh/lh mice and WAG/Rij rats with opposite effects in both models. LY379268 
reduced absence epilepsy in lh/lh mice, while enhanced absence epilepsy in WAG/Rij rat, 
suggesting that the two animals model are really different regarding the role of group II 
mGluR in absence epilepsy. Fourthly, the cortex and thalamus could play a different role in 
each of these absence models. In lh/lh mice the ventrolateral and nRT are the dynamo 
networks of the seizures (Hosford et al., 1995), whereas in WAG/Rij rats, SWDs origin is in 
the peri-oral region of the somatosensory cortex and the nRT has a resonance function 
(Meeren et al., 2002; Lüttjohann and van Luijtelaar, 2015). In WAG/Rij rats mGlu5 receptors 
in the thalamus are hypofunctional, and neither this nor the cortical focal origin is 
investigated in lh/lh mice. Sixthly: as was previously discussed, a functional coupling of 
mGlu1 receptors and T-type VSCCs (Hildebrand et al., 2007, 2009) could be implicated in 
the control of SWDs by mGlu1 receptors. lh/lh mice are characterized by a mutation in the 
β4 subunit of VSCCs and the above mentioned coupling of mGluR1 and T-type VSCCs 
may be affected and this might be a reason for the results at variance with those found in 
WAG/Rij rats (Burgess et al., 1999). Whether this is also the case in WAG/Rij rats is not 
known. 
Table 5   Overview of group I mGlu receptors in convulsive and non-convulsive epilepsy. 
1Moldrich et al., 2003; 2Shannon et al., 2005;  3Chapman et al., 1999; 4Ngomba  
et al., 2012; 5D’Amore et al., 2013.
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 All these factors may contribute to an explanation for the different effects seen in 
these two absence models, with respect to the direction of the pharmacological effects 
with mGluR agonist and antagonist and modulators. A comparison between the two 
absence models with the same PAMs and NAMS should solve the issue whether the 
opposite outcomes as obtained in the two models are due to differences between an 
orthosteric agonist and a PAM (or orthosteric antagonist and a NAM) or to differences 
between the two absence models. The available evidence goes in the direction of 
differences between the two models. 
Does tolerance develop against group I  PAMs?
The outcomes of the acute pharmacological experiments (Chapters 2 and 3) with 
RO0711401 and VU0360172, respectively have potential relevance from a therapeutic 
standpoint since antiepileptic drugs will be chronically administered. In Chapter 4 the 
effects of mGlu1 and mGlu5 PAMs during chronic treatment were investigated. Rats were 
treated with an effective dose of RO0711401 (10 mg/kg) or VU0360172 (3 mg/kg) twice 
daily for ten days, and then after 3 days of withdrawal in response to the drug, re-challenge 
with VU0360172 or RO0711401 respectively. Complete tolerance developed to RO0711401 
on the third day of treatment and the rats were still refractory to the drug two days after 
Table 6   1Burgess et al. (1997); 2Chapman et al. (1999); 3Chapman et al. (2000); 4Lojkova´ 
and Mares (2005); 5Cheong et al. (2009); 6Ngomba et al. (2005); 7Moldrich et al. 
(2001); 8Ngomba et al. (2008); 9Ngomba et al. (2011); 10D’Amore et al. (2013).
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treatment withdrawal, whereas VU0360172 maintained its anti-absence activity during 
and after the treatment. In order to explain why tolerance developed to RO0711401 phar-
macokinetic data of the two drugs were collected: VU0360172 has high plasma-protein 
binding and small first-pass metabolism (Rodriguez et al., 2010). R00711401 shows a little 
elimination half-life (<2 h), although we found that the effects in terms of SWD reduction 
lasted 6 hours, it might be due to some active metabolite that are still able to reduce 
SWDs. However, no information is available on liver metabolism (Vieira et al., 2009). It is 
also undiscovered if RO0711401 might inhibit or accelerate its own metabolism with time. 
However, it was discovered that cortical levels of both drugs decreased across the days, 
while thalamic levels were constant across chronic treatment (8 days). The diminished 
levels in the cortex could indicate a contribution of pharmacokinetic tolerance to the loss 
of effects of RO0711401. Both PAMs were able to increase the expression of the respective 
subtypes in the thalamus and cortex on different days of drug treatment. Interestingly, 
RO0711401 in the thalamus on day eight of treatment increased the expression of mGlu1 
receptors and mGlu5 receptors as well. In the cortex the drug increased mGlu1 receptor 
levels on day three. Contrastingly, treatment with VU0360172 increased the mGlu5 
receptor expression in the thalamus, without any increase or decrease of mGlu1 receptor 
levels in thalamus and/or cortex. It may be that the amount of mGlu1-mGlu1 homodimers 
and mGlu1-mGlu5 heterodimers is predominant over mGlu5-mGlu5 homodimers in the 
cortex and in the thalamus of WAG/Rij. This would explain why the mGlu1 receptor PAM, 
RO0711401, caused changes in both mGlu1 and mGlu5 receptors, while on the contrary 
the mGlu5 receptor PAM, VU0360172, caused changes in mGluR5 only. Thereby, it might 
be that, VU0360172 did not develop pharmacodynamic tolerance due to it did not causes 
any changes in the mGlu1 receptor. 
Glutamatergic drugs in the cortico-thalamo-cortical network
Although the findings in Chapters 3 and 4 clearly suggest that VU0360172 might be 
develop for the treatment of absence epilepsy, it is still not known where within the C-T-C 
network activation of both mGlu1 or mGlu5 receptors reduces SWDs. In Chapter 5, this 
question is addressed by locally injecting either RO0711401 or VU0360172 in the cortex or 
in the thalamus. It was found that the effect in terms of SWD reduction might be caused 
by both intracortical and intrathalamic administration of mGlu1 or mGlu5 receptor PAMs. 
However, there was a different outcome between the thalamic and the cortical injection 
to RO0711401 and VU0360172. The two drugs were identically efficient in reducing SWDs 
into the cortex; conversely, the mGlu5 PAM, VU0360172, displayed a larger efficacy than 
the mGlu1 PAM, RO0711401, when administered in the thalamus. 
 Cortex: The identical effects of intracortically injected VU0360172 and RO0711401 can 
be explained by that in the somatosensory cortex, the two subtypes of group I mGlu 
receptors, localized postsynaptically on GABAergic interneurons, and have a familiar 
target. mGlu1 receptors are expressed by somatostatin-positive, calretinin-positive, and 
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calbindin-positive and mGlu5 receptors are discovered in both parvalbumin-positive 
GABAergic interneurons and somatostatin-positive (Stinehelfer et al., 2000; Sun et al., 
2009). Therefore, it is possible that, a familiar target for the two PAMs could be a cell type 
expressing both mGlu1 and mGlu5 receptors, i.e. the somatostatin sensitive GABA-ergic 
interneurons. It may also be that pharmacological enhancement of mGluR1 or mGluR5 
expressed by somatostatin sensitive and/or different types of regular spiking GABAergic 
interneurons decreases SWDs by increasing GABAergic inhibition toward pyramidal neurons.
 Thalamus: VU0360172 showed a greater efficacy than RO0711401. Activation of either 
mGlu1 or mGlu5 receptors present in the VB and other thalamic neurons may restrain the 
occurrence of SWDs by negatively regulating the activity of T-type Ca2+ channels on 
thalamo- cortical cells (Hildebrand et al., 2007; 2009). 
 However, a significant difference between mGlu1 and mGlu5 receptors is that only 
mGluR5 are located on astrocytes in the thalamus (Liu et al., 1998; Muly et al., 2003). 
Astrocytes are essential in the control of thalamic oscillations because they clear up 
extracellular glutamate and GABA from the extracellular space. In this way, they limit the 
activity of extra-synaptic glutamate and GABA receptors. The reduction in SWD seen with 
VU0360172 is in line with the pro-absence action observed after systemic administration 
of drugs that increase GABAergic neurotransmission, for instance tiagabine, which 
enhances the inhibitory GABAergic transmission at the synapses between RTN and VB 
neurons (Blumenfeld, 2005).
GABAergic drug in cortico-thalamo-cortical network
Beyond glutamate, also GABA plays a key role in the control of SWDs. Indeed, local 
injections in cortex and thalamus with GABAergic drugs, and in combination with group I 
PAMs were performed (Chapter 5). This allowed us to establish the sites of action where 
GABA in its interaction with group I PAMs exerts its action. Rats were injected in cortex 
and thalamus with tiagabine. Tiagabine is known to enhance tonic-inhibition of thalamic 
relay neurons by inhibiting GABA re-uptake via the high affinity GABA transporter GAT-1, 
and aggravates the occurrence of SWDs after systemic injection therefore facilitating the 
endogenous activation of extra-synaptic GABA receptors (Coenen et al., 1995; Pow et al., 
2005 Cope et al., 2009; Belelli et al., 2003; Errington et al., 2011). 
Tiagabine: which part of the C-T-C network is responsible for the 
increase/reduction of SWDs?
Cortex: tiagabine micro-infused in the cortex dose dependently decreased SWDs. It is 
thought by blocking the reuptake of GABA, thus enhancing GABAergic inhibition. The 
same result (decrease of SWDs) was obtained after the administration of either  mGlu1 or 
mGlu5 PAM. This suggests that activation of both mGlu1 and mGlu5 receptors might 
suppress SWDs by increasing GABA-ergic inhibition onto pyramidal neurons, perhaps by 
stimulating somatostatin sensitive GABA-ergic neurons.
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 Thalamus: tiagabine micro-infused in the thalamus increased SWDs. As described in 
Chapters 1 and 5, drugs that increase inhibitory GABAergic transmission in WAG/Rij rats, 
such as tiagabine and vigabatrin, have a pro-absence effect. Therefore, the heightened 
incidence of SWDs after intra-thalamic injection of tiagabine was anticipated, and 
suggests that the pro-absence action in the thalamus prevails over the anti-absence 
activity in the cortex after systemic administration of tiagabine. It is proposed that 
thalamic administered tiagabine facilitated SWD by increasing tonic-inhibition of thalamic 
relay neurons by inhibiting GABA re-uptake via the high affinity GABA transporter GAT-1.
Glutamatergic drugs plus GABAergic drugs in the cortico-
thalamo-cortical network
Cortex: the combination of VU0360172 plus tiagabine in the cortex showed a reduction in 
SWDs. There was however, a small difference in terms of the duration of the SWD reduction 
between VU0360172 and tiagabine when compared to VU0360172 alone. The combination 
was still effective in reducing the incidence of SWDs till 40 min post-injection, while 
VU0360172 alone lasted 30 min post-injection (Figure 5A).Therefore, it was proposed by us 
that the reduced SWDs seen in both cases occurs by enhancing GABA-ergic inhibition 
onto pyramidal neurons (Figure 6A) and that the combination showed a small albeit 
significant prolongation of SWD suppressing effects.  
 Thalamus: the combination of VU0360172 plus tiagabine in the thalamus produced 
intriguing results. After co-administration, initially the SWD reducing effects of VU0360172 
prevailed since the incidence of SWDs in the early post-injection time (10 min) was 
Figure 5A-B  Effects of VU0360172 alone, tiagabine alone, the combination of VU0360172 
and tiagabine and vehicle. infused in the thalamus and in the cortex (D’Amore et al., 2015). 
Notice the decrease in SWD incidence after both single drugs and the slightly prolonged 
effects of the combination in the cortex, while in the thalamus VU0360172 alone 
suppressed SWDs, tiagabine showed no effects, while the combitation showed that the 
action of VU0360172 was completely reversed in combination with tiagabine (D’Amore 
et al., 2015).
A B
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Figure 6A-B  Mechanistic hypothesis of the role played by cortical (A) or thalamic (B) 
mGlu1 and mGlu5 receptors in the modulation of absence seizures. The diffusion of either 
GABA (rounded dots and arrows in green) or glutamate (rounded dots and arrows in red) 
within and out of the synaptic terminals and glia cells are depicted. In the S1po cortex, 
pharmacologic enhancement of mGlu1 or mGlu5 receptors might reduce absence 
seizures by activating somatostatin (SST)–positive GABAergic interneurons, and tiagabine 
might produce the same effect by enhancing GABA levels at the synapses between SST+ 
interneurons and pyramidal neurons. In the ventrobasal thalamus, tiagabine enhances 
absence seizures by increasing synaptic and extrasynaptic GABA levels, thereby facilitating 
the activity of T-type voltage-sensitive Ca2+ channels. mGlu1 and mGlu5 receptors might 
protect against absence seizures by directing modulating T-type Ca2+ channels or through 
a blockade of the glial glutamate transporter. Tiagabine might act via blockade of the 
presynaptic and glial GABA transporter. Data on the interaction between VU0360172 and 
tiagabine raise the possibility that mGlu5 receptors regulate the expression or activity of 
GAT-1 in GABAergic terminals and/or astrocytes (D’Amore et al., 2015).
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reduced. Next, this effect was lost at 20 min, and a pro-absence effect at 30 and 40 min 
occurred (see Figure 5 B). These results suggest that the activity of mGlu5 receptors is 
modulated by GABAergic transmission. It is known that the mGluR5 may control the 
activity of GAT-1 (Aronica et al., 2003) in astrocytes or in GABAergic fibers afferent to the 
ventrobasal thalamus. This implies that, in the presence of the GAT-1 inhibitor tiagabine 
activation of mGluR5 will not stimulate GABA reuptake, and the continuous enhancement 
in extracellular GABA will stop the anti-absence effect mediated by mGlu5-receptor 
stimulation (Figure 6B). In order to verify this hypothesis, experiments on tonic inhibition 
in thalamic slices or studies on GABA uptake alone and in the presence of mGlu5 PAM’s in 
cultured of astrocytes in epileptic and non-epileptic rats are needed. 
Figure 6  Continued.
Dendrite
of layer V-VI
pyramidal neuron
GABAergic 
 terminal of SST   interneuron
Astrocyte
TC glutamatergic 
 pre-synaptic 
terminal 
TiagabineGAT
SST
interneuron 
mGlu5
mGlu1
GABAB
GABA
mGlu5
Astrocyte
+
A
GAT
+
mGlu5
GABAergic 
nRT neuron
Tiagabine
Presynaptic 
terminal from 
layer V-VI
pyramidal neuron
GAT
Dendrite of 
thalamo-cortical
neuron
Astrocyte
GAT
mGlu5
Tiagabine
mGlu5 GLT1/ 
GLAST
?
GABAB
GABAA
Astrocyte
?
?
}
mGlu5
mGlu1
T-type Ca   channel 
2+
THALAMUS
CORTEX
B
503055-L-bw-DAmore
General discussion  |  187
8
VU0360172 vs. ethosuximide in the cortico-thalamo- 
cortical network
As described in Chapter 1, Chapter 6, and Chapter 7, ETX is a first choice antiabsence 
medicine (Leresche et al., 1998). However when infused into either the VB or RTN of GAERS 
(Marescaux et al., 1992; Danober et al., 1998) it had only a moderate and delayed decrease 
in SWDs, when compared to the instantaneous and labeled decrease observed after 
systemic injection (Richards et al., 2003). When injected into the somatosensory cortex it 
did result in a direct and almost full interruption of SWDs, equivalent to that found after 
systemic or intracerebroventricular administration (Marescaux et al., 1984; van Luijtelaar et 
al., 2013; Richards et al., 2003; Gurbanova et al., 2006). In Chapter 5, it has been shown that 
VU0360172 reduced SWDs equally well when locally injected in cortex and thalamus. 
Taking these data together, it may be possible to highlight a difference in terms of SWD 
reduction between ETX and VU0360172. VU0360172 targets both locations equally 
effective, and this is less the case for ETX. Therefore it could be proposed that this factor 
may contribute to successful seizure suppression of mGluR group I PAMs (see Table 7).
Need for new treatment options in absence epilepsy
In Chapter 6, ‘‘Is there a future for mGlu5 PAMs in absence epilepsy? A comparison 
between VU0360172 and Ethosuximide’’, emphasizes the need for new treatment options 
in absence epilepsy. ETX is the drug of choice in the treatment of various types of absence 
seizures. However, there is room for other anti-absence drugs considering that not all 
subjects become seizure free and in about 47% of subjects, ETX therapy failed (Tenney 
Table 7   Action of mGlu and GABAergic drugs and their combination in the cortico- 
thalamo-cortical circuitry.
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and Glauser, 2013). Another issue is that since it is frequently hard to get good seizure 
control with only a single antiepileptic drug, interaction studies among several 
antiepileptic drugs are pointed out. The review highlighted that ETX had infra-additive 
effects with valproic acid in WAG/Rij rats, so combination studies of PAMs with ETX and 
valproic acid are indicated. A newly discovered action of chronic ETX, but also with some 
other compounds, is antiepileptogenesis in the genetic absence models. Therefore it is 
also important to investigate whether antiepileptogenesis is also achievable with group I 
PAMs and whether antiepileptogenesis affects the sensitivity of the other anti-absence 
drugs. Thereby, this chapter emphasized that a good candidate to investigate antiepilep-
togenesis in combination with ETX might be the mGlu5 PAM, VU0360172. 
Could VU0360172 be combined with other AED?
In Chapter 7, the anti-absence and anti-epileptogenetic effects of ETX and the interaction 
between VU0360172 and ETX was evaluated. In this case ETX was chronically administered 
for 4 months in order to induce anti-epileptogenesis, next it was evaluated whether and 
how VU0360172 interacted with ETX. The anti-absence and antiepileptogenic effects of 
ETX were successfully established, in line with outcomes of earlier studies (Blumenfeld et 
al., 2008; Sarkisova et al., 2010; Russo et al., 2010, 2011; van Luijtelaar et al., 2013). VU0360172, 
as expected (Chapters 3, 4 and 5), reduced  SWDs in a dose and time dependent way in 
the untreated control group. However, the same injections with VU0360172 in chronically 
ETX treated rats induced a small reduction in  SWD incidence throughout the whole 
recording session without returning to the baseline. This effect was found both during 
and after ETX treatment had stopped. It seems that the combination of chronic ETX plus 
acute VU0360172 seemed to have larger effects than ETX alone and therefore a better 
pharmacological profile in terms of SWD diminishment when compared to ETX alone, 
although the size of the SWD reducing effects of VU0360172 was diminished compared to 
the size of the effects in the water treated control group. The favourable profile is 
important if we take into consideration the life-compliance of the patients with respect to 
the dose/drug administration protocol. Considering the decrease in the sensitivity of 
VU0360172 in the chronic treated rats, western blots was done measuring the protein for 
mGluR5 in this group. The results did not show a down- or up-regulation of mGlu5 
receptor for the chronic treated ETX group when compared with the age matched 
non-treated control group. This suggests that this part of the system is not modified and 
indeed VU0360172 kept some of its anti-absence effects.
Hypothetical signaling pathway of ETX
Identification of primary cell signaling pathways that trigger different downstream 
mechanisms mediating epileptogenesis are beginning to gain important roles, and many 
current research has been focused on this signaling identification (Dichter, 2006; Pitkänen 
and Lukasiuk, 2011). The rapamycin (mTOR) pathway is one signal transduction system 
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that has gained attention as a significant regulator of cellular changes concerned in epi-
leptogenesis (McDaniel & Wong, 2011; Russo et al., 2012; 2013; Zeng et al., 2009a). Quite a 
few studies have showed a potential role of mTOR signaling in epilepsy and in particular, 
epileptogenesis in both convulsive and non-convulsive epilepsies. A recent study has 
shown that acute and sub-chronic administration of the mTOR inhibitor rapamycin 
decreased SWD activity. Moreover, in the same study it has been found that rapamycin 
has antiepileptogenic effects in WAG/Rij rats, most likely through mTOR inhibition as well 
(Russo et al., 2013). Moreover, it is well known that, mTOR affect a variety of cellular and 
molecular processes, such as ion channel expression and neurotransmitter receptor, and 
apoptosis, neurogenesis and synaptic plasticity, all of which are known to influence 
neuronal excitability and epileptogenesis (Tang et al., 2002; Kumar et al., 2005; Wang et al., 
2006). However, the exact mechanisms involved in these processes have not yet been 
clarified (Galanopoulou et al., 2012; Russo et al., 2012; Wong, 2013). Interestingly,  vigabatrin 
has the same kinds of antiepileptogenic action in WAG/Rij rats through  inhibition of the 
mTOR pathway (Russo et al., 2011; Zhang et al., 2013). 
 Although, the engagement of the mTOR pathway in epileptogenic mechanisms has 
been discussed in detail (Cho, 2011), investigations to define the mechanisms by which 
rapamycin may influence both the initial development and the ongoing maintenance of 
epilepsy, and to determine the clinical utilization of rapamycin for preventing epilepsy still 
need to be addressed.  
Has ETX and VU0360172 mTOR a common signaling pathway?
A common target between ETX and VU0360172 may be the mTOR pathway. It is known 
that the mGluR5 antagonist, CHPG, activated the mTOR pathway (Cao et al., 2015). It is 
therefore possible to speculate that VU0360172 is able to inhibit the activity of the mTOR 
pathway. So it might be that VU0360172, although it maintained its anti-absence effect 
during and after ETX treatment (see Chapter 6 and above), lost its common dose- 
dependency effect due to the already inhibited mTOR signaling by chronic ETX treatment.
ETX and VU0360172; behavior and motivation 
Most AED such as ETX, VPA, and LTG have a negative impact on cognition (Conant et al., 
2010; Pavone, 2001). Moreover, the antiepileptogenic effects of chronic ETX were 
accompanied by a decrease in depressive-like behavior in WAG/Rij rats (Sarkisova et al., 
2010; van Luijtelaar et al., 2013). In Chapter 7, it was also investigated whether  cognitive 
aspects have been modified as a consequence of chronic ETX treatment. Rats were 
exposed to a cue discrimination learning task in a Y-maze and in a sucrose motivation task 
during and after chronic treatment. The outcomes showed that chronic ETX enhanced 
motivation to collect sucrose pallets, and this was followed by an increase in cued 
discrimination learning. The cognitive enhancing effects of ETX, as found at the end of 
the experiment (when the rats had received also the challenge with VU0360172), might 
503055-L-bw-DAmore
190  |  Chapter 8
be mediated to the antidepressant action of ETX as expressed by an increase in the 
rewarding properties of sucrose pallets. As for the mGluR5, the activation with a PAM (see 
Chapter 1) might increase at the same time both forms of synaptic plasticity (long-term 
potentiation and long-term depression of synaptic strength), thereby enhancing cognitive 
function (Noetzel et al., 2012; Ayala et al., 2009). This supplies an ideal profile for enhancing 
cognitive function, and indeed mGluR5 PAMs increase cognitive function in several 
rodent models (Chan et al., 2008; Gastambide et al., 2013). It is also known that comparable 
PAMS are proposed for the treatment of psychosis and cognitive disturbances in 
schizophrenic patients (Cleva et al., 2011).
mGluR drugs in clinical use and future development
Several mGluR ligands are under clinical development for the treatment of different 
nervous disorders such as; Parkinson’s disease, schizophrenia, Fragile-X syndrome, chronic 
pain, and generalized anxiety disorder. Those compounds, selectively target Group I or 
Group II mGluRs, principally mGluR2/3 and mGluR5 (Yasuhara et al., 2010; Nicoletti et al., 
2011; Levenga et al., 2011; Fell et al., 2012). The mGluR5 antagonists MPEP and correlated 
mGluR5 NAMs have strong efficacy in plural animal models of anxiolytic activity (Swanson 
et al., 2005; Pecknold et al., 1982). Moreover, outcomes from animal studies recommend 
that, mGluR5 NAMs also have utility in the treatment of Fragile-X syndrome, because the 
primary mutation-giving origin to the sickness leads to enhanced mGluR5 function 
(Ronesi et al., 2008). But also, mGluR5 NAM might for instance normalize the excessive 
protein synthesis, which might give origin to symptoms correlated with Fragile X 
syndrome (Bear et al., 2004). MGluR5 NAM might also be used for chronic pain, depression 
and some neurodegenerative disorders (Yan et al., 2005; Slassi et al., 2005; Lehmann, 2008). 
Next to the efficacy of mGluR5 NAMs, mGluR5 PAMs might have also advantage in the 
treatment of schizophrenia (Conn et al., 2008; Moghaddam, 2004; Kinney et al., 2005; Liu et 
al., 2008; Darrah et al., 2008). 
Conclusions 
Acute and chronic treatment with positive allosteric modulator of mGlu5 metabotropic 
glutamate receptors, VU0360172, decrease the SWD occurrence in the WAG/Rij rat model 
of absence epilepsy without development of tolerance and/or clear behaviour 
disturbances. RO0711401 was also effective acutely and in cortex and thalamus, but 
tolerance developed quickly. Therefore, VU0360172 might be preferentially developed in 
the near future for the treatment of absence epilepsy. Secondly, opposite effects of 
targeting group I mGluR were found in WAG/Rij rats compared to results targeting the 
same receptors with orthostatic agonists and antagonists obtained in another genetic 
absence model, the lethargic mice; many factors such as genetic background, behavioural 
phenotype, and differences in mGlu receptor distributions and densities in thalamus and 
cortex, might be the cause of these differences. Thirdly, as for the mechanisms, in cortex 
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VU0360172 might enhance GABAergic inhibition, conversely, in thalamus, the activity of 
mGlu5 receptors might reduce the enhanced tonic inhibition and the action of VU0360172 
might be affected by the availability of extra-synaptic GABA. Fourthly, VU0360172 targets 
both locations equally effective (cortex and thalamus) while the drug of choice, 
ethosuximide, is less effective in the thalamus when compared to the  injection in the 
cortex. Therefore, it is proposed that this contributes to the  efficacy of mGlu5 PAM in 
successful seizure suppression. But also that VU0360172 might be combined with other 
anti-epileptic drugs such as ETX for a better seizure control. 
Direction for future research 
Future research is needed in order to settle out whether or not the mGlu5 receptor PAMs, 
might be introduced for clinical use, and are safe in combination with other drugs used 
for the treatment of absence epilepsy. 
 In order to predict the safety and tolerability profile of VU0360172, neurotoxic studies 
need to be done with higher doses of the mGlu5 PAM, such as the measurement of 
stereotyped motor coordination tasks e.g. rotarod. Given the notion that the PAMs might 
modulate glutamate, but also that VU0360172 might act via enhancing GABA-ergic 
transmission, its sedative properties should be investigated. 
 If group I PAM receptor can be further developed as an anti-absence drug, the 
preclinical profile of VU0360172 in other generalized and focal epilepsy models, including 
mesial temporal epilepsy, needs to be determined. The fact that it may aggravate the 
action of GABA-ergic interneurons, as was established in the focal excitable area in the 
WAG/Rij model, could point toward this.
Further studies should be aimed at establishing whether VU0360172 has antiepileptogen-
ic effects and pharmacological challenges after chronic VU0360172 treatment with ETX, 
and/or other AEDs should be performed to establish whether chronic treatment can 
modulate the direction of drug’s effects. 
 Since it is frequently hard to achieve good seizure control with just a single 
antiepileptic drug, interaction studies among various antiepileptic drugs are suggested. 
Acute and chronic studies with VU0360172 and other AED must be evaluated.
 Research towards mechanisms regarding antiepileptogenesis need to be done. As 
described in this thesis, the mTOR signaling pathway may be involved in antiepileptogen-
esis.  Additionally, acute studies with VU0360172 and ETX could be helpful in clarifying the 
interaction seen between the two drugs and the hypothetical involvement of the mTOR 
pathway.
 Future studies should be focused on how and in what ways VU0360172 interacts 
with GABA. It is proposed that studies towards GABA reuptake in cultured astrocytes or on 
tonic inhibition in thalamic slices in epileptic and non-epileptic rats under normal 
circumstances and or in the presence of VU0360172. 
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 To review our knowledge on the desensitization of mGlu receptors, and perhaps 
discover the real nature of the tolerance developed to RO0711401, and not versus 
VU0360172. Studies are needed of the molecules involved in desensitization and internal-
ization of mGlu1 and mGlu5 receptors, such as the G-protein coupled receptor kinases 
and β-arrestin.
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English Summary
Childhood absence epilepsy (CAE) accounts for 2% to 8% of patients with epilepsy, with 
the main cause being predominantly genetic. About one-third of the families of children 
with CAE report a family history of similar seizures. The siblings of children with CAE have 
about a 10% chance of developing epilepsy. CAE is considered to be one of the relatively 
benign childhood epilepsies. It typically begins between 4 and 8 years of age and is 
characterized by daily, frequent, brief staring spells, often with the eyes fluttering and the 
child being unresponsive to external stimuli. New anti-epileptic drugs are badly needed 
considering that not all subjects (57%–74%) become seizure-free, and in about 47% of 
subjects Ethosuximide (ETX) therapy, one of the preferred anti-absence drugs, failed. New 
anti-absence drugs might target glutamatergic and/or GABA-ergic neurotransmission, the 
key players in the network involved in the cortico-thalamo-cortical (C-T-C) oscillations 
responsible for the highly stereotyped spike-wave discharges (SWDs). There is quite some 
evidence that in rodent models the facial area of the somatosensory cortex contains a 
hyper-excitable area from which the SWDs originate. The presence of metabotropic 
glutamate receptors (mGluRs) within the C-T-C circuit suggests that these receptors are 
possible targets for the treatment of absence epilepsy. Moreover, since targeting mGluRs 
might be less toxic than targeting ionotropic glutamate receptors, it was imperative to 
explore the role of mGluRs in absence epilepsy, also considering that drugs targeting 
mGluR have been shown to exert pro- or anti-epileptic effects in various seizure and 
epilepsy models. A final reason was also that  allosteric modulators of group I have been 
shown to be safe and have already entered clinical development for other neurological 
and psychiatric disorders.
 In particular, the roles of group I mGlu receptors—both mGlu1 and mGlu5 belong to 
this category—will be investigated. They are preferentially expressed in the peripheral 
portion of the postsynaptic density, where they cause excitatory responses and control 
mechanisms of synaptic plasticity. 
 The experiments, as described in this thesis, investigated the involvement of group I 
mGluR in the pathophysiology of absence epilepsy, and this was done in a well-validated 
and frequently used model: rats of the WAG/Rij strain. The role of mGluR1 and mGluR5 
was investigated by establishing their expression and signaling in the brain regions where 
the pathological SWDs initiate, spread and are maintained: the C-T-C circuitry. Most often, 
symptomatic rats were compared with non-symptomatic rats and age-matched control 
(ACI) rats. Furthermore, pharmacological EEG-behavioral studies were carried out with 
the aim to establish whether positive allosteric modulators (PAMs) or negative allosteric 
modulators (NAMs) of this group can be developed as putative anti-absence drugs.
 First, in Chapter 1 the ‘’General Introduction’’, epilepsy in general and absence 
epilepsy in particular were introduced, and the animal model used in this thesis, the WAG/
Rij rat model, was placed in its context. Next, glutamate receptors were introduced, while 
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literature regarding the relation of epilepsy and glutamate receptors of the metabotropic 
type were reviewed, narrowing this topic to group I mGluR. Also, an overview of possible 
clinical applications were given. Lastly, the involvement of group I mGluR in the patho-
physiology of absence epilepsy was described. 
 In Chapter 2, the role of mGluR1 in the occurrence of SWDs, the expression, and 
signaling of mGlu1 receptors were evaluated in thalamic nuclei. This study showed that 
the mGlu1 PAM, RO0711401 decreased the number of SWD in WAG/Rij rats and slightly 
increased spontaneous motor activity (not significantly). To further prove a protective role 
for mGlu1 receptors against SWDs, the same animal model was treated with the mGlu1 
NAM, JNJ16259685. The outcome showed an increase in the number of SWDs without 
any effect on spontaneous motor activity. Next the expression and signaling of mGlu1 
receptors was evaluated and the results showed a reduction in the mGluR1 function and 
expression in the thalamus of symptomatic WAG/Rij rats when compared to non-epileptic 
control rats. Therefore, it is possible that the effects of the PAM, in terms of SWD 
occurrence, is due to a hypo-function of mGlu1 receptors in the thalamus. In any case, it is 
proposed that the PAM of this group could be further developed as an anti-absence 
agent.
 Next, in Chapter 3, the mGlu5 receptors function, the expression, the pharmacological 
manipulation with a PAM, VU0360172, and of the rat’s behavior were evaluated. A decrease 
in both the mGlu5 receptor protein levels and mGlu5-receptor function in the thalamus 
was found when compared to the age matched non-epileptic ACI rats. Conversely, the 
expression of mGlu5 receptors was enhanced in the motor cortex and in the 
somatosensory cortex without an accompanying change in mGlu5-receptor function 
when compared to ACI rats. It is proposed that VU0360172 might reduce SWDs. It was 
found that VU0360172 significantly reduced SWDs, without affecting motor behavior. To 
answer whether this mGlu5 PAM was selective versus mGlu5 receptors, VU0360172 was 
administered in WAG/Rij rats, pretreated with the antagonist MTEP. It was found that the 
effect of VU0360172 was prevented by co-treatment with MTEP, demonstrating that the 
drug decreased absence seizures by amplifying the endogenous activation of mGlu5 
receptors. Whether or not the pharmacological effects are due to a hypo-functional 
thalamus needs to be determined.  It now seems that both group I PAMs (RO0711401 and 
VU0360172) could be further developed as anti-absence drugs. 
 In the experiments as described in Chapter 4, it has been evaluated whether 
RO0711401 and VU0360172 develop tolerance. This is important since treatment with 
antiepileptic drugs will always be in chronic cases. Rats were injected twice daily for 10 
consecutive days while the EEG was recorded. The outcome showed that rats developed 
tolerance to RO0711401 on the third day of treatment and were refractory to the drug two 
days after treatment withdrawal. In contrast, VU0360172 kept its activity during and after 
the treatment. Biochemical studies revealed that RO0711401 increased the expression of 
both mGluR1 and mGluR5 in the thalamus, while in the cortex the drug increased mGlu1 
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receptor levels only. VU0360172 caused an early and constant increase in mGlu5 receptor 
expression in the thalamus, a late decrease of mGlu5 receptor expression in the cortex, 
and no changes in mGlu1 receptors. It is proposed that there is a prevalence of mGlu1-mGlu1 
homodimers and mGlu1-mGlu5 heterodimers over mGlu5-mGlu5 homodimers in the 
cortex and thalamus of WAG/Rij. This could explain why the mGlu1 receptor PAM, 
RO0711401, caused adaptive changes in both mGluR1 and mGluR5, whereas the mGlu5 
receptor PAM, VU0360172, selectively induced changes in mGlu5 receptors only. 
 In Chapter 5, a C-T-C circuit demarcation strategy has been adopted by bilateral 
intra-cortex or intra-thalamus micro-infusions of RO0711401 and VU0360172 respectively 
to elucidate site-specific effects on the regulation of SWDs. The study showed that the 
two drugs were equally effective in decreasing SWDs when administered into the cortex; 
in contrast, the mGlu5 PAM, VU0360172, displayed a greater efficacy than the mGlu1 PAM, 
RO0711401, when administered into the thalamus. Next to the role of glutamate, GABA 
also play an important role in the control of SWDs. It is known that systemically 
administered GABA-mimetic, such as tiagabine, acting by blocking the reuptake of GABA 
via the high affinity GABA transporter, GAT-1, aggravates the incidence of SWDs. Therefore, 
by the use of tiagabine, we explored whether, and in which direction, an enhanced 
availability of extra-synaptic GABA might influence responses to VU0360172, in the 
thalamus and somatosensory cortex as well. Firstly, tiagabine infused in the cortex dose 
dependently decreased SWDs. It is thought that by blocking the reuptake of GABA, it is 
possible to enhance GABA-ergic inhibition. Whereas, tiagabine infused in the thalamus 
enhanced SWDs. It is proposed that thalamic administered tiagabine facilitated SWD by 
increasing tonic-inhibition of thalamic relay neurons by inhibiting GABA re-uptake via the 
high affinity GABA transporter GAT-1.The combination of VU0360172 plus tiagabine in the 
cortex displayed a SWDs reduction. Instead, the combination of VU0360172 plus tiagabine 
in the thalamus produced fascinating results. After co-administration, initially the SWD 
reducing effects of VU0360172 prevailed since the incidence of SWDs in the early 
post-injection time (10 min) was decreased. Next, this effect was lost at 20 min, and a 
pro-absence effect at 30 and 40 min occurred. Therefore, we proposed that the reduced 
SWDs seen in the cortex occurs by enhancing GABA-ergic inhibition onto pyramidal 
neurons. The intriguing results after the drugs were combined in the thalamus suggest 
that the activity of mGlu5 receptors is modulated by GABAergic transmission.
 In Chapter 6, “Is there a future for mGlu5 PAMs in absence epilepsy?” A comparison 
between ETX, which has become the drug of choice in the treatment of patients with 
absence seizures taking into account both its tolerability, efficacy, and anti-epileptogenic 
properties in human and in genetic absence models, and VU0360172 has been made. 
Here, the need for new treatment options in absence epilepsy was emphasized since 47% 
of subjects treated with ETX failed in therapy. The assumed working mechanisms of ETX, 
the neurochemical and pharmacological studies of the new anti-absence drugs mGlu1 
and mGlu5 PAMs, RO0711401 and VU0360172, were described and also a comparison 
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between ETX and VU0360172 was made. The main conclusion of this chapter was that, 
although both ETX and VU0360172 decreased SWDs when administered in the cortex 
and thalamus, VU0360172 targets both locations equally effectively, and this is less the 
case for ETX. This outcome gives us reason to believe that VU0360172 could be  successful 
in seizure suppression in patients.
 In Chapter 7, the anti-absence and anti-epileptogenetic effects of ETX, and the 
interaction between VU0360172 and ETX, has been evaluated. Moreover, considering that 
epileptogenesis and chronic ETX treatment, inducing antiepileptogenesis, might affect 
mood and cognitive processes such as learning and memory. These latter processes were 
investigated after chronic ETX treatment as well. The study showed that the anti-absence 
and anti-epileptogenic effects were successfully induced by ETX. VU0360172, as expected, 
reduced the SWDs in the untreated control group. However, VU0360172 in chronically ETX 
treated rats kept the SWD incidence low throughout the whole EEG recording session 
without returning back to the baseline. This effect occurred both during and after chronic 
treatment were ended. This data may suggest that a kind of synergism between ETX and 
VU0360172 has occurred.
 Many AEDs, such as ETX, valproic acid, and lamotrigine, have a negative impact on 
cognition. Therefore it has also been investigated in Chapter 7 if a cognitive aspect, in this 
case cued spatial discrimation learning in a Y-maze, has been modified after chronic ETX 
treatment. The outcome showed that chronic ETX enhanced motivation to collect 
sucrose pallets in the Y-maze, and this was followed by an increase in cued discrimination 
learning.
 In Chapter 8, the “General Discussion”, the most important findings of the experimental 
chapters were summarized and their implications were given. First, pharmacological 
manipulation of group I mGluR was shown to differentially affect SWD activity. Systemic 
administration of mGlu agonist drugs (RO0711401 and VU0360172) resulted in a decrease 
of SWD activity, while the antagonist in an increased SWD activity. In the chronic treatment 
study, tolerance developed against mGlu1 PAM, RO0711401, while tolerance was not 
developed for the mGlu5 PAM, VU0360172.  It was also shown that the function of mGlu1 
and mGlu5 receptors in two genetic absence models (lh/lh mice and WAG/Rij rats) was 
not similar, and the role of mGlu receptor PAMs/NAMs is dependent on the genetic 
background of the animals. It has also shown where within the C-T-C circuit activation of 
either mGlu1 or mGlu5 receptors (cortex or thalamus)  SWDs were reduced. The two 
drugs were equally effective in reducing SWDs when injected into the cortex; in contrast, 
the mGlu5 PAM, VU0360172, displayed a greater efficacy than the mGlu1 PAM, RO0711401, 
when injected into the thalamus. In this thesis it has also been  shown which brain area—
cortex or thalamus—is involved in the anti-absence and pro-absence effect of tiagabine. 
Tiagabine micro-infused in the cortex reduced SWDs, while in the thalamus it increased 
SWDs. The combination of VU0360172 and tiagabine micro-infused in the thalamus but 
not in the cortex showed that mGlu5 receptors might play a role also through GABAergic 
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transmission, with mGluR5 also able to control the activity of the GABA transporter (GAT-1). 
The combination study of ETX plus VU0360172 showed a better pharmacological profile 
in terms of SWD diminishment when compared to ETX alone. It is also shown that 
VU0360172 could be combined with ETX since the combination of the two drugs kept the 
SWD incidence low throughout the whole recording session without returning to the 
baseline. Future studies are suggested regarding the development of VU0360172 as an 
anti-absence drug. If the group I PAM receptor can be further developed as a new 
anti-absence drug, the preclinical profile of VU0360172 in other generalized and focal 
epilepsy models, including mesial temporal epilepsy, needs to be determined. The fact 
that it may aggravate the action of GABA-ergic interneurons, as was settled in the focal 
excitable area in the WAG/Rij model, could point toward this drug being effective in 
treating other types of epilepsy as well. 
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Absence-epilepsie op kinderleeftijd (childhood absence epilepsy, verder CAE genoemd) 
betreft 2% tot 8% van de patiënten met epilepsie. De belangrijkste oorzaak is hoofdzakelijk 
genetisch. In ongeveer een derde van de gezinnen met kinderen met CAE is in de familie-
geschiedenis sprake van vergelijkbare gevallen. De broers en zussen van kinderen met 
CAE lopen een kans van ongeveer 10% om ook epilepsie te krijgen. CAE wordt gezien als 
een van de relatief goedaardige vormen van kinderepilepsie. Deze aandoening begint meestal 
op een leeftijd van vier tot acht jaar en wordt gekenmerkt door dagelijkse, regelmatig 
terugkerende, korte periodes van staren, waarbij het kind vaak knipperende oogleden 
heeft en niet reageert op externe stimuli. Er zijn dringend nieuwe geneesmiddelen 
tegen epilepsie nodig, ook gezien het feit dat niet alle proefpersonen (57% à 74%) vrij 
is van aanvallen en dat een behandeling met ethosuximide (ETX), een van de voorkeurs-
geneesmiddelen tegen absences, faalt bij ongeveer 47% van de proefpersonen. 
 Nieuwe geneesmiddelen tegen absences kunnen zowel ingrijpen in de glutamaterge 
en/of GABA-erge neurotransmissie, de beide hoofdrolspelers in het netwerk dat betrokken 
is bij de cortico-thalamo-corticale oscillaties (C-T-C-oscillaties) die verantwoordelijk zijn 
voor de zeer stereotype piekgolfontladingen (spike-wave discharges, verder te noemen 
SWD’s). Op grond van knaagdiermodellen is inmiddels  aangetoond dat het faciale gedeelte 
van de somatosensorische cortex beschikt over een hyperexciteerbaar gebied waar de 
SWD’s hun oorsprong hebben. De aanwezigheid van metabotrope glutamaatreceptoren 
(mGluRs) binnen het C-T-C-circuit is een aanwijzing dat deze receptoren een mogelijk 
target zijn bij de behandeling van absence-epilepsie. Bovendien is er bij mGluRs als target 
van behandeling minder sprake van toxiciteit dan bij ionotrope glutamaatreceptoren het 
geval zou zijn. Het was daarom absoluut geboden om te verkennen welke rol mGluRs 
speelden bij absence-epilepsie, ook omdat geneesmiddelen die mGluR als target hadden in 
verschillende modellen voor toevallen en epilepsie een pro- of anti-epileptische werking 
vertoonden. Een laatste reden was daarnaast nog dat allostere modulatoren uit groep I 
veilig zijn gebleken en zich ook al in de klinische ontwikkelingsfase bevinden voor 
behandelingen van andere neurologische en psychiatrische aandoeningen.
 Er zal in het bijzonder gekeken worden naar de rol van mGlu-receptoren die behoren 
tot  groep I — zowel mGlu1 als mGlu5 behoren tot deze categorie. Ze komen preferentieel 
tot expressie in het perifere gedeelte van de postsynaptische verdichting, waar ze excitatie-
responsen oproepen en controle uitoefenen op  mechanismen van  synaptische plasticiteit. 
 Bij de experimenten die in dit proefschrift beschreven worden, is onderzoek gedaan 
naar de betrokkenheid van mGluRs van groep I in de pathofysiologie van absence-epilep-
sie. Dit werd gedaan in een goed gevalideerd en veelgebruikt model: ratten van de WAG/
Rij-stam. De rol van mGluR1 en mGluR5 is onderzocht door vaststelling van hun expressie 
en signalering in de hersengebieden waar zich de pathologische SWD’s voordoen, waar 
ze zich vanuit verspreiden en waarin ze in stand worden gehouden: het C-T-C-circuit. In de 
503055-L-bw-DAmore
208  |  Addendum
meeste gevallen werden ratten met symptomen vergeleken met ratten zonder symptomen 
en met ACI-ratten in dezelfde leeftijdsgroep. Bovendien werd er farmacologisch EEG- 
gedragsonderzoek uitgevoerd, met als doel om vast te stellen of positieve allostere 
modulatoren (PAM’s) of negatieve allostere modulatoren (NAM’s) uit deze groep mogelijk 
kunnen worden ingezet als geneesmiddel tegen absences.
 In Hoofdstuk 1, de ‘Algemene inleiding’, wordt een introductie gegeven tot epilepsie 
in het algemeen en absence-epilepsie in het bijzonder. Daarnaast wordt het diermodel 
dat in dit promotieonderzoek is gebruikt, het WAG/Rij-rattenmodel, in de juiste context 
geplaatst. Daarna worden de glutamaatreceptoren geïntroduceerd en wordt ingegaan 
op literatuur over het verband tussen epilepsie en glutamaatreceptoren van het 
metabotrope type. Daarna spitst dit onderwerp zich toe op mGluRs in groep I. Vervogens 
wordt een overzicht gegeven van mogelijke klinische toepassingen. Ten slotte volgt er 
een omschrijving van de wijze waarop mGluRs uit groep I betrokken zijn bij de pathofy-
siologie van absence-epilepsie. 
 In Hoofdstuk 2 wordt de rol besproken die mGluR1 speelt bij het optreden van 
SWD’s en wordt ingegaan op de expressie en signalering van mGlu1-receptoren in de 
thalamuskernen. In dit onderzoek is aangetoond dat de mGlu1-PAM RO0711401 het aantal 
SWD’s in WAG/Rij-ratten verminderde en de spontane motorische activiteit iets deed 
toenemen (niet-significant). Om verder aan te tonen dat mGlu1-receptoren bescherming 
kunnen bieden tegen SWD’s, werd hetzelfde diermodel ook behandeld met mGlu1-NAM 
JNJ16259685. Het resultaat hiervan was een toename van het aantal SWD’s, zonder dat er 
sprake was van een effect op de spontane motorische activiteit. Vervolgens wordt de 
expressie en signalering van mGlu1-receptoren besproken en wordt gewezen op de 
resultaten, waaruit blijkt dat er bij WAG/Rij-ratten met symptomen sprake is van een 
vermindering in de werking en expressie van mGluR1 in de thalamus vergeleken met de 
niet-epileptische ratten uit de controlegroep. Het is dan ook mogelijk dat de effecten van 
de PAM, gemeten naar het optreden van SWD’s, het gevolg zijn van een hypofunctie van 
de mGlu1-receptoren in de thalamus. In elk geval wordt het voorstel gedaan om te 
onderzoeken of de PAM’s uit deze groep verder kunnen worden ontwikkeld tot een 
middel tegen absences.
 In Hoofdstuk 3 wordt ingegaan op de werking van de mGlu5-receptor, op de 
expressie en de farmacologische manipulatie ervan met behulp van een PAM, VU0360172, 
en op het gedrag van de rat. Vergeleken met de niet-epileptische ACI-ratten uit dezelfde 
leeftijdsgroep was er sprake van een afname in zowel de receptoreiwitspiegel van mGlu5 
als van de werking van de mGlu5-receptor in de thalamus. Tegengesteld daaraan was er 
in vergelijking met ACI-ratten sprake van sterkere expressie van de mGlu5-receptoren in 
de motorische  en in de somatosensorische cortex, zonder dat dit gepaard ging met een 
verandering in de werking van de mGlu5-receptor. Er wordt het vermoeden geuit dat 
VU0360172 SWD’s zou kunnen verminderen. Er werd vastgesteld dat VU0360172 zorgde 
voor een significante vermindering van de SWD’s, zonder dat dit van invloed was op het 
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motorische gedrag. Om te kunnen beantwoorden of deze mGlu5-PAM selectief was voor 
mGlu5-receptoren, kregen met de antagonist MTEP voorbehandelde WAG/Rij-ratten 
VU0360172 toegediend. Er werd vastgesteld dat bij concomitante behandeling met MTEP 
de werking van VU0360172 werd tegengegaan. Hiermee werd aangetoond dat het 
geneesmiddel absence-toevallen verminderde door versterking van de endogene 
activering van de mGlu5-receptoren. Of de farmacologische effecten het gevolg zijn van 
een hypofunctie van de thalamus of niet moet nog worden bepaald. Naar nu blijkt 
kunnen PAM’s uit groep I (RO0711401 en VU0360172) mogelijk verder worden ontwikkeld 
tot geneesmiddelen tegen absences. 
 Tijdens de experimenten die in Hoofdstuk 4 beschreven worden, is nagegaan of er 
bij RO0711401 en VU0360172 sprake is van de ontwikkeling van tolerantie. Dit is een punt 
dat van groot belang is, aangezien behandelingen met geneesmiddelen tegen epilepsie 
altijd in chronische gevallen zullen worden toegepast. Ratten werden twee keer per dag 
gedurende tien achtereenvolgende dagen geïnjecteerd en er werden EEG’s gemaakt. 
Het resultaat was dat de ratten op de derde dag van de behandeling een tolerantie 
ontwikkelden voor RO0711401 en twee dagen na intrekken van de behandeling farmaco-
resistent waren. De werking van VU0360172 bleef echter wel in stand, zowel tijdens als na 
de behandeling. Uit biochemisch onderzoek bleek dat bij RO0711401 zowel mGluR1 als 
mGluR5 sterker tot expressie kwam in de thalamus, terwijl het geneesmiddel in de cortex 
alleen de spiegel van de mGlu1-receptor deed stijgen. VU0360172 veroorzaakte een 
vroege en constante toename in de expressie van de mGlu5-receptor in de thalamus, een 
late afname van de expressie van de mGlu5-receptor in de cortex en geen veranderingen 
in de mGlu1-receptoren. Er wordt aangenomen dat er in de cortex en de thalamus van 
WAG/Rij-ratten sprake is van een prevalentie van mGlu1-mGlu1-homodimeren en 
mGlu1-mGlu5-heterodimeren ten opzichte van mGlu5-mGlu5-homodimeren. Dit zou 
een verklaring kunnen zijn waarom de mGlu1-receptor-PAM RO0711401 zowel in mGluR1 
als in mGluR5 adaptieve veranderingen tot stand bracht, terwijl de mGlu5-receptor-PAM 
VU0360172 alleen selectieve veranderingen teweegbracht in de mGlu5-receptoren. 
 In Hoofdstuk 5 wordt beschreven hoe er een demarcatiemethode in het C-T-C-circuit 
tot stand werd gebracht door middel van bilaterale intra-corticale of intra-thalamische 
micro-infusies met respectievelijk RO0711401 en VU0360172, om zo de specifieke 
plaatselijke effecten op de regulering van SWD’s duidelijker te kunnen bepalen. Uit het 
onderzoek bleek dat beide geneesmiddelen bij toediening in de cortex in gelijke mate 
effectief waren bij de vermindering van SWD’s. Bij toediening in de thalamus bleek de 
mGlu5-PAM VU0360172 effectiever te zijn dan de mGlu1-PAM RO0711401. Naast de rol van 
glutamaat speelt ook GABA een belangrijke rol bij de beperking van SWD’s. Het is bekend 
dat een systemisch toegediend GABA-mimeticum tot een toename in de incidentie van 
SWD’s leidt. Een voorbeeld van een dergelijk GABA-mimeticum is tiagabine, waarvan de 
werking zorgt voor blokkering van de heropname van GABA via GAT-1, een GABA-trans-
porteiwit met een hoge affiniteit. Door toepassing van tiagabine verkenden wij in 
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hoeverre en in welke richting een grotere beschikbaarheid van extra-synaptisch GABA de 
respons op VU0360172 beïnvloedt, zowel in de thalamus als in de somatosensorische 
cortex. Bij infusie in de cortex verminderde tiagabine het aantal SWD’s dosis afhankelijk. Er 
bestaat het vermoeden dat het door blokkering van de heropname van GABA mogelijk is 
om de GABA-erge inhibitie te versterken. De infusie van tiagabine in de thalamus deed 
het aantal SWD’s echter toenemen. Er wordt aangenomen dat de toediening van 
tiagabine in de thalamus bevorderlijk was voor SWD’s door een toename van de tonische 
inhibitie van schakelneuronen in de thalamus, als gevolg van inhibitie van de heropname 
van GABA via GAT-1.  De combinatie van VU0360172 plus tiagabine in de cortex leidde tot 
een vermindering van de SWD’s. De combinatie van VU0360172 plus tiagabine leidde in 
de thalamus echter tot fascinerende resultaten. Na concomitante toediening overheerste 
in eerste instantie het dempende effect op SWD’s van VU0360172, aangezien de incidentie 
van SWD’s afnam in de vroege periode post-injectie (10 min.). Dit effect ging echter na 20 
min. verloren en na 30 en 40 min. was er sprake van een pro-absence-effect. Wij veron-
derstelden dan ook dat de afname van SWD’s in de cortex het gevolg is van een 
versterking van de GABA-erge inhibitie op de piramidale neuronen. De intrigerende 
resultaten na combinatie van de geneesmiddelen in de thalamus doen vermoeden dat 
de activiteit van mGlu5-receptoren wordt gemoduleerd door GABA-erge transmissie.
 In Hoofdstuk 6, “Is er een toekomst voor mGlu5-PAM’s bij absence-epilepsie?”, wordt 
er een vergelijking gemaakt tussen VU0360172 en ETX, een geneesmiddel dat is 
uitgegroeid tot de voorkeursbehandeling bij patiënten met absence-toevallen, rekening 
houdende met zowel de verdraagbaarheid, werking en anti-epileptogene eigenschappen 
in mensen en in genetische absence-modellen. Hierbij werd duidelijk hoezeer er nieuwe 
behandelmogelijkheden nodig zijn bij absence-epilepsie, aangezien bij 47% van de 
proefpersonen die met ETX behandeld werden, de behandeling niet aansloeg. Er wordt 
een beschrijving gegeven van de vermoedelijke werkingsmechanismen van ETX, de 
neurochemische en farmacologische onderzoeken naar de nieuwe anti-absence-genees-
middelen RO0711401 en VU0360172, de mGlu1- en mGlu5-PAM’s, en daarnaast wordt er 
een vergelijking gemaakt tussen ETX en VU0360172. De belangrijkste conclusie van dit 
hoofdstuk is dat weliswaar zowel ETX als VU0360172 bij toediening in de cortex en de 
thalamus zorgden voor een afname van SWD’s, maar dat VU0360172 op beide locaties 
even effectief bleek te zijn, wat bij ETX slechts in mindere mate het geval is. Dit resultaat is 
voor ons een reden om aan te nemen dat VU0360172 succesvol bij patiënten zou kunnen 
worden ingezet voor het onderdrukken van toevallen.
 In Hoofdstuk 7 wordt gekeken naar de anti-absence-effecten en anti-epileptogene 
effecten van ETX en naar de interactie tussen VU0360172 en ETX. Bovendien werd 
gekeken naar de effecten van epileptogenese en chronische behandelingen met ETX, 
waardoor anti-epileptogenese tot stand komt, op iemands stemming en op cognitieve 
processen, zoals leer- en geheugenprestaties. Naar deze laatste processen werd ook 
onderzoek gedaan naar een chronische behandeling met ETX. Uit het onderzoek bleek 
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dat de anti-absence-effecten en anti-epileptogene effecten door middel van ETX met 
succes kunnen worden opgeroepen. Zoals verwacht verminderde VU0360172 de SWD’s 
in de onbehandelde controlegroep. Bij ratten die chronisch waren behandeld met ETX, 
bleek VU0360172 de incidentie van SWD’s echter laag te houden gedurende de hele 
periode van EEG-registratie, zonder terug te keren naar de beginwaarde. Dit effect hield 
zowel tijdens als na afloop van de chronische behandeling aan. Uit deze gegevens blijkt 
dat er mogelijk sprake is van een soort synergie tussen ETX en VU0360172.
 Veel anti-epileptische geneesmiddelen, zoals ETX, valproïnezuur en lamotrigine, 
hebben een negatief effect op de cognitie. Daarom is in hoofdstuk 7 ook onderzoek 
gedaan naar de vraag of een cognitief aspect, in dit geval een impulsgestuurde leertaak 
op het gebied van ruimtelijk onderscheidingsvermogen in een Y-vormig doolhof 
(‘Y-maze’), na een chronische behandeling met ETX veranderingen heeft ondergaan. Het 
resultaat was dat chronische ETX de motivatie versterkte om sucrosekorrels op te halen in 
het Y-vormige doolhof, gevolgd door een toename in impulsgestuurd leren ten aanzien 
van het onderscheidingsvermogen.
 In Hoofdstuk 8, de ‘Algemene discussie’, worden de belangrijkste bevindingen uit 
de hoofdstukken met beschrijvingen van de experimenten samengevat en worden de 
implicaties genoemd. Ten eerste bleek de SWD-activiteit door farmacologische manipulatie 
van mGluRs uit groep I op verschillende manieren te kunnen worden beïnvloed. 
Systemische toediening van de mGlu-agonisten (RO0711401 en VU0360172) leidde tot 
een afname van de SWD-activiteit, terwijl de antagonist de SWD-activiteit deed 
toenemen. In het onderzoek naar chronische behandelingen bleek zich tolerantie te 
ontwikkelen voor de mGlu1-PAM RO0711401, terwijl dit niet het geval was  mGlu5-PAM 
VU0360172.  Er werd ook aangetoond dat de werking van mGlu1- en mGlu5-receptoren in 
twee genetische absence-modellen (lh/lh-muizen en WAG/Rij-ratten) niet vergelijkbaar 
was en dat de rol van de mGlu-receptor-PAM’s/NAM’s afhangt van de genetische 
achtergrond van de dieren. Er is ook aangetoond waar in het C-T-C-circuit de activering 
van de mGlu1- of mGlu5-receptoren (cortex of thalamus) leidde tot een afname van de 
SWD’s. Beide geneesmiddelen waren bij injectie in de cortex in gelijke mate effectief bij 
de vermindering van SWD’s. Bij injectie in de thalamus bleek de mGlu5-PAM VU0360172 
effectiever te zijn dan de mGlu1-PAM RO0711401. In dit promotieonderzoek is ook 
aangetoond welk hersengebied – cortex of thalamus – betrokken is bij de anti-absence- en 
pro-absence-effecten van tiagabine. Micro-infusie van tiagabine in de cortex verminderde 
het aantal SWD’s, terwijl er bij micro-infusie in de thalamus sprake was van een toename 
van de SWD’s. De combinatie van VU0360172 en micro-infusie van tiagabine in de 
thalamus toonde aan dat mGlu5-receptoren mogelijk ook een rol spelen in de vorm van 
GABA-erge transmissie, waarbij mGluR5 ook in staat is om de activiteit van het GA-
BA-transporteiwit (GAT-1) te controleren. Dit effect deed zich niet voor in de cortex. Uit het 
onderzoek naar de combinatie van ETX plus VU0360172 kwam naar voren dat het 
 farmacologische profiel, in termen van vermindering van SWD’s, beter was in vergelijking 
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met alleen ETX. Er werd ook aangetoond dat VU0360172 zou kunnen worden gecombineerd 
met ETX, aangezien de combinatie van de beide geneesmiddelen de incidentie van 
SWD’s gedurende de hele registratiesessie laag hield, zonder terug te keren naar de 
beginwaarde. 
 Aanbevolen wordt  om verder onderzoek te doen naar de ontwikkeling van VU0360172 
tot een geneesmiddel tegen absences. Als de PAM-receptor van groep I verder kan 
worden ontwikkeld tot een nieuw anti-absencegeneesmiddel, dan moet het preklinische 
profiel van VU0360172 ook worden bepaald voor andere gegeneraliseerde en focale 
 epilepsiemodellen, waaronder mesiale temporaalkwabepilepsie. Het feit dat dit genees- 
middel in staat bleek om de werking van GABA-erge interneuronen te versterken, zoals 
bleek uit het focale exciteerbare gebied in het WAG/Rij-model, kan erop wijzen dat dit 
geneesmiddel ook effect kan hebben bij de behandeling van andere vormen van 
epilepsie.
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